{"text": "In addition , final results from the C - SWIFT study evaluating grazoprevir / elbasvir in combination with sofosbuvir 400 mg in treatment - na\u00efve patients with or without liver cirrhosis chronically infected with HCV GT1 or GT3 were presented as proof - of - concept for potentially shortening HCV treatment duration below 12 weeks .", "label": "", "metadata": {}, "score": "20.898619"}
{"text": "Merck undertakes no obligation to publicly update any forward - looking statement , whether as a result of new information , future events or otherwise except as required by applicable law . 1 Grazoprevir is an HCV NS3/4A protease inhibitor and elbasvir is an HCV NS5A replication complex inhibitor .", "label": "", "metadata": {}, "score": "21.957214"}
{"text": "Grazoprevir / elbasvir is an investigational , once - daily single tablet regimen consisting of grazoprevir ( NS3/4A protease inhibitor ) and elbasvir ( NS5A replication complex inhibitor ) .", "label": "", "metadata": {}, "score": "22.744282"}
{"text": "Following 12 weeks of treatment with a combination of grazoprevir and elbasvir plus RBV , 96 percent of the patients ( 76/79 ) with chronic HCV GT1 infection who had failed prior treatment with specified DAA - based regimens achieved SVR12 .", "label": "", "metadata": {}, "score": "26.533436"}
{"text": "Serious adverse events were reported in four patients in the grazoprevir / elbasvir only arm ( 4 % ) and three patients in the grazoprevir / elbasvir plus RBV arm ( 3 % ) .", "label": "", "metadata": {}, "score": "27.406664"}
{"text": "Serious adverse events were reported in three patients in the grazoprevir / elbasvir only arm ( 3 % ) and four patients in the grazoprevir / elbasvir plus RBV arm ( 4 % ) .", "label": "", "metadata": {}, "score": "27.58744"}
{"text": "Read more ...... .The collaborative trial will evaluate Presidio 's pan - genotypic HCV NS5A inhibitor ( PPI-668 ) in combination with Boehringer Ingelheim 's HCV protease inhibitor faldaprevir ( BI201335 ) and its non - nucleoside HCV polymerase inhibitor ( BI207127 ) , with or without ribavirin .", "label": "", "metadata": {}, "score": "29.283966"}
{"text": "Patients were randomized to an immediate treatment group that received grazoprevir / elbasvir for 12 weeks or to a deferred treatment group that received placebo for 12 weeks , were followed for an additional four weeks , and then received open label grazoprevir / elbasvir for the next 12 weeks .", "label": "", "metadata": {}, "score": "30.075142"}
{"text": "In this review , we summarize the development of anti - HCV agents and the clinical efficacy of sofosbuvir and ABT-450-based therapies as well as the potential for future HCV studies .", "label": "", "metadata": {}, "score": "31.007332"}
{"text": "Of the 211 patients enrolled in the 16 week arms , 105 patients received grazoprevir / elbasvir only and 106 patients received grazoprevir / elbasvir plus RBV .", "label": "", "metadata": {}, "score": "31.05138"}
{"text": "Abstract 84 .Sulkowski MS , Gardiner DF , Rodriguez - Torres M , et al ; AI444040 Study Group .High rate of sustained virologic response with the all - oral combination of daclatisvir ( NS5a inhibitor ) plus sofosbuvir ( nucleotide NS5b inhibitor ) with or without ribavirin , in treatment - naive patients chronically infected with HCV GT 1 , 2 , or 3 .", "label": "", "metadata": {}, "score": "31.086597"}
{"text": "Preclinical studies have shown that this NS5A inhibitor has broad genotype antiviral activity , but the associated mechanism is unclear .A phase IIa study compared the efficacy of the combination of daclatasvir and asunaprevir ( two - drug treatment ) with or without the addition of PegIFN - \u03b1 and RBV for the treatment of HCV genotype 1 prior null responders over a 24-wk duration .", "label": "", "metadata": {}, "score": "31.1721"}
{"text": "Abstract .Two direct - acting antivirals ( DAAs ) against hepatitis C virus ( HCV ) : telaprevir and boceprevir , are now available in combination with peginterferon plus ribavirin for the treatment of chronic hepatitis C infection .", "label": "", "metadata": {}, "score": "31.265076"}
{"text": "\" We continue to advance our Phase 3 clinical program for grazoprevir / elbasvir evaluating diverse patient populations with chronic HCV infection , including those widely considered among the most difficult to treat , \" said Dr. Eliav Barr , vice president , infectious diseases , Merck Research Laboratories . \" Findings from these Phase 2 studies formed part of the basis for our decision to rapidly advance our large and comprehensive clinical development program that incorporates studies dedicated to patient populations with specific unmet medical needs . \" C - SALVAGE Overview and Findings .", "label": "", "metadata": {}, "score": "32.18235"}
{"text": "In the grazoprevir / elbasvir only and grazoprevir / elbasvir plus RBV arms , six patients in each arm ( 6 % ) were reported to have virologic relapse .", "label": "", "metadata": {}, "score": "32.297375"}
{"text": "The EASL guidelines now list daclatasvir+sofosbuvir regimens as options for treating all HCV genotypes and for use with patients coinfected with HCV / HIV .( Guidelines available here . )", "label": "", "metadata": {}, "score": "32.34464"}
{"text": "To date , the resistance mutations R155 K and D168V / E have been observed .Danoprevir is another second - generation NS3 protease inhibitor used for the treatment in naive or experienced HCV genotype 1 patients , and it is expected to eliminate the use of IFN - based drugs .", "label": "", "metadata": {}, "score": "32.502983"}
{"text": "These advantages may lower the threshold for HCV treatment for both patients and physicians .Gilead has applied for approval of sofosbuvir and ribavirin as an all - oral therapy for patients with genotypes 2 and 3-the minority of patients with hep .", "label": "", "metadata": {}, "score": "32.594078"}
{"text": "Among the patients receiving grazoprevir / elbasvir only , three patients ( 3 % ) were reported to have virologic breakthrough or rebound and four patients ( 4 % ) were reported to have virologic relapse .", "label": "", "metadata": {}, "score": "32.82692"}
{"text": "Abstract 759 .Jacobson IM , Jensen DM , Pol S , et al .Safety and efficacy of ritonavir - boosted danoprevir ( DNVr ) , peginterferon alfa-2a ( 40KD ) and ribavirin with or without mericitabine in genotype 1-infected treatment - experienced patients with advanced hepatic fibrosis : the MATTERHORN study .", "label": "", "metadata": {}, "score": "33.46819"}
{"text": "The triple combination therapy of telaprevir or boceprevir plus ribavirin and peginterferon - alfa is the NSOC treatment for chronic HCV genotype 1-infected patients [ 35 - 42 ] .", "label": "", "metadata": {}, "score": "33.844116"}
{"text": "12 week arms .Of the 209 patients randomized to the 12 week arms , 105 patients received grazoprevir / elbasvir only and 104 patients received grazoprevir / elbasvir plus RBV .", "label": "", "metadata": {}, "score": "35.0356"}
{"text": "Abstract 786 .Lok AS , Gardiner DF , H\u00e9zode C , et al .Sustained virologic response in chronic HCV genotype ( GT)1-infected null responders with combination of daclatisvir ( DCV ; NS5a inhibitor ) and asunaprevir ( ASV ; NS3 inhibitor ) with or without peginterferon alfa-2a / ribavirin ( PEG / RBV ) .", "label": "", "metadata": {}, "score": "35.038452"}
{"text": "Overall , 35 percent had liver cirrhosis .Among the 104 patients receiving grazoprevir / elbasvir plus RBV , 58 percent were infected with chronic HCV GT1a , 28 percent GT1b or other GT1 , and 14 percent GT4 .", "label": "", "metadata": {}, "score": "35.093674"}
{"text": "Another clinical trial showed that the 12-wk treatment of HCV genotype 1 naive patients with sofosbuvir , PegIFN - \u03b1 and RBV was safe and effective .", "label": "", "metadata": {}, "score": "35.538235"}
{"text": "C - EDGE CO - INFXN Overview and Additional Findings .C - EDGE CO - INFXN is an open label , single - arm study evaluating the efficacy and safety of grazoprevir / elbasvir in treatment - na\u00efve patients with or without cirrhosis infected with chronic HCV GT1 , 4 or 6 and HIV who received therapy for 12 weeks .", "label": "", "metadata": {}, "score": "36.05896"}
{"text": "Two HCV NS3 protease inhibitors , telaprevir and boceprevir , were approved by the United States FDA in 2011 , and their combined treatment with the SOC not only significantly improved the SVR rate in HCV naive patients but also showed good efficacy in patients with previous treatment failure .", "label": "", "metadata": {}, "score": "36.394886"}
{"text": "Cross - resistance to other HCV NS3/4A PIs ( e.g. , telaprevir ) reported with many treatment - emergent substitutions observed in patients not achieving SVR with boceprevir in clinical trials .", "label": "", "metadata": {}, "score": "36.467194"}
{"text": "Sofosbuvir plus peginterferon / ribavirin in treatment - naive patients with HCV genotype 1 leads to higher RVR rates and SVR rates than SOC ( 88 - 94 % vs. 21 % ; and 56 - 83 % vs. 43 % , respectively ) [ 58 ] .", "label": "", "metadata": {}, "score": "36.47979"}
{"text": "Phase 3b Studies To Assess Long - term Clinical Outcomes In HCV GT1-infected Patients Treated With Ombitasvir / Paritaprevir / Ritonavir And Dasabuvir With Or Without Ribavirin .", "label": "", "metadata": {}, "score": "36.55303"}
{"text": "With the potent , complementary antiviral activities of PPI-668 , faldaprevir , and BI207127 , the present study focuses on patients with HCV genotype-1a infection , which has been harder to treat than HCV genotype-1b in many studies .", "label": "", "metadata": {}, "score": "36.816097"}
{"text": "Risk of severe or life - threatening neutropenia , including life - threatening infections associated with neutropenia .Thromboembolic events reported during boceprevir clinical trials . 1 Ribavirin dosage reduction recommended for initial management of anemia in HCV patients receiving boceprevir , peginterferon alfa , and ribavirin . 1 Some evidence of a greater risk of thromboembolic events ( e.g. , PE , acute MI , cerebrovascular accident , DVT ) when an erythropoiesis stimulating agent ( ESA ) used for initial management compared with use of ribavirin dosage reduction in such patients .", "label": "", "metadata": {}, "score": "36.881546"}
{"text": "Abstract 79 .Feld JJ , Jacobson IM , Jensen DM , et al .Up to 100 % SVR4 rates with ritonavir - boosted danoprevir ( DNVr ) , mericitabine and ribavirin with or without peginterferon alfa-2a ( 40KD ) in genotype 1-infected partial and null responders : results from the MATTERHORN study .", "label": "", "metadata": {}, "score": "36.88549"}
{"text": "de Kanter CT , Colbers AP , Blonk MI et al .Lack of a clinically significant drug - drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole .", "label": "", "metadata": {}, "score": "36.972878"}
{"text": "Overall , 36 percent of patients had liver cirrhosis .Among those in the grazoprevir / elbasvir plus RBV arm , 55 percent were infected with chronic HCV GT1a , 36 percent with GT1b or other GT1 , eight percent with GT4 , and two percent with GT6 .", "label": "", "metadata": {}, "score": "36.98962"}
{"text": "Of the 316 patients who received immediate treatment with grazoprevir / elbasvir , 50 percent were infected with GT1a , 42 percent with GT1b , six percent with GT4 and three percent with GT6 .", "label": "", "metadata": {}, "score": "37.00381"}
{"text": "Abstract 284 .Vierling JM , Lataillade M , Gane EJ , et al ; D - LITE Study Team .Sustained virologic response ( SVR12 ) in HCV genotype 1 patients receiving peginterferon lambda in combination with ribavirin and either daclatasvir or asunaprevir : interim results from The D - LITE study .", "label": "", "metadata": {}, "score": "37.035576"}
{"text": "Update : HCV Genotypes 2 and 3 , Treatment - Naive and Treatment - Experienced ) .For people with HCV genotypes 4 and 6 , big news came in a small group of treatment naive , non - cirrhotic people in the ATOMIC study , treated with 24 weeks of sofosbuvir , peginterferon and ribavirin .", "label": "", "metadata": {}, "score": "37.137897"}
{"text": "Advertisement .Sofosbuvir is already being studied in HIV / HCV coinfected people with HCV genotypes 2 and 3 ; a clinical trial is comparing 12 vs. 24 weeks of sofosbuvir and ribavirin is ongoing .", "label": "", "metadata": {}, "score": "37.143166"}
{"text": "Ogert RA , Howe JA , Vierling JM et al .Resistance - associated amino acid variants associated with boceprevir plus pegylated interferon - \u03b12b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 Trial .", "label": "", "metadata": {}, "score": "37.16276"}
{"text": "Abstract LB-4 .Sulkowski MS , Jacobson IM , Gane EJ .The safety of telaprevir in the absence of interferon and/or ribavirin : analysis of on - treatment data from the ZENITH trial .", "label": "", "metadata": {}, "score": "37.32203"}
{"text": "Sulkowski MS , Sherman KE , Soriano V , et al ; Study 110 Team .Telaprevir in combination with peginterferon alfa-2a / ribavirin in HIV / HCV co - infected patients : SVR24 final study results .", "label": "", "metadata": {}, "score": "37.350334"}
{"text": "Zeuzem S , Asselah T , Angus PW , et al .Strong antiviral activity and safety of IFN- sparing treatment with the protease in- hibitor BI 201335 , the HCV polymerase inhibitor BI 207127 and ribavirin in pa- tients with chronic hepatitis C. Hepatol- ogy 2010;52:Suppl:876A. abstract .", "label": "", "metadata": {}, "score": "37.412743"}
{"text": "BMS-650032 , an NS3 inhibitor , in combination with peginterferon alpha-2a and ribavirin in treatment - naive subjects with genotype 1 chronic hepatitis C infec- tion .", "label": "", "metadata": {}, "score": "37.585167"}
{"text": "Abstract 54 .Kirby B , Mathias A , Rossi S , et al .No clinically significant pharmacokinetic drug interactions between sofosbuvir ( GS-7977 ) and HIV antiretrovirals atripla \u00ae , rilpivirine , darunavir / ritonavir , or raltegravir in healthy volunteers .", "label": "", "metadata": {}, "score": "37.63527"}
{"text": "Other drugs may be combined to create interferon - and ribavirin - free regimens in the post - transplant setting : drug - drug interaction studies with simeprevir ( TMC-435 , a protease inhibitor currently in phase III ) and sofosbuvir did not report clinically significant interactions with immunosuppressants in healthy volunteers .", "label": "", "metadata": {}, "score": "37.821774"}
{"text": "Note that this uncontrolled trial demonstrated similar rates of virologic response among patients with and without psychiatric comorbidities treated with sofosbuvir and ribavirin .... .Patients who achieve SVR12 are considered cured of HCV infection . \"", "label": "", "metadata": {}, "score": "37.896893"}
{"text": "The trial will evaluate an all - oral 12-week interferon - free regimen consisting of sovaprevir , ACH-3102 , and ribavirin in patients with chronic HCV who have not received prior therapy .", "label": "", "metadata": {}, "score": "38.188572"}
{"text": "Poster P0887 ) .A paper detailing the findings of C - EDGE TN was published online in the Annals of Internal Medicine today .\" These findings are important because they demonstrate that a single pill of grazoprevir / elbasvir taken once - daily achieved consistently high rates of SVR12 in the patient populations studied . \"", "label": "", "metadata": {}, "score": "38.275684"}
{"text": "Used in conjunction with peginterferon alfa ( alfa-2a , alfa-2b ) and ribavirin ; 1 do not use alone .American Association for the Study of Liver Diseases ( AASLD ) and others recommend an NS3/4A PI ( i.e. , boceprevir , telaprevir ) in conjunction with peginterferon alfa and ribavirin as the standard of care for initial treatment of chronic HCV genotype 1 infection in treatment - naive adults .", "label": "", "metadata": {}, "score": "38.364204"}
{"text": "Abstract LB-2 .Everson GT , Sims KD , Rodriguez - Torres M , et al .An interferon - free , ribavirin - free 12-week regimen of daclatasvir ( DCV ) , asunaprevir ( ASV ) , and BMS-791325 yielded SVR4 of 94 % in treatment - naive Patients with genotype ( GT ) 1 chronic hepatitis C virus ( HCV ) infection .", "label": "", "metadata": {}, "score": "38.377876"}
{"text": "Abstract 229 .Osinusi A , Heytens L , Lee YJ , et al .High efficacy of GS-7977 in combination with low or full dose ribavirin for 24 weeks in difficult to treat HCV infected genotype 1 patients .", "label": "", "metadata": {}, "score": "38.473835"}
{"text": "Cyclosporine - a cyclophilin inhibitor : Cyclophilins are a family of cell isomerases , including cyclophilins A , B , and C. The importance of human cyclophilins in HCV replication was confirmed by the anti - HCV activity of cyclosporine A. The mechanism of action of cyclosporine A involves NS5A and/or NS5B. Alisporivir ( Debio-025 ) is a derivative of cyclosporine A , which removed the immunosuppressive activity but retained the potent antiviral activity against a wide range of HCV genotypes .", "label": "", "metadata": {}, "score": "38.67965"}
{"text": "[ PubMed 23075915 ] .Hulskotte E , Feng HP , Xuan F et al .Pharmacokinetic Evaluation of the Interaction Between the HCV Protease Inhibitor Boceprevir and the HMG - CoA Reductase Inhibitors Atorvastatin and Pravastatin .", "label": "", "metadata": {}, "score": "38.76748"}
{"text": "Overall , these results sug- gest that further research with combinations of direct - acting antiviral agents , with or without peginterferon and ribavirin , is warranted .", "label": "", "metadata": {}, "score": "38.767513"}
{"text": "Patients with chronic hepatitis C virus ( HCV ) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addition of multiple direct - acting antiviral agents to their treatment regimen .", "label": "", "metadata": {}, "score": "38.79368"}
{"text": "The primary endpoint was sustained virological response at post - treatment week 12 ( SVR12 ) among genotype 1-infected patients .Daclatasvir plus asunaprevir and peginterferon / ribavirin demonstrated SVR12 rates of 93 % ( 95 % CI 90 - 96 ) in prior non - responders infected with HCV genotype 1 . SVR12 rates among genotype 4-infected patients were 98 % ( 95 % CI 93 - 100 ) ; one patient had a missing post - treatment week 12 HCV - RNA measurement , but achieved an SVR at post - treatment week 24 , yielding a 100 % SVR rate in genotype 4 patients .", "label": "", "metadata": {}, "score": "38.829544"}
{"text": "Results from the BOSON study of Sovaldi \u00ae ( sofosbuvir 400 mg ) in combination with ribavirin ( RBV ) or with pegylated interferon ( PEG)/RBV demonstrated high cure rates across all patients with genotypes 2 and 3 .", "label": "", "metadata": {}, "score": "39.003548"}
{"text": "[PubMed ] [ DOI ] .Lancet .[PubMed ] [ DOI ] .Gane EJ , Pockros P , Zeuzem S , Marcellin P , Shikhman A , Bernaards C , Yetzer ES , Shulman N , Tong X , Najera I. Interferon - Free Treatment with a Combination of Mericitabine and Danoprevir / R with or without Ribavirin in Treatment - Naive Hcv Genotype 1-Infected Patients .", "label": "", "metadata": {}, "score": "39.12859"}
{"text": "In looking at clinicaltrials.gov , it appears that they are recruiting such a study now ( includes PPI-668 , an NS5A inhibitor like daclatasvir and GS5885 ) .", "label": "", "metadata": {}, "score": "39.151913"}
{"text": "Group A included patients who received the NS5A replication complex inhibitor daclatasvir and the NS3 protease in- hibitor asunaprevir alone for 24 weeks .Group B included patients who re- ceived daclatasvir and asunaprevir in combination with peginterferon alfa-2a and ribavirin for 24 weeks .", "label": "", "metadata": {}, "score": "39.164665"}
{"text": "AASLD brought good news for treatment - experienced people with HCV genotypes 2 and 3 , since there is currently no recommended retreatment option when peginterferon and ribavirin are unsuccessful .", "label": "", "metadata": {}, "score": "39.20936"}
{"text": "[ PubMed 22239501 ] .Reddy SS .Dear healthcare professional letter .Results of pharmacokinetic study in healthy volunteers given victrelis ( boceprevir ) and ritonavir - boosted HIV protease inhibitors may indicate clinically significant drug interactions for patients coinfected with chronic hepatitis C and HIV .", "label": "", "metadata": {}, "score": "39.3116"}
{"text": "MALACHITE - II : Phase 3b Trial Of Ombitasvir / Paritaprevir / R And Dasabuvir + Ribavirin Or Telaprevir + Peginterferon / Ribavirin In Peginterferon / Ribavirin Treatment - experienced Adults With HCV Genotype 1 .", "label": "", "metadata": {}, "score": "39.461315"}
{"text": "H\u00e9zode C , Dorival C , Zoulim F , et al .Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa / ribavirin , in 455 cirrhotic non responders .", "label": "", "metadata": {}, "score": "39.584595"}
{"text": "Abstract 694 .Mathias A , Cornpropst M , Clemons D , et al .No clinically significant pharmacokinetic drug - drug interactions between sofosbuvir ( GS-7977 ) and the immunosuppressants , cyclosporine A or tacrolimus in healthy volunteers .", "label": "", "metadata": {}, "score": "39.633987"}
{"text": "Viewed from the clinical data of first - generation protease inhibitors , telaprevir and boceprevir , these drugs showed potent inhibition of HCV , although they occasionally led to severe adverse events [ 46 , 47 ] .", "label": "", "metadata": {}, "score": "39.64207"}
{"text": "Abstract 230 .H\u00e9zode C , Shiffman ML , Cooper C , et al .Ritonavir - boosted danoprevir plus PegIFN alfa-2a/ ribavirin ( P / R ) demonstrates up to 100 % SVR24 with 12 or 24 weeks of total treatment in treatment - naive patients with HCV genotype 4 infection in the DAUPHINE study .", "label": "", "metadata": {}, "score": "39.71363"}
{"text": "Izumi et al .14Vierling et al .15 Daclatasvir more tolerable than asunaprevir .EMERGE Phase 2b Bristol Myers Squib Drugs : peginterferon alfa-2a and ribavirin or peginterferon lambda and ribavirin .", "label": "", "metadata": {}, "score": "40.046165"}
{"text": "Combined with PegIFN - \u03b1 and RBV , these DAAs resulted in a higher SVR rate in patients with HCV genotype 1 .Thus , this treatment regimen became the SOC regimen for such patients .", "label": "", "metadata": {}, "score": "40.28656"}
{"text": "Abstract 229 .Kowdley KV , Lawitz E , Poordad F , et al .A 12-week interferon - free treatment regimen with ABT-450/r , ABT 267 , ABT-333 , and ribavirin achieves SVR12 Rates ( observed data ) of 99 % in treatment - naive patients and 93 % in prior null responders with HCV genotype 1 infection .", "label": "", "metadata": {}, "score": "40.34292"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Improved therapies for peginterferon / ribavirin null or partial responders are needed .This study evaluated daclatasvir ( NS5A inhibitor ) and asunaprevir ( NS3 protease inhibitor ) plus peginterferon - alfa-2a and ribavirin in this patient population .", "label": "", "metadata": {}, "score": "40.42273"}
{"text": "This is the first report to describe DCV - resistance in patients infected with GT4d , supporting a possible role for a recently described RAV ( L28S ) , and presenting the dynamics of HCV quasispecies during therapy failure , with indications of changes of diversity and association of mutations .", "label": "", "metadata": {}, "score": "40.78038"}
{"text": "Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibi- tor BMS-650032 in HCV genotype 1b- infected null responders .Hepatology 2011October 10 ( Epub ahead of print ) .", "label": "", "metadata": {}, "score": "40.841965"}
{"text": "As a first step , Janssen Pharmaceutical Inc. will conduct a drug - drug interaction ( DDI ) study with simeprevir and VX-135 .Janssen Pharmaceutical Inc. also recently announced plans to initiate a phase IIa trial of an investigational interferon - free regimen with simeprevir , TMC647055 and Idenix 's IDX719 , a once - daily NS5A inhibitor , with and without ribavirin .", "label": "", "metadata": {}, "score": "41.128944"}
{"text": "Darunavir .Ritonavir - boosted darunavir : Decreased concentrations and AUC of boceprevir , darunavir , and ritonavir ; 1 19 200 possible reduced efficacy of HCV and HIV treatment regimens 17 18 .", "label": "", "metadata": {}, "score": "41.201645"}
{"text": "J Antimicrob Chemother .[ PubMed 22258932 ] .Vermehren J , Susser S , Lange CM et al .Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b .", "label": "", "metadata": {}, "score": "41.204315"}
{"text": "The use of ritonavir 100 mg with ABT-450 for the treatment of HCV is investigational .Poster Presentations .Poster # 867 , Tami Pilot - Matias et al . ; Friday , April 20 ( 11:00 - 11:30 , 12:30 - 14:00 , 15:30 - 16:00 CET ) \" In vitro combinatory effect of HCV NS3/4A protease inhibitor ABT-450 , NS5A inhibitor ABT-267 , and non - nucleoside NS5B polymerase inhibitor ABT-333 \" .", "label": "", "metadata": {}, "score": "41.279766"}
{"text": "McHutchison JG , Everson GT , Gordon SC , Jacobson IM , Sulkowski M , Kauffman R , McNair L , Alam J , Muir AJ , PROVE1 Study Team : Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection .", "label": "", "metadata": {}, "score": "41.304993"}
{"text": "An IFN - free study of mericitabine as a monotherapy or in combination with danoprevir showed that the rs12979860 CC genotype was related to faster and earlier viral decline [ 74 ] .", "label": "", "metadata": {}, "score": "41.39788"}
{"text": "About AbbVie 's Two Direct - Acting Antiviral HCV Treatment AbbVie 's proposed all - oral antiviral treatment consists of the fixed - dose combination of paritaprevir / ritonavir ( 150/100 mg ) co - formulated with ombitasvir ( 25 mg ) dosed once daily , co - administered with weight - based ribavirin ( 1000 mg or 1200 mg in divided doses , twice daily ) .", "label": "", "metadata": {}, "score": "41.45041"}
{"text": "The addition of HCV protease inhibitors to the SOC has significantly improved the efficacy of treatments for HCV infection .Factors affecting the efficacy of anti - HCV treatments based on IFN - \u03b1 include the HCV genotype , baseline viral load , virological response during treatment , host IL28B gene polymorphisms and hepatic steatosis .", "label": "", "metadata": {}, "score": "41.468697"}
{"text": "Oct 2 2013 Drugs in Development : Genotype 2 and 3 Sofosbuvir / Ribavirin : Next Standard of Care The next treatment for genotype 2 and 3 will be the combination of Gilead 's sofosbuvir ( HCV polymerase inhibitor ) and ribavirin .", "label": "", "metadata": {}, "score": "41.536613"}
{"text": "MALACHITE - I : Phase 3b Trial Of Ombitasvir / Paritaprevir / R And Dasabuvir + /-Ribavirin Or Telaprevir + Peginterferon / Ribavirin In Treatment - na\u00efve Adults With HCV Genotype 1 .", "label": "", "metadata": {}, "score": "41.660873"}
{"text": "[ PubMed 23293300 ] .Susser S , Vermehren J , Forestier N et al .Analysis of long - term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir .", "label": "", "metadata": {}, "score": "41.68253"}
{"text": "This is our second phase IIb trial .Initially ( in the SOUND - C2 trial ) we tested our interferon - free treatment regimen of faldaprevir , deleobuvir and ribavirin in a large study .", "label": "", "metadata": {}, "score": "41.720375"}
{"text": "Conclusions : Twelve or 16 weeks of treatment with daclatasvir , in combination with peginterferon alfa-2a and ribavirin , is a well tolerated and effective therapy for patients with HCV genotype 2 or 3 infections .", "label": "", "metadata": {}, "score": "41.74031"}
{"text": "C - SWIFT Overview and Findings .C - SWIFT ( Abstract # O006 ) is a proof - of - concept Phase 2 open label clinical trial conducted to evaluate the efficacy and safety of grazoprevir / elbasvir plus sofosbuvir over shorter treatment durations .", "label": "", "metadata": {}, "score": "41.970818"}
{"text": "Studies have demonstrated that the SVR rate resulting from the combined treatment of albinterferon and RBV was equivalent to that resulting from the SOC treatments , and the incidence rates of adverse drug reactions were also similar [ 17 , 18 ] .", "label": "", "metadata": {}, "score": "42.099792"}
{"text": "Abstract 211 .Fontana RJ , Bifano M , Hindes R , et al .First ever successful use of daclatasvir and GS-7977 , an interferon - free oral regimen , in a liver transplant recipient with severe recurrent hepatitis .", "label": "", "metadata": {}, "score": "42.138844"}
{"text": "Abstract LB-1 .Soriano V , Gane EJ , Angus P , et al .Efficacy and safety of the interferon - free combination of faldaprevir ( BI 201335)+ BI 207127 \u00b1 ribavirin in treatment - naive patients with HCV GT-1 and compensated liver cirrhosis : results from the SOUND - C2 study .", "label": "", "metadata": {}, "score": "42.143715"}
{"text": "Pasquinelli C , Eley T , Villegas C , et al .Safety , tolerability , pharmacokinetics and antiviral activity following single- and mul- tiple - dose administration of BMS-650032 , a novel HCV NS3 inhibitor , in subjects with chronic genotype 1 HCV infection . Hepatol-", "label": "", "metadata": {}, "score": "42.27867"}
{"text": "The 65-patient , 3-arm study tested MK-5172 , a protease inhibitor , combined with MK-8742 from a highly promising new class of drugs called NS5A inhibitors for 12 weeks of treatment .", "label": "", "metadata": {}, "score": "42.280945"}
{"text": "In the early 2000s , polyethylene glycol interferon - \u03b1 ( PegIFN - \u03b1 ) combined with ribavirin ( RBV ) became the standard of care ( SOC ) regimen for HCV , which showed a SVR that was mainly associated with its genotype .", "label": "", "metadata": {}, "score": "42.570084"}
{"text": "[PubMed ] [ DOI ] .Sulkowski MS , Bourli\u00e8re M , Bronowicki JP , Asselah T , Pawlotsky JM , Shafran SD , Pol S , Mauss S , Larrey D , Datsenko Y. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse : SILEN - C2 trial .", "label": "", "metadata": {}, "score": "42.605255"}
{"text": "Some DAAs are potent inhibitors independently of HCV genotypes [ 56 , 64 - 66 ] .The all - oral combination of daclatasvir plus sofosbuvir , with or without ribavirin , leads to higher SVR rates in treatment - naive patients chronically infected with HCV genotypes 1 , 2 and 3 [ 67 ] .", "label": "", "metadata": {}, "score": "42.6419"}
{"text": "References : 1 Pockros P , et al .Safety Of Ombitasvir / Paritaprevir / Ritonavir Plus Dasabuvir For Treating HCV GT1 Infection In Patients With Severe Renal Impairment Or End - stage Renal Disease : The RUBY - I Study .", "label": "", "metadata": {}, "score": "42.7737"}
{"text": "Gane EJ , Roberts SK , Stedman CA , et al .Oral combination therapy with a nucleoside polymerase inhibitor ( RG7128 ) and dano- previr for chronic hepatitis C genotype 1 infection ( INFORM-1 ) : a randomised , dou- ble - blind , placebo - controlled , dose - escala- tion trial .", "label": "", "metadata": {}, "score": "42.799767"}
{"text": "Clinicaltrials.gov number : NCT01257204 .[ Show abstract ] [ Hide abstract ] ABSTRACT : Background : ABT-450 is an HCV NS3/4A protease inhibitor dosed with ritonavir ( r ) 100 mg , identified by AbbVie and Enanta .", "label": "", "metadata": {}, "score": "42.856422"}
{"text": "From FDA website .Accessed 2012 Jul 9 .Hulskotte EG , Feng HP , Xuan F et al .Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir - boosted HIV-1 protease inhibitors atazanavir , darunavir , and lopinavir .", "label": "", "metadata": {}, "score": "42.865406"}
{"text": "However , due the high burden of treatment - related side effects and low likelihood of sustained virologic response , the impact of treatment with peginterferon / ribavirin on the burden of HCV disease in has been limited .", "label": "", "metadata": {}, "score": "42.946068"}
{"text": "Then we modified the regimen ...July 11 Interferon - free Regimen for Hepatitis C Advances The direct - acting antiviral combination , manufactured by AbbVie Pharmaceuticals , consists of the protease inhibitor ABT-450 , the non - nucleoside NS5B polymerase inhibitor ABT-333 , and the novel NS5A inhibitor ABT-267 .", "label": "", "metadata": {}, "score": "42.94632"}
{"text": "[PubMed ] [ DOI ] .Hepatology .[PubMed ] [ DOI ] .Sulkowski MS , Asselah T , Lalezari J , Ferenci P , Fainboim H , Leggett B , Bessone F , Mauss S , Heo J , Datsenko Y. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment - na\u00efve patients with chronic genotype 1 HCV : SILEN - C1 trial .", "label": "", "metadata": {}, "score": "42.983307"}
{"text": "The addition of boceprevir to SOC results in higher SVR rates in both treatment - na\u00efve and re - treated patients infected with HCV genotype 1 ( Table 3 ) [ 41 , 42 ] .", "label": "", "metadata": {}, "score": "42.984753"}
{"text": "Efficacy not established in patients who previously failed therapy with a regimen containing boceprevir or other HCV NS3/4A PI .Safety and efficacy not established in chronic HCV patients with HBV or HIV coinfection or in recipients of liver or other organ transplantations .", "label": "", "metadata": {}, "score": "43.017426"}
{"text": "In vitro studies have shown a lack of significant cross - resistance with NS3/4A or other protease inhibitors .Moreover , there is an additive effect when cyclophilin inhibitors are combined with PEGIFN - \u03b1 .", "label": "", "metadata": {}, "score": "43.08294"}
{"text": "Phase II clinical trials compared the efficacy of simeprevir , PegIFN - \u03b1 and RBV with the SOC treatment for naive or previous treatment failure HCV genotype 1 patients .", "label": "", "metadata": {}, "score": "43.178486"}
{"text": "The MALACHITE studies evaluate adult patients with GT1 chronic HCV infection without cirrhosis receiving VIEKIRAX + EXVIERA with or without RBV compared to treatment with telaprevir with pegylated - interferon and RBV , which remains the standard of care in many regions of the world .", "label": "", "metadata": {}, "score": "43.244034"}
{"text": "[ PubMed 23155151 ] .Hammond KP , Wolfe P , Burton JR et al .Pharmacokinetic interaction between boceprevir and etravirine in HIV / HCV seronegative volunteers .", "label": "", "metadata": {}, "score": "43.31182"}
{"text": "Has in vitro activity against HCV genotypes 1a and 1b , but is less active against HCV genotypes 2 , 2a , and 3a .Certain amino acid substitutions in the NS3 protease domain of HCV genotype 1a and 1b have been selected in vitro and are associated with reduced susceptibility to boceprevir .", "label": "", "metadata": {}, "score": "43.338566"}
{"text": "In patients with HCV genotype 2/3 infections , those given a standard dose of PegIFN - \u03b1-2b ( 1.5 \u03bcg / kg ) had a higher SVR rate than those given a low dose [ 10 - 12 ] .", "label": "", "metadata": {}, "score": "43.3444"}
{"text": "The trial will measure on - treatment antiviral responses and sustained virologic response rates ( SVR ) to the triple DAA combination regimen , with or without ribavirin .", "label": "", "metadata": {}, "score": "43.371933"}
{"text": "It is conceivable that off - label use ....Oct 8 2013 Daclatasvir / Asunaprevir / BMS-791325 A triple - drug regimen for hepatitis C ( HCV ) led to a cure in about 90 % of patients without using elements of the standard therapy for the disease , a researcher said .", "label": "", "metadata": {}, "score": "43.606277"}
{"text": "Dosage adjustments not required in patients with mild , moderate , or severe renal impairment .Cautions for Victrelis .Contraindications .Because boceprevir must be used in conjunction with peginterferon alfa and ribavirin , it is contraindicated in women who are or may become pregnant and in male partners of pregnant women .", "label": "", "metadata": {}, "score": "43.656013"}
{"text": "This study evaluated the efficacy and safety of beclabuvir , in combination with peginterferon alfa-2a ( pegIFN ) and ribavirin ( RBV ) , in HCV genotype 1 .", "label": "", "metadata": {}, "score": "43.66369"}
{"text": "Abstract 81 .Izumi N , Lataillade M , Chayama K , et al ; D - LITE Study Team .First report of peginterferon lambda / ribavirin in combination with either daclatasvir or asunaprevir in HCV genotype 1 Japanese patients : early sustained virologic response ( SVR4 ) results from the D - LITE Japanese substudy .", "label": "", "metadata": {}, "score": "43.670544"}
{"text": "In the patients in group A who had viral breakthrough , HCV RNA levels were measured every 4 weeks after the addition of peginterferon and ribavirin .", "label": "", "metadata": {}, "score": "43.776703"}
{"text": "In the near future , we might be using all - oral DAAs and interferon - free regimens for the treatment of HCV - infected patients , and these would be potent inhibitors of HCV and have less adverse events .", "label": "", "metadata": {}, "score": "43.95264"}
{"text": "Aug 16 Interferon - free HCV regimens on the horizon ?NEW YORK ( Reuters Health ) - Among patients with HCV genotype 1 infection , more than half had a sustained virologic response 12 weeks after completing an interferon - free regimen consisting of faldaprevir with deleobuvir plus ribavirin .", "label": "", "metadata": {}, "score": "43.96973"}
{"text": "Additionally , the Phase 2 LONESTAR-2 study evaluated 12 weeks of sofosbuvir , RBV and pegylated interferon ( peg - IFN ) among patients who had previously failed treatment with peg - IFN / RBV , approximately half of whom had cirrhosis .", "label": "", "metadata": {}, "score": "44.052475"}
{"text": "This finding suggests that L - carnitine supplementation may be useful in patients treated for HCV .Other supplementations including erythropoietin , zinc and probiotics have been assessed in clinical studies , but the effects of those on SVR are still not clear .", "label": "", "metadata": {}, "score": "44.13981"}
{"text": "N Engl J Med .[PubMed ] [ DOI ] .e1 ; quiz e14 .[PubMed ] [ DOI ] .H\u00e9zode C , Forestier N , Dusheiko G , Ferenci P , Pol S , Goeser T , Bronowicki JP , Bourli\u00e8re M , Gharakhanian S , Bengtsson L. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection .", "label": "", "metadata": {}, "score": "44.33283"}
{"text": "[PubMed ] [ DOI ] .Marcellin P , Cooper C , Balart L , Larrey D , Box T , Yoshida E , Lawitz E , Buggisch P , Ferenci P , Weltman M. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment - na\u00efve patients with hepatitis C virus genotype 1 infection .", "label": "", "metadata": {}, "score": "44.443447"}
{"text": "Final results from a Phase 2 trial of telaprevir plus peginterferon and ribavirin in HIV / HCV coinfected people were presented at AASLD .In this trial , there were no relapses between 12 and 24 weeks post - treatment : 74 % of people who received telaprevir - based triple therapy versus 45 % of people given peginterferon and ribavirin plus placebo achieved SVR-24 .", "label": "", "metadata": {}, "score": "44.46731"}
{"text": ": en gang om dagen ; EoT : behandlingsslut ; SVR4 och SVR12 : patienter med odetekterbara nivaer HCV RNA ( HCV RNA .The regimen of once - daily simeprevir and sofosbuvir with or without ribavirin was generally well tolerated and no serious adverse events occurred during the treatment period for the patients involved in the study .", "label": "", "metadata": {}, "score": "44.46954"}
{"text": "If ribavirin or peginterferon alfa is discontinued because of adverse effects ( e.g. , anemia ) , boceprevir also must be discontinued .Dermatologic Reactions .", "label": "", "metadata": {}, "score": "44.486885"}
{"text": "Hematologic Effects .Risk of anemia . 1 Concomitant use of boceprevir , peginterferon alfa , and ribavirin has been associated with greater decreases in hemoglobin than use of peginterferon alfa and ribavirin without boceprevir . 1 Increased incidence of adverse reactions consistent with symptoms of anemia ( e.g. , dizziness , dyspnea , syncope ) reported when boceprevir added to peginterferon alfa and ribavirin regimen . 1", "label": "", "metadata": {}, "score": "44.52346"}
{"text": "Superior efficacies of simeprevir and peginterferon plus ribavirin were observed compared to those of peginterferon plus ribavirin alone in treatment - naive [ 49 ] and previously treated patients ( Table 4 ) [ 50 ] .", "label": "", "metadata": {}, "score": "44.547657"}
{"text": "Because telaprevir treatment can lead to resistant mutants over the short term , the long - term use of the drug should be limited .Drug resistant mutants have been found to exhibit the following changes : V36A / M , T54A / S , R155K / T , and A156S / T. Boceprevir is another NS3 protease inhibitor approved at the same time as telaprevir .", "label": "", "metadata": {}, "score": "44.577477"}
{"text": "DAAs .NS3 protease inhibitors : The unique structure and function of NS3 protease in the HCV life cycle makes it a new target for anti - HCV drug development .", "label": "", "metadata": {}, "score": "44.81862"}
{"text": "Differences between genotypes largely were attributable to the higher frequency of post - treatment relapse among patients infected with HCV genotype 3 .In both daclatasvir arms for both HCV genotypes , the lower bound of the 80 % confidence interval of the difference in SVR24 rates between the daclatasvir and placebo arms was above -20 % , establishing noninferiority .", "label": "", "metadata": {}, "score": "44.8797"}
{"text": "Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment - naive patients with hepatitis C genotype-1 infection ( ATOMIC ) : an open - label , randomised , multicentre phase 2 trial .", "label": "", "metadata": {}, "score": "45.08942"}
{"text": "9 Only 3/9 null responders have completed treatment ; the other 6 are being followed .MATTERHORN Phase 2 . Hoffman - La Roche Drugs : danoprevir / r ( boosted protease inhibitor ) with mericitabine ( nucleoside polymerase inhibitor ) with ribavirin Duration : 24 weeks . SVR-12Partial", "label": "", "metadata": {}, "score": "45.1084"}
{"text": "Sofosbuvir was well tolerated in VALENCE and adverse events in LONESTAR-2 were consistent with the safety profile of peg - IFN / RBV .Patients randomized to receive placebo were offered treatment in an alternative protocol .", "label": "", "metadata": {}, "score": "45.174774"}
{"text": "All 12 patients with relapse are being retreated with daclatasvir and sofosbuvir with ribavirin for 24 weeks .HCV is the leading indication for liver transplantation worldwide .", "label": "", "metadata": {}, "score": "45.196884"}
{"text": "In phase I and II clinical studies , the results showed that BI 207127 and VX-222 , regardless of whether they were combined with PegIFN - \u03b1 treatment , can both improve the genotype 1 HCV infection RVR or EVR rate and demonstrate good tolerance .", "label": "", "metadata": {}, "score": "45.36953"}
{"text": "Both are taken once a day orally .The study evaluated the efficacy and safety of the sofosbuvir - ledipasvir fixed - dose combination for 12 weeks in treatment - experienced patients with HCV genotype 1 and advanced fibrosis or cirrhosis .....", "label": "", "metadata": {}, "score": "45.37028"}
{"text": "[PubMed ] [ DOI ] .Jacobson IM , Brown RS , Freilich B , Afdhal N , Kwo PY , Santoro J , Becker S , Wakil AE , Pound D , Godofsky E. Peginterferon alfa-2b and weight - based or flat - dose ribavirin in chronic hepatitis C patients : a randomized trial .", "label": "", "metadata": {}, "score": "45.555965"}
{"text": "Gao M , Nettles RE , Belema M , et al .Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect .", "label": "", "metadata": {}, "score": "45.67907"}
{"text": "C - EDGE is the Phase 3 clinical development program for Merck 's investigational HCV treatment grazoprevir / elbasvir comprising five studies with more than 1,700 patients across more than 25 countries .", "label": "", "metadata": {}, "score": "45.72267"}
{"text": "Abstract LB-3 .Gane EJ , Stedman CJ , Hyland RH et al .Once daily sofosbuvir ( GS-7977 ) regimens in HCV genotype 1 - 3 : The ELECTRON trial .", "label": "", "metadata": {}, "score": "45.75421"}
{"text": "Thus , SVR rates were higher among patients who had previously had relapses than among nonresponders .Response - guided therapy is also useful in the telaprevir - included regimen ( Table 2 ) [ 40 ] .", "label": "", "metadata": {}, "score": "45.862522"}
{"text": "18 - 22 April 2012 , Barcelona , Spain .Abstract 13 .Zeuzem S , Soriano V , Asselah T , et al .Interferon ( IFN)-free combination treatment with the HCV NS3/4A protease inhibitor faldaprevir ( BI 201335 ) and the non - nucleoside NS5B inhibitor BI 207127\u00b1 ribavirin : final results of SOUND - C2 and predictors of response .", "label": "", "metadata": {}, "score": "46.11734"}
{"text": "It is notable that no viral breakthrough or resistance development during therapy has been described .Because of the absence of cross - resistance with the other DAAs , including NS5A inhibitors , sofosbuvir can be used for salvage therapy .", "label": "", "metadata": {}, "score": "46.24848"}
{"text": "Abstract 232 .Gane EJ , Stedman CJ , Hyland RH et al .Once daily sofosbuvir ( GS-7977 ) regimens in HCV genotype 1 - 3 : The ELECTRON trial .", "label": "", "metadata": {}, "score": "46.32905"}
{"text": "Lok et al .12 In this trial , the same combination , plus ribavirin , was given to people with HCV genotypes 1a and 1b .", "label": "", "metadata": {}, "score": "46.400623"}
{"text": "Simeprevir is being studied in phase II interferon - free trials with and without ribavirin in combination with : . -- Janssen 's non - nucleoside inhibitor TMC647055 and ritonavir in treatment - naive genotype 1a and 1b HCV patients ; . -- Gilead Sciences , Inc. 's nucleotide inhibitor sofosbuvir ( GS-7977 ) in treatment - naive and previous null - responder genotype 1 HCV patients ; and .", "label": "", "metadata": {}, "score": "46.558846"}
{"text": "Figure 1 .Treatments for chronic hepatitis C in the present and future .PegIFN , peginterferon ; RBV , ribavirin .Standard of care ( SOC ) treatment for HCV infection .", "label": "", "metadata": {}, "score": "46.609497"}
{"text": "But there are positive trade - offs in using the all - oral combination .....All - Oral Therapy With Sofosbuvir and GS-0938 for 14 Days in Treatment - Naive Geno 1 Hepatitis C ( NUCLEAR ) .", "label": "", "metadata": {}, "score": "46.612995"}
{"text": "N Engl J Med .[PubMed ] [ DOI ] .[PubMed ] [ DOI ] .Krawitt EL , Gordon SR , Grace ND , Ashikaga T , Ray MA , Palmer M , Yarze JC , Moskowitz S. A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol .", "label": "", "metadata": {}, "score": "46.688744"}
{"text": "Phase II clinical study data showed that the treatment with mericitabine combined with PegIFN - \u03b1 and RBV was safe and well tolerated .In the triple regimen for 24 wk , the SVR rate in HCV genotype 1/4 treatment - naive patients was higher than the SOC group [ 46 ] .", "label": "", "metadata": {}, "score": "46.7244"}
{"text": "New standard of care treatment with telaprevir for chronic hepatitis C patients .Table 3 .New standard of care treatment with boceprevir for chronic hepatitis C patients .", "label": "", "metadata": {}, "score": "46.74298"}
{"text": "Among treatment - experienced patients with advanced fibrosis or cirrhosis , previous relapsers are likely to respond very well to telaprevir- or boceprevir - based treatment , although advanced liver disease had a greater influence on SVR rates in previous nonresponders [ 39 , 42 , 62 , 63 ] .", "label": "", "metadata": {}, "score": "46.76465"}
{"text": "Analyses of resistance in vivo and in vitro showed mutations in the amino acid residues L31V / M and Y93H / N. Several other NS5A inhibitors have also entered clinical trials , including ABT-267 , ledipasvir ( GS-5885 ) , ACH-2928 , and IDX791 .", "label": "", "metadata": {}, "score": "46.776566"}
{"text": "A 12-week interferon - free regimen of ABT-450/r , ABT-072 and ribavirin was well tolerated and achieved sustained virologic response in 91 % treatment - naive HCV IL28B CC genotype-1-infected subjects .", "label": "", "metadata": {}, "score": "46.89994"}
{"text": "Thompson A , Shiffman M , Rossaro L , et al .Six weeks of an NS5a inhibitor ( GS-5885 ) and a protease inhibitor ( GS-9451 ) plus peginterferon and ribavirin achieves high SVR4 rates in genotype 1 IL28B CC treatment naive hepatitis C virus patients : interim results of a prospective , randomized trial .", "label": "", "metadata": {}, "score": "47.030144"}
{"text": "Virologic response rates with 150 mg simeprevir ( SMV ) and 400 mg sofosbuvir ( SOF ) q.d .with or without ribavirin ( RBV ) .", "label": "", "metadata": {}, "score": "47.144127"}
{"text": "Cohort 1 of the phase IIa open - label COSMOS study randomized 80 genotype 1 patients into one of four arms including 150 mg of once - daily simeprevir plus 400 mg of sofosbuvir for 24 weeks with or without ribavirin or for 12 weeks with or without ribavirin .", "label": "", "metadata": {}, "score": "47.152153"}
{"text": "In the present clinical trials , in their stead , several second - generation DAAs are being investigated .Most of them are being viewed with high expectations , but they also require the combination with peginterferon plus ribavirin .", "label": "", "metadata": {}, "score": "47.233963"}
{"text": "In the application of the combined treatment of ABT-333 [ non - nucleoside inhibitors ( NNI ) ] , RBV , and ritonavir , the curative effects of different doses of ABT-450 over 12 wk were assessed .", "label": "", "metadata": {}, "score": "47.255516"}
{"text": "Faldaprevir ( BI 201335 ) is an inhibitor of HCV NS3/4A protease and is undergoing phase III clinical trials [ 52 , 53 ] .HCV NS5A and NS5B inhibitors .", "label": "", "metadata": {}, "score": "47.36488"}
{"text": "About AbbVie 's HCV Clinical Development Program AbbVie 's HCV clinical development program is intended to advance scientific knowledge and clinical care by investigating interferon - free , all - oral treatments with and without ribavirin with the goal of achieving high sustained virologic response rates in as many patients as possible .", "label": "", "metadata": {}, "score": "47.406013"}
{"text": "Similar elevations of alanine aminotrans- ferase levels were observed in a separate dose- ranging study of asunaprevir in combination with peginterferon and ribavirin,26 and a lower dose of asunaprevir was selected for ongoing and fu- ture studies .", "label": "", "metadata": {}, "score": "47.584343"}
{"text": "About the COSMOS Trial .COSMOS is a randomized , open - label study investigating the efficacy and safety of 12 or 24 weeks of simeprevir and sofosbuvir with or without ribavirin in HCV genotype 1 patients who are treatment naive or have prior null response to pegylated interferon and ribavirin therapy .", "label": "", "metadata": {}, "score": "47.649017"}
{"text": "Abstract 82 .Hassanein T , Lawitz E , Crespo I , et al ; the ATOMIC Investigators .Once - daily sofosbuvir ( GS-7977 ) plus PEG / RBV in treatment - naive patients with HCV genotype 1 , 4 , and 6 infection : The ATOMIC study .", "label": "", "metadata": {}, "score": "47.714733"}
{"text": "AI447 - 011 Phase 2 .Bristol - Myers Squibb Drugs : daclatasvir ( NS5a inhibitor ) with asunaprevir ( protease inhibitor ) once - or twice - daily with peginterferon and ribavirin ( QUAD ) .", "label": "", "metadata": {}, "score": "47.750565"}
{"text": "AASLD also brought good news for treatment - experienced people with HCV genotype 1 ( see Table 3 .Update : Interferon - free regimens in HCV genotype 1 , treatment - experienced ) .", "label": "", "metadata": {}, "score": "47.800705"}
{"text": "Abstract LB-9 .Muir A , Hilson J , Gray T , et al ; EMERGE Study Group .Peginterferon lambda-1a ( lamdba ) compared with peginterferon alfa-2a ( alfa ) in treatment naive patients with HCV genotypes 1 or 4 : SVR24 results from EMERGE phase 2b .", "label": "", "metadata": {}, "score": "47.803604"}
{"text": "The INFORM - SVR study provided SVR data for the combination of mericitabine and danoprevir / ritonavir with or without RBV for 12 - 24 wk .", "label": "", "metadata": {}, "score": "47.811783"}
{"text": "The ALLY-1 study is the third study to report out of the Phase III ALLY program , which evaluates daclatasvir in combination with sofosbuvir in multiple high - unmet need patient populations and is at the center of Bristol - Myers Squibb 's HCV research focus .", "label": "", "metadata": {}, "score": "47.839603"}
{"text": "Fetal / Neonatal Morbidity and Mortality .Boceprevir must be used in conjunction with peginterferon alfa and ribavirin . 1 Ribavirin may cause birth defects and/or fetal death ; 1 interferons may have abortifacient effects in humans .", "label": "", "metadata": {}, "score": "47.95764"}
{"text": "In genotype 6 , 100 % of 5 people had an SVR-12 .No relapses were reported between weeks 12 and 24 .Adding an HCV protease inhibitor to peginterferon and ribavirin boosted SVR and shortened treatment duration for 30 non - cirrhotic , treatment - naive people with HCV genotype 4 .", "label": "", "metadata": {}, "score": "48.096176"}
{"text": "June 6 Hepatitis C : The Pace of Progress In recently published studies , [ 9 ] sofosbuvir combined with ribavirin alone was shown to be effective for hepatitis C genotype 2 and 3 and possibly genotype 1 .", "label": "", "metadata": {}, "score": "48.17727"}
{"text": "J Gastroenterol Hepatol .[PubMed ] [ DOI ] .Hadziyannis SJ , Sette H , Morgan TR , Balan V , Diago M , Marcellin P , Ramadori G , Bodenheimer H , Bernstein D , Rizzetto M. Peginterferon - alpha2a and ribavirin combination therapy in chronic hepatitis C : a randomized study of treatment duration and ribavirin dose .", "label": "", "metadata": {}, "score": "48.232834"}
{"text": "Victrelis Dosage and Administration .General .Must be used in conjunction with peginterferon alfa and ribavirin ; do not use as monotherapy .After an initial 4-week regimen ( lead - in ) of peginterferon alfa and ribavirin , add boceprevir to the regimen for total treatment duration that depends on presence of cirrhosis , prior treatment experience , and current treatment response ( response - guided therapy ) . 1", "label": "", "metadata": {}, "score": "48.29012"}
{"text": "\" The first agent reported in this class , daclatasvir , demonstrated rapid and profound HCV RNA suppression after a single dose administered as monotherapy [ 51].", "label": "", "metadata": {}, "score": "48.3376"}
{"text": "In recent years , PegIFN - \u03bb-1 has been confirmed to have anti - HCV activity and mild adverse reactions [ 20 ] .One clinical trial assessed the efficacy and safety of PegIFN - \u03bb-1a plus RBV compared to the SOC for the treatment of naive patients with HCV genotypes 2/3 .", "label": "", "metadata": {}, "score": "48.34187"}
{"text": "The most common adverse reactions are nausea , fatigue and hyperbilirubinemia , which are generally mild and reversible .The resistance mutations include Q8 K and R155K. Faldaprevir is a second - generation HCV NS3/4A protease inhibitor .", "label": "", "metadata": {}, "score": "48.42337"}
{"text": "Six patients had transient elevations of alanine aminotransferase levels to more than 3 times the upper limit of the normal range .This preliminary study involving patients with HCV genotype 1 infection who had not had a response to prior therapy showed that a sustained virologic response can be achieved with two direct - acting antiviral agents only .", "label": "", "metadata": {}, "score": "48.45497"}
{"text": "Preliminary data from studies of such oral DAA regimens in HIV / HCV coinfected patients suggest that coinfection with HIV will not impair HCV cure with these regimens .", "label": "", "metadata": {}, "score": "48.527637"}
{"text": "Kowdley et al .5 Regimen slightly more effective in G1b vs. G1a , and for IL28b CC vs. non - CC .AI447 - 011 Phase Bristol - Myers Squib Drugs : daclatasvir ( NS5a inhibitor ) with asunaprevir ( protease inhibitor ) , once- or twice - daily .", "label": "", "metadata": {}, "score": "48.57769"}
{"text": "Sofosbuvir ( formerly referred to as GS-7977 ) is a once - daily nucleotide analog polymerase inhibitor for the treatment of HCV infection being developed by Gilead Sciences .", "label": "", "metadata": {}, "score": "48.59789"}
{"text": "In patients who have never received treatment for hepatitis C , or na\u00efve patients , and have genotypes 1 , 4 , 5 and 6 , the oral drug would be used in combination with peg - interferon and ribavirin .", "label": "", "metadata": {}, "score": "48.61149"}
{"text": "Multiple ascending dose study of BMS- 790052 , a nonstructural protein 5A repli- cation complex inhibitor , in patients in- fected with hepatitis C virus genotype 1 .", "label": "", "metadata": {}, "score": "48.90722"}
{"text": "Table 4 .New standard of care treatment with other drugs ( second - generation DAAs ) chronic hepatitis C patients .MK-5172 , a novel P2-P4 quinoxaline macrocyclic peptide , maintained potency across a genetically diverse panel of genotype 1a and 1b sequences from plasma of HCV - infected patients .", "label": "", "metadata": {}, "score": "48.9944"}
{"text": "Nonetheless , these results suggest that these drugs can be co - administered with sofosbuvir , though careful monitoring in clinical trials is still warranted .", "label": "", "metadata": {}, "score": "49.11032"}
{"text": "3- but not 2-infected patients treated with 12 weeks of pegylated interferon - \u03b1-2a plus ribavirin and RVR .J Viral Hepat .[", "label": "", "metadata": {}, "score": "49.233746"}
{"text": "Abstract 1869 .Ouwerkerk - Mahadevan S , Simion A , Mortier S , et al .No clinically significant interaction between the investigational HCV protease inhibitor TMC435 and the immunosuppressives cyclosporine and tacrolimus .", "label": "", "metadata": {}, "score": "49.336365"}
{"text": "SVR-12 , 65 % ( 13/20 ) to 78 % ( 14/18 ) for once- versus twice - daily asunaprevir .Enrollment in asunaprevir / daclatasvir arms limited to G1b due to lack of efficacy in G1a .", "label": "", "metadata": {}, "score": "49.391235"}
{"text": "Six patients had transient elevations of alanine aminotrans- ferase levels to more than 3 times the upper limit of the normal range .Conclusions This preliminary study involving patients with HCV genotype 1 infection who had not had a response to prior therapy showed that a sustained virologic response can be achieved with two direct - acting antiviral agents only .", "label": "", "metadata": {}, "score": "49.47724"}
{"text": "Bifano M , Sevinsky H , Bedford BR , et al .Coadministration of BMS-790052 and BMS-650032 does not result in a clinically meaningful pharmacokinetic interaction in healthy subjects .", "label": "", "metadata": {}, "score": "49.520454"}
{"text": "Further research is necessary to develop an even higher SVR rate -- possibly 100 percent .Combination therapy with polymerase inhibitors is one way .Combination of these DAAs with peg - interferon ( or interferon lambda ) with or without ribavirin should be considered for patients with multi - drug resistance .", "label": "", "metadata": {}, "score": "49.592255"}
{"text": "Coadministration of Harvoni is not recommended with simeprevir due to increased concentrations of ledipasvir and simeprevir .Coadministration is also not recommended with rosuvastatin or co - formulated elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate due to increased concentrations of rosuvastatin and tenofovir , respectively .", "label": "", "metadata": {}, "score": "49.705757"}
{"text": "The purpose of this paper is to provide an overview of the clinical results recently reported for the treatment of hepatitis C virus infection with interferon - free regimens , focusing on the most promising new compounds and combinations .", "label": "", "metadata": {}, "score": "49.77977"}
{"text": "ture 2009;461:399 - 401 .Zeuzem S , Buggisch P , Agarwal K , et al .Dual , triple , and quadruple combina- tion treatment with a protease inhibitor ( GS-9256 ) and a polymerase inhibitor ( GS-9190 ) alone and in combination with ribavirin ( RBV ) or PegIFN / RBV for up to 28 days in treatment naive , genotype 1 HCV subjects .", "label": "", "metadata": {}, "score": "49.83574"}
{"text": "Many clinical studies have compared the SVR rates in patients receiving different PegIFN - \u03b1 ( e.g . , IFN - \u03b1-2a and IFN - \u03b1-2b ) , dosages , and treatment durations .", "label": "", "metadata": {}, "score": "49.8603"}
{"text": "\" [ Show abstract ] [ Hide abstract ] ABSTRACT : Daclatasvir ( DCV ) is an approved NS5A inhibitor with potent anti - HCV activity and broad genotype coverage .", "label": "", "metadata": {}, "score": "49.86666"}
{"text": "Two HCV Drugs to Be Discontinued The Food and Drug Administration ( FDA ) announced that Rebetol ( ribavirin ; Merck ) capsules and PegIntron ( peginterferon alfa-2b ; Merck ) for Injection are being discontinued .", "label": "", "metadata": {}, "score": "49.898438"}
{"text": "Characterization of human liver enzymes involved in the biotransformation of boceprevir , a hepatitis C virus protease inhibitor .Drug Metab Dispos .[ PubMed 21123164 ] .", "label": "", "metadata": {}, "score": "49.936028"}
{"text": "N Engl J Med .[PubMed ] [ DOI ] .Sherman KE , Flamm SL , Afdhal NH , Nelson DR , Sulkowski MS , Everson GT , Fried MW , Adler M , Reesink HW , Martin M. Response - guided telaprevir combination treatment for hepatitis C virus infection .", "label": "", "metadata": {}, "score": "50.132305"}
{"text": "The aim of this study was to describe cancer rates in our cohort of HCV patients compared to cancer rates in the non - HCV population .", "label": "", "metadata": {}, "score": "50.41237"}
{"text": "ADVANCES IN ANTIVIRAL TREATMENT .Interferon .PegIFN- \u03b1 : When administered as a once - a - week injection , PegIFN - \u03b1 increased the SVR rate and compliance in patients by delaying renal clearance to extend the in vivo half - life by cross - linking polyethylene glycol and interferon - \u03b1 .", "label": "", "metadata": {}, "score": "50.426407"}
{"text": "The common adverse responses of ABT-450 include fatigue , pain , hyperbilirubinemia , and vomiting .There are many other NS3 protease inhibitors in clinical studies , such as asunaprevir ( BMS 650032 ) , vaniprevir ( MK-7009 ) , narlaprevir ( SCH 900518 ) , VX 985 , and MK-5172 .", "label": "", "metadata": {}, "score": "50.46042"}
{"text": "1 Oral contraceptives containing drospirenone contraindicated in patients receiving boceprevir . 1 ( See Specific Drugs under Interactions . )Hypersensitivity Reactions .Serious acute hypersensitivity reactions , including urticaria and angioedema , reported .", "label": "", "metadata": {}, "score": "50.580627"}
{"text": "[PubMed ] [ DOI ] .Lagging M , Langeland N , Pedersen C , F\u00e4rkkil\u00e4 M , Buhl MR , M\u00f8rch K , Dhillon AP , Alsi\u00f6 A , Hellstrand K , Westin J. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection .", "label": "", "metadata": {}, "score": "50.63844"}
{"text": "The treatments tested with and without the older drug ribavirin led to cure rates of 96 percent to 100 percent , according to interim data from a small midstage clinical trial .", "label": "", "metadata": {}, "score": "50.642902"}
{"text": "Daclatasvir is a potent NS5A replication complex inhibitor and increases the antiviral potency of peginterferon and ribavirin [ 55 ] ( Tables 4 ) .Table 5 .", "label": "", "metadata": {}, "score": "50.727333"}
{"text": "Another study showed that sofosbuvir combined with RBV resulted in a SVR rate of 84 % in genotype 1 treatment - naive patients and 100 % in patients with genotype 2/3 [ 57 ] .", "label": "", "metadata": {}, "score": "50.728817"}
{"text": "Unlike telaprevir , boceprevir is started at week 4 of treatment , following a 4-wk lead - in period of treatment with peg - IFN and RBV , and RBV is required to enhance the efficacy of boceprevir [ 29 ] .", "label": "", "metadata": {}, "score": "50.88464"}
{"text": "Among the previous treatment failure patients , the telaprevir triple therapy group had a higher SVR rate than that of the SOC group , but the overall effect was poor , especially for non - responders , with an SVR rate of 29%-33 % [ 28 ] .", "label": "", "metadata": {}, "score": "50.88492"}
{"text": "Gilead Sciences Phase 2 .Drugs : GS-5885 ( NS5a inhibitor ) with GS-9451 ( protease inhibitor ) with peginterferon and ribavirin .Duration : 6 or 12 weeks .", "label": "", "metadata": {}, "score": "50.89476"}
{"text": "As expected in the case of a cohort of patients who did not have a response to prior treatment with peginter- feron and ribavirin , genotyping of the IL28B rs12979860", "label": "", "metadata": {}, "score": "50.921112"}
{"text": "Abstract 760 .Rodriguez - Torres M , Ishak L , Fontana D , et al ; EMERGE Study Group .Peginterferon lambda-1a ( LAMBDA ) shows superior viral response with improved safety and tolerability versus peginterferon alfa-2a ( alfa-2a ) in patients with chronic HCV infection ( G 1/2/3/4 ) : EMERGE phase 2b through week 12 results . 22nd", "label": "", "metadata": {}, "score": "51.082558"}
{"text": "Merck 's ' breakthrough ' hep C combo plays catch - up Now its combination of MK-5172 , an NS3/4A protease inhibitor , and the NS5A treatment MK-8742 produced cure rates ranging from 96 % to 100 % among small groups of genotype 1a and 1b patients .", "label": "", "metadata": {}, "score": "51.12397"}
{"text": "Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers .Hepatology .[ PubMed 22576324 ] .Vicenti I , Rosi A , Saladini F et al .", "label": "", "metadata": {}, "score": "51.178993"}
{"text": "Preventive measures against HCV , including vaccine development , are now in progress [ 13 ] .Rash also occurs in 56 % of patients treated with NSOC , compared to 34 % of patients treated with SOC alone .", "label": "", "metadata": {}, "score": "51.2987"}
{"text": "The results showed that the telaprevir triple therapy for 24 wk yielded a higher SVR rate than the SOC [ 22 , 24 - 26 ] .", "label": "", "metadata": {}, "score": "51.38022"}
{"text": "Clin Gastroenterol Hepatol .[PubMed ] [ DOI ] The following off - label uses are discussed : simeprevir , sofosbuvir , daclatasvir , asunaprevir , ABT-450 , ABT-267 , MK-5172 , MK-8742 , faldaprevir , deleobuvir , PPI-668 , and ledipasvir .... Begin Here ........... .", "label": "", "metadata": {}, "score": "51.585617"}
{"text": "For patients who had viral breakthrough , HCV RNA levels are shown up to the time rescue therapy was initiated .In one patient , HCV RNA levels were less than the lower limit of quantifi- cation ( LLOQ ; 25 IU per milliliter ) at post - treatment ( PT ) week 48 ( asterisk ) and were undetectable on retesting 43 days later .", "label": "", "metadata": {}, "score": "51.81198"}
{"text": "In parallel to these trials , phase III studies for simeprevir are ongoing in treatment - naive and treatment - experienced HIV - HCV co - infected patients , HCV genotype 4 patients and Japanese HCV genotype 1 patients .", "label": "", "metadata": {}, "score": "51.826057"}
{"text": "Therefore , regimens that shorten duration of pegylated interferon and/or ribavirin or substitute peginterferon lambda ( a potentially more tolerable type of interferon ) for peginterferon alfa , are moving forward ( see Table 4 .", "label": "", "metadata": {}, "score": "51.872826"}
{"text": "[PubMed ] [ DOI ] .Malaguarnera M , Vacante M , Giordano M , Motta M , Bertino G , Pennisi M , Neri S , Malaguarnera M , Li Volti G , Galvano F. L - carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon - \u03b1 2b plus ribavirin .", "label": "", "metadata": {}, "score": "51.87929"}
{"text": "Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepati- tis C. Gastroenterology 2010;138:108 - 15 .McHutchison JG , Lawitz EJ , Shiffman ML , et al .", "label": "", "metadata": {}, "score": "51.91073"}
{"text": "1 Cohort 1 consists of 20 patients without cirrhosis and cohort 2 will evaluate approximately 20 patients with or without compensated cirrhosis .Ribavirin was started at 200 mg once daily for all genotype 1a ( GT1a)- infected patients and dosed four hours prior to the start of GT1a patients on hemodialysis .", "label": "", "metadata": {}, "score": "51.939297"}
{"text": "Simeprevir , an investigational NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB , is currently in late phase III studies as a once - daily capsule ( 150 mg ) taken in combination with pegylated interferon and ribavirin for the treatment of genotypes 1 and 4 HCV .", "label": "", "metadata": {}, "score": "52.1192"}
{"text": "Resistance An analysis of samples from the six patients in group A with viral breakthrough showed that there were no resistance variants at baseline and that resistance variants to both daclatasvir and asunaprevir had emerged in all cases by the time of viral breakthrough .", "label": "", "metadata": {}, "score": "52.194878"}
{"text": "Advice to Patients .Importance of using boceprevir in conjunction with ribavirin and peginterferon alfa ; not for monotherapy .Importance of proper storage ; refrigerate until expiration date or store at room temperature for up to 3 months . 1 Advise patient that each bottle contains capsules for one full day of treatment .", "label": "", "metadata": {}, "score": "52.358696"}
{"text": "Safety Information Ombitasvir , paritaprevir , and ritonavir ( OBV / PTV / r ) and RBV are not approved for the investigational use discussed above , and no conclusions can or should be drawn regarding the safety or efficacy of these products for this use .", "label": "", "metadata": {}, "score": "52.386795"}
{"text": "The mechanism behind the findings has not been established .More about the medicine .Harvoni , Sovaldi and Daklinza are among several novel hepatitis C treatments recently evaluated by EMA , which are available as tablets .", "label": "", "metadata": {}, "score": "52.411354"}
{"text": "63rd AASLD , 2012 , Boston .Abstract 51 .Gallegos - Orozco JF , Chervenak AE , Carey EJ , et al .Liver transplant center focused experience with peginterferon alfa-2a , ribavirin and telaprevir therapy in patients with genotype 1 hepatitis C cirrhosis .", "label": "", "metadata": {}, "score": "52.559105"}
{"text": "From FDA website .Accessed 2012 Apr 23 .Food and Drug Administration .FDA drug safety communication : Updated information on drug interactions between Victrelis ( boceprevir ) and certain boosted HIV protease inhibitor drugs .", "label": "", "metadata": {}, "score": "52.71979"}
{"text": "Paritaprevir has been developed by AbbVie for use in combination with AbbVie 's other investigational medicines for the treatment of chronic hepatitis C. .About AbbVie 's HCV Clinical Development Program The AbbVie HCV clinical development program is intended to advance scientific knowledge and clinical care by investigating interferon - free , all - oral treatments with or without ribavirin with the goal of achieving high sustained virologic response rates in as many patients as possible .", "label": "", "metadata": {}, "score": "52.722565"}
{"text": "In late November 2012 , Gilead Sciences issued the somewhat disappointing top - line results from POSITRON , a 278-person , interferon - free phase III trial in HCV genotypes 2 and 3 .", "label": "", "metadata": {}, "score": "52.81168"}
{"text": "AbbVie 's regimen is the first all - oral , interferon - free therapy being evaluated by the FDA for patients in the United States with chronic GT4 HCV infection .", "label": "", "metadata": {}, "score": "52.972504"}
{"text": "NS5A inhibitors : NS5A is an essential viral component of the membrane - associated HCV replication complex and plays an important role in the formation of HCV infectious particles .", "label": "", "metadata": {}, "score": "53.05357"}
{"text": "MATTERHORN Phase 2 . Hoffman - La Roche Drugs : danoprevir / r ( boosted protease inhibitor ) with peginterferon and ribavirin ( triple therapy ) with or without mericitabine ( nucleoside polymerase inhibitor ) ( QUAD )", "label": "", "metadata": {}, "score": "53.059036"}
{"text": "Although SVR-12 and SVR-24 are primary outcomes for interferon - free trials , monitoring for late relapse will continue .Results from trials in both treatment - naive and treatment experienced people with HCV genotypes 2 and 3 were presented at AASLD ( see Table 5 .", "label": "", "metadata": {}, "score": "53.061806"}
{"text": "The HCV NS3 pro- tease domain and the NS5A domain were ana- lyzed by means of population sequencing and clonal analysis .Secondary efficacy end points included the proportions of patients with undetectable HCV RNA at weeks 4 , 12 , and 24 during the treatment period and at weeks 24 and 48 after the end of the treatment period .", "label": "", "metadata": {}, "score": "53.178318"}
{"text": "Peginterferon lambda may be a good option for people with HCV genotype 4 , if phase III trials confirm the favourable side effect profile seen in phase 2 .", "label": "", "metadata": {}, "score": "53.25081"}
{"text": "Peginterferon - alpha2a and riba- virin combination therapy in chronic hepatitis C : a randomized study of treat- ment duration and ribavirin dose .Ann Intern Med 2004;140:346 - 55 .", "label": "", "metadata": {}, "score": "53.259624"}
{"text": "Table 6 .New drugs for the treatment of hepatitis C in phase III study ( combinations with peginterferon plus ribavirin , or DAA combinations ) .", "label": "", "metadata": {}, "score": "53.316444"}
{"text": "Although these drugs are potent inhibitors of HCV replication , they occasionally result in severe adverse events .In the present clinical trials , in their stead , several second - generation DAAs are being investigated .", "label": "", "metadata": {}, "score": "53.40067"}
{"text": "[PubMed ] [ DOI ] .Zeuzem S , Andreone P , Pol S , Lawitz E , Diago M , Roberts S , Focaccia R , Younossi Z , Foster GR , Horban A. Telaprevir for retreatment of HCV infection .", "label": "", "metadata": {}, "score": "53.480324"}
{"text": "Establishment of NS5A variability in treatment - naive patients with HCV genotype 4 infection and a case study of the dynamics of resistance - associated variants in a virologic failure receiving pIFN / RBV+DCV , as assessed by ultra - deep sequencing .", "label": "", "metadata": {}, "score": "53.51429"}
{"text": "Many patients also have contraindications to pegylated interferon .Faldaprevir is a protease inhibitor , and deleobuvir is a polymerase inhibitor .There were no significant differences in sustained virologic response according to treatment duration or deleobuvir dosage .", "label": "", "metadata": {}, "score": "53.524536"}
{"text": "Of Interest July / August 2013 Pipeline Oral HCV Drugs and Generic Global Access to DAAs : The Need to Mirror ARV Programs By Simon Collins From HIV i - Base Predicted generic costs for ribavirin and four DAAs ....... 15 year deferred timeline unacceptable .......", "label": "", "metadata": {}, "score": "53.684807"}
{"text": "RGT principles are also applied to NS3 protease inhibitors .For HCV genotype 1 naive patients , using telaprevir or boceprevir combined with SOC and having acquired RVR and EVR , shortening the duration can be considered , but for patients with liver cirrhosis , a recommended treatment for 48 wk would be appropriate .", "label": "", "metadata": {}, "score": "53.701965"}
{"text": "Simeprevir ( TMC435 ) is an investigational HCV NS3/4A protease inhibitor administered orally once daily , and it is currently in phase III clinical development [ 48 ] .", "label": "", "metadata": {}, "score": "53.73246"}
{"text": "[PubMed ] [ DOI ] .Schiff E , Poordad E , Jacobson I , Flamm S , Bacon B , Lawitz E , Gordon S , McHutchison J , Ghalib R , Poynard T. Boceprevir ( B ) combination therapy in null responders ( NR ) : Response dependent on interferon responsiveness .", "label": "", "metadata": {}, "score": "53.787453"}
{"text": "Additionally , the Company has created a new class of antibiotics , called Bicyclolides , which overcomes bacterial resistance .Antibacterial focus areas include overcoming resistance to superbugs , treating respiratory tract infections , and developing intravenous and oral treatments for hospital and community MRSA infections .", "label": "", "metadata": {}, "score": "53.847862"}
{"text": "[PubMed ] [ DOI ] .J Hepatol .[PubMed ] [ DOI ] .Shiffman ML , Suter F , Bacon BR , Nelson D , Harley H , Sol\u00e1 R , Shafran SD , Barange K , Lin A , Soman A. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 .", "label": "", "metadata": {}, "score": "53.930523"}
{"text": "The application of many HCV antiviral drugs provides clinicians with more effective treatment choices for CHC .Host genetic factors guide individualized treatment strategies and aid in determining the best treatment plan for each patient .", "label": "", "metadata": {}, "score": "54.053246"}
{"text": "Fried MW , Shiffman ML , Reddy KR , et al .Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection .N Engl J Med 2002;347:975 - 82 .", "label": "", "metadata": {}, "score": "54.077553"}
{"text": "History of hypersensitivity reaction to boceprevir . 1 ( See Hypersensitivity Reactions under Cautions . ) 1 ( See Specific Drugs under Interactions . )Concomitant use with potent inducers of CYP3A4/5 , where substantially reduced plasma boceprevir concentrations may be associated with reduced efficacy ( e.g. , carbamazepine , phenobarbital , phenytoin , rifampin , St. John 's wort [ Hypericum perforatum ] ) . 1 ( See Specific Drugs under Interactions . )", "label": "", "metadata": {}, "score": "54.174507"}
{"text": "WATERTOWN , Mass. , April .Oral presentations will discuss Phase 2 results from \" Pilot \" and \" Co - Pilot \" , which investigated two different interferon - free combination regimens containing ABT-450 , the lead candidate from Enanta 's collaborative HCV protease inhibitor program with Abbott .", "label": "", "metadata": {}, "score": "54.203884"}
{"text": "\" In the current study , most events of diarrhoea were grade 1/2 , and none led to treatment discontinuation .In the current study , incidences of grade 3/4 aminotransferase elevations were higher with asunaprevir , but there were no associated signs or symptoms of liver decompensation and no patients met the criteria for possible drug - induced liver injury ( pDILI ) .", "label": "", "metadata": {}, "score": "54.237724"}
{"text": "Food and Drug Administration .FDA drug safety communication : Important drug interactions between Victrelis ( boceprevir ) and ritonavir - boosted human immunodeficiency virus ( HIV ) protease inhibitor drugs .", "label": "", "metadata": {}, "score": "54.277267"}
{"text": "In treatment naive people with HCV genotypes 2 and 3 , interferon - free regimens offer the advantage of improved tolerability and ease of administration .", "label": "", "metadata": {}, "score": "54.443356"}
{"text": "Total Treatment Duration .Treatment - naive ( not detected / not detected ) .Weeks 1 - 4 : Peginterferon alfa and ribavirin ; Weeks 5 - 28 : Boceprevir , peginterferon alfa , and ribavirin .", "label": "", "metadata": {}, "score": "54.543526"}
{"text": "Three patients experienced virologic breakthrough on treatment , all in the beclabuvir 150-mg treatment group .Beclabuvir was well tolerated at both doses , with the most commonly observed adverse events ( headache , fatigue , nausea , decreased appetite , irritability , depression and insomnia ) consistent with those observed with pegIFN / RBV .", "label": "", "metadata": {}, "score": "54.607468"}
{"text": "These data suggest that new therapeutic strategies are necessary for this subgroup of HCV genotype 3 [ 59 , 78 ] .In patients with these factors , either the treatment duration may need to be extended or the dose may need to be increased .", "label": "", "metadata": {}, "score": "54.81609"}
{"text": "J Hep- atol 2008;48:Suppl 2:S46 . abstract .Zeuzem S , Andreone P , Pol S , et al .Telaprevir for retreatment of HCV infec- tion .", "label": "", "metadata": {}, "score": "54.950558"}
{"text": "Low dose ritonavir , which is part of VIEKIRAX , may select for PI resistance in HIV co - infected patients without ongoing antiretroviral therapy .", "label": "", "metadata": {}, "score": "54.97151"}
{"text": "The SVR rate in the group given danoprevir 600 mg q12h was the highest at up to 85 % , whereas the group receiving the SOC had a SVR rate of 42 % .", "label": "", "metadata": {}, "score": "55.23718"}
{"text": "Prior null response ( any / not detected ) .Weeks 1 - 4 : Peginterferon alfa and ribavirin ; Weeks 5 - 48 : Boceprevir , peginterferon alfa , and ribavirin .", "label": "", "metadata": {}, "score": "55.399445"}
{"text": "Treatment - naive ( detected / not detected ) .Weeks 1 - 4 : Peginterferon alfa and ribavirin ; Weeks 5 - 36 : Boceprevir , peginterferon alfa , and ribavirin ; Weeks 37 - 48 : Peginterferon alfa and ribavirin .", "label": "", "metadata": {}, "score": "55.692863"}
{"text": "[PubMed ] [ DOI ] .Bacon BR , Gordon SC , Lawitz E , Marcellin P , Vierling JM , Zeuzem S , Poordad F , Goodman ZD , Sings HL , Boparai N. Boceprevir for previously treated chronic HCV genotype 1 infection .", "label": "", "metadata": {}, "score": "55.755234"}
{"text": "[PubMed ] [ DOI ] .Hepatology .[PubMed ] [ DOI ] .Poordad F , Bronowicki JP , Gordon SC , Zeuzem S , Jacobson IM , Sulkowski MS , Poynard T , Morgan TR , Burroughs M , Sniukiene V. Il28b Polymorphism Predicts Virologic Response in Patients with Hepatitis C Genotype 1 Treated with Boceprevir ( Boc ) Combination Therapy .", "label": "", "metadata": {}, "score": "55.776993"}
{"text": "( 8 GT 1a , 3 GT 1b ) .Ribavirin 1000 - 1200 mg / day was weight - based and dosed twice daily .", "label": "", "metadata": {}, "score": "55.819687"}
{"text": "Steatosis has been associated with significantly higher rates of relapse , irrespective of viral load , in patients infected with HCV genotype 3 who had a rapid virological response ( RVR ) [ 78 ] .", "label": "", "metadata": {}, "score": "56.021492"}
{"text": "[PubMed ] [ DOI ] .Suppiah V , Moldovan M , Ahlenstiel G , Berg T , Weltman M , Abate ML , Bassendine M , Spengler U , Dore GJ , Powell E. IL28B is associated with response to chronic hepatitis C interferon - alpha and ribavirin therapy .", "label": "", "metadata": {}, "score": "56.173676"}
{"text": "Thus , SVR-12 became the new primary outcome for clinical trials studying peginterferon - based regimens .The hunger for information about cure rates from interferon - free regimens has led to earlier reporting of results ; SVR-4 ( undetectable HCV RNA four weeks after finishing treatment ) is now commonly used .", "label": "", "metadata": {}, "score": "56.246326"}
{"text": "[ PubMed 21924672 ] .Ghany MG , Nelson DR , Strader DB et al .An update on treatment of genotype 1 chronic hepatitis C virus infection : 2011 practice guideline by the American Association for the Study of Liver Diseases .", "label": "", "metadata": {}, "score": "56.299416"}
{"text": "Those at high risk of bradyarrhythmia should be monitored in an appropriate clinical setting for 48 hours after starting concomitant treatment .Due to its long half - life , patients who have discontinued amiodarone within the past few months should also be monitored when starting hepatitis C treatment with Harvoni or Sovaldi plus Daklinza .", "label": "", "metadata": {}, "score": "56.31382"}
{"text": "As part of the agreement , Vertex plans to conduct two Phase 2 studies of the combination , including an initial study in treatment - naive people with genotype 1 hepatitis C virus , planned for the second quarter .", "label": "", "metadata": {}, "score": "56.358658"}
{"text": "Ribavirin monotherapy is not effective for the treatment of chronic hepatitis C virus and must not be used alone for this use .Ribavirin causes significant teratogenic effects and must not be used in women who are pregnant or breast - feeding and in men whose female partners are pregnant .", "label": "", "metadata": {}, "score": "56.380356"}
{"text": "In a multivariate regression model , the IL28B polymorphism was the best predictor of treatment response , being better than the ethnic background , baseline viral load , degree of liver fibrosis , fasting glucose level , BMI , and other predictors [ 66 ] .", "label": "", "metadata": {}, "score": "56.39173"}
{"text": "A higher homocysteine level is also one of factors predicting a nonresponse to treatment [ 28 ] .IL28B SNPs help to improve the treatment outcomes in HCV - patients treated with SOC [ 29 - 34 ] .", "label": "", "metadata": {}, "score": "56.491074"}
{"text": "No forward - looking statement can be guaranteed .Among other risks , there can be no guarantee that daclatasvir will receive regulatory approval in the United States , or if approved , that it will become a commercially successful product .", "label": "", "metadata": {}, "score": "56.511425"}
{"text": "All - oral , IFN - free therapies are an evolutionary step for future anti-HCV therapies .Initial results of clinical studies conducted during the last year give hope for \" a pill for HCV \" at least in selected CHC populations .", "label": "", "metadata": {}, "score": "56.51732"}
{"text": "-74 .Ghany M , Nelson DR , Strader DB , Thomas DL , Seeff LB .An update on treat- ment of genotype 1 chronic hepatitis C virus infection : 2011 practice guideline by the American Association for the Study of Liver Diseases .", "label": "", "metadata": {}, "score": "56.52307"}
{"text": "[PubMed ] [ DOI ] .Cummings MD , Lindberg J , Lin TI , de Kock H , Lenz O , Lilja E , Fell\u00e4nder S , Baraznenok V , Nystr\u00f6m S , Nilsson M. Induced - fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target .", "label": "", "metadata": {}, "score": "56.600723"}
{"text": "Sovaldi is used in combination with other agents and its efficacy has been established in patients with genotypes 1 - 4 ; Harvoni is indicated for patients with genotype 1 .", "label": "", "metadata": {}, "score": "56.678883"}
{"text": "They adjusted the analyses for age , sex , body mass index , presence or absence of cirrhosis or diabetes , baseline alanine aminotransferase and \u03b3 - glutamyl transferase levels , viral subtype , IL28B genotype , and baseline HCV RNA level .", "label": "", "metadata": {}, "score": "56.684723"}
{"text": "Only 14 % discontinued treatment for adverse events , but most participants required dose reductions of peginterferon , ribavirin or both drugs and/or growth factors , and 48 % required blood transfusions .", "label": "", "metadata": {}, "score": "56.69005"}
{"text": "The aim of the study was to describe the rates of all cancers in the cohort of HCV patients compared to the non - HCV population .", "label": "", "metadata": {}, "score": "56.759315"}
{"text": "Refer to the prescribing information for ribavirin .Use with Potent P - gp Inducers : Rifampin and St. John 's wort should not be used with Sovaldi as they may significantly decrease sofosbuvir plasma concentration , reducing its therapeutic effect .", "label": "", "metadata": {}, "score": "56.76405"}
{"text": "Both regimens more effective in G1b : 93 % ( 13/14 ) of G1b in the daclatasvir group vs. 65 % ( 15/23 of G1a ; 91 % ( 10/11 ) of G1b in the asunaprevir group vs. 67 % ( 14/21 ) of G1a .", "label": "", "metadata": {}, "score": "56.8151"}
{"text": "47 percent ( 8 of 17 ) of patients with HCV GT1( 16 GT1a , 1 GT1b ) who had previously not responded to other HCV treatments achieved SVR12 with ABT 450/r 150/100 mg QD + ABT-333 400 mg BID + ribavirin ( Arm 3 ) .", "label": "", "metadata": {}, "score": "56.833572"}
{"text": "Ribavirin is dosed twice daily .The application with the clinical trial data has been submitted to the FDA .It is estimated that the two - drug combination will be approved by the FDA by the end of 2013 or early 2014 .", "label": "", "metadata": {}, "score": "56.882004"}
{"text": "We tested the clinical significance of quantitative total and IgM - anti - HBc in well characterized chronic - HBsAg - carriers .In 35 patients treated with Peg - IFN\u00b1nucleos(t)ide - analogues ( NUCs ) sera were obtained at baseline , end - of - therapy and week-24-off - therapy and in 22 treated with NUCs ( for 60 months , 42 - 134 m ) at baseline and end - of - follow - up . HBsAg and IgM - anti - HBc were measured by Architect - assays ( Abbott , USA ) ; total - anti - HBc by double - antigen - sandwich - immune - assay ( Wantai , China ) ; HBV - DNA by COBAS - TaqMan ( Roche , Germany ) .", "label": "", "metadata": {}, "score": "56.97326"}
{"text": "Information about safety , efficacy and tolerability of interferon - free regimens is needed in other groups , including people coinfected with HIV , liver transplant candidates and recipients , and people with cirrhosis ( especially those who are treatment - experienced ) .", "label": "", "metadata": {}, "score": "57.006004"}
{"text": "In the near future , all - oral DAAs will treat HCV - infected patients ( Figure 1 ) .Conclusions .We expect that all - oral DAAs and interferon - free regimens will be applied in the treatment of HCV - infected patients and that they will have more potent efficacy and less adverse events .", "label": "", "metadata": {}, "score": "57.03112"}
{"text": "A deterministic bio - mathematical model of the infected cell dynamics was validated in a cohort of 135 patients treated with dual therapy .A decision - analytic economic model was then developed to compare model - guided and guideline - guided strategies in the Italian setting .", "label": "", "metadata": {}, "score": "57.0647"}
{"text": "Virologic Response Group A HCV RNA levels in the patients in group A de- clined rapidly after the initiation of treatment ( Fig .1A ) .", "label": "", "metadata": {}, "score": "57.120903"}
{"text": "Direct - acting antivirals ( DAAs ) against HCV are classified into several categories : 1 ) HCV NS3/4A protease inhibitors , 2 ) HCV NS5B polymerase inhibitors , 3 ) HCV NS5A inhibitors , and others .", "label": "", "metadata": {}, "score": "57.233795"}
{"text": "\" Post - liver transplant and cirrhotic patients represent a still - unmet need and continue to present challenges to currently available regimens . \"About ALLY-1 : Study Design .", "label": "", "metadata": {}, "score": "57.239655"}
{"text": "Antimicrob Agents Chemother .[PubMed ] [ DOI ] .Rocco A , Compare D , Coccoli P , Esposito C , Di Spirito A , Barbato A , Strazzullo P , Nardone G. Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus .", "label": "", "metadata": {}, "score": "57.30477"}
{"text": "Contraindications to peginterferon alfa and ribavirin also apply to Sovaldi combination treatment .Refer to the prescribing information of peginterferon alfa and ribavirin for a list of their contraindications .", "label": "", "metadata": {}, "score": "57.389572"}
{"text": "However , further research is still needed to confirm these observations .Hepatic steatosis and other negative predictors : The value of steatosis as a negative predictor of response to anti - HCV therapy was confirmed in two large clinical trials .", "label": "", "metadata": {}, "score": "57.481888"}
{"text": "Data in patients with severe renal impairment , including patients on hemodialysis , will be presented at ILC .Additionally , AbbVie 's Phase 3b HCV program includes studies in patients with decompensated and compensated cirrhosis .", "label": "", "metadata": {}, "score": "57.513252"}
{"text": "HCV genotype : Genotype plays an important role in predicting the response to the SOC treatments and determining the appropriate antiviral treatment .The response of patients with HCV genotype 1/4/5/6 infection is worse than that of patients with genotype 2/3 infection .", "label": "", "metadata": {}, "score": "57.624077"}
{"text": "This suggests that another extrahepatic manifestation of HCV may be an increased risk of cancer .Concomitant use may increase risk of slow heart rate and related problems .", "label": "", "metadata": {}, "score": "57.807346"}
{"text": "26 Clearly , DAA combination trials are needed in people with cirrhosis , to avert transplantation or treat post - transplant reinfection .In CRUSH - C , a 103-person trial of protease - inhibitor - based triple therapy in post - transplant , treatment efficacy is promising : 57 % of participants had an early response ; HCV RNA was undetectable during treatment , at week 4 and week 12 .", "label": "", "metadata": {}, "score": "58.036095"}
{"text": "1 If serious adverse reactions potentially related to peginterferon alfa and/or ribavirin occur , adjust dosage or discontinue peginterferon alfa and ribavirin according to the respective manufacturer 's prescribing information .", "label": "", "metadata": {}, "score": "58.082893"}
{"text": "AIDS .[PubMed ] [ DOI ] .Lok AS , Gardiner DF , Lawitz E , Martorell C , Everson GT , Ghalib R , Reindollar R , Rustgi V , McPhee F , Wind - Rotolo M. Preliminary study of two antiviral agents for hepatitis C genotype 1 .", "label": "", "metadata": {}, "score": "58.314545"}
{"text": "( 3 kilobases upstream of the IL28B gene encoding the type III interferon IFN - l3 ) showed a strong correlation with the treatment response .", "label": "", "metadata": {}, "score": "58.314632"}
{"text": "When we treat patients infected with HCV in daily clinical practice , it seems important to be aware of the potential treatments of HCV in the near future , as the development of new drugs is always ongoing .", "label": "", "metadata": {}, "score": "58.349037"}
{"text": "Two patients receiving sofosbuvir and one patient receiving placebo discontinued treatment due to adverse events .All patients in the study had previously failed treatment with peg - IFN / RBV and 55 percent had cirrhosis .", "label": "", "metadata": {}, "score": "58.35382"}
{"text": "Prior partial response or relapse ( not detected / not detected ) .Weeks 1 - 4 : Peginterferon alfa and ribavirin ; Weeks 5 - 36 : Boceprevir , peginterferon alfa , and ribavirin .", "label": "", "metadata": {}, "score": "58.43503"}
{"text": "2008 ; 48 : S46 .[PubMed ] [ DOI ] .Lancet .[PubMed ] [ DOI ] .Poordad F , McCone J , Bacon BR , Bruno S , Manns MP , Sulkowski MS , Jacobson IM , Reddy KR , Goodman ZD , Boparai N. Boceprevir for untreated chronic HCV genotype 1 infection .", "label": "", "metadata": {}, "score": "58.44436"}
{"text": "Telaprevir , as the first approved DAA , has a recommended dose of 750 mg tid , combined with PegIFN - \u03b1 and RBV treatment ( triple therapy ) , for a duration of 48 wk for naive or previous treatment failure HCV genotype 1 patients .", "label": "", "metadata": {}, "score": "58.565"}
{"text": "A related analysis of previously untreated people without cirrhosis found that reducing treatment duration to six weeks led to relapses ... .Daclatasvir and Asunaprevir AASLD - Phase III all - oral hepatitis C regimen daclatasvir and asunaprevir For the 24-week study , 222 patients were studied , and 85.6 percent of those patients had a sustained virologic response ( SVR ) by week 12 .", "label": "", "metadata": {}, "score": "58.626858"}
{"text": "Abstract 53 .Burton JR , O'Leary J , Verna EC , et al .A multicenter study of protease inhibitor - triple therapy in HCV - infected liver transplant recipients : report from the CRUSH - C group .", "label": "", "metadata": {}, "score": "58.808258"}
{"text": "Bristol Myers Squib Drugs : peginterferon lambda and ribavirin with asunaprevir ( HCV protease inhibitor ) or daclatasvir ( NS5a inhibitor ) .Duration : 24 weeks or 48 weeks ( response - guided ) .", "label": "", "metadata": {}, "score": "58.853287"}
{"text": "With pegylated interferon and ribavirin , a person was considered cured when HCV RNA became undetectable during treatment and remained undetectable for 24 weeks after completing therapy ( known as SVR-24 ) .", "label": "", "metadata": {}, "score": "58.892265"}
{"text": "Therefore , determining how to prevent infection with HCV is an important research direction .Over the years , HCV vaccine development strategies are mostly based on the viral genome , unable to overcome HCV high variability , and starting from the human genome to explore other ways to prevent HCV infection may open up a new era in infection prevention .", "label": "", "metadata": {}, "score": "59.070656"}
{"text": "It has been demonstrated that subjects who achieve sustained virological response ( SVR ) have a clear advantage at histological and clinical levels compared to those who do not achieve SVR [ 8 - 12 ] .", "label": "", "metadata": {}, "score": "59.0732"}
{"text": "Prior partial response or relapse ( detected / not detected ) .Weeks 1 - 4 : Peginterferon alfa and ribavirin ; Weeks 5 - 36 : Boceprevir , peginterferon alfa , and ribavirin ; Weeks 37 - 48 : Peginterferon alfa and ribavirin .", "label": "", "metadata": {}, "score": "59.393707"}
{"text": "Combination therapy was administered for up to 2 wk , resulting in a reduction in viral load and undetectable HCV RNA levels at the end of dosing in 63 % of treatment - naive patients [ 38 ] .", "label": "", "metadata": {}, "score": "59.396538"}
{"text": "Recent studies have confirmed that RVR is a good indicator for SVR in genotype 2 , but not in genotype 3 , in which steatosis is a predictor of relapse .", "label": "", "metadata": {}, "score": "59.42479"}
{"text": "In another study , 231 HCV patients treated with the SOC were evaluated [ 76 ] .The results showed that steatosis negatively affected SVR in HCV genotype non-3-infected patients .", "label": "", "metadata": {}, "score": "59.53759"}
{"text": "Phase 2 Data Highlights .In these patients , response was independent of HCV subtype , host IL28B genotype or dose of ABT-450/r .", "label": "", "metadata": {}, "score": "59.803795"}
{"text": "Current studies are focusing on investigating the optimal combination of antiviral therapies to achieve higher efficacy , shorter treatment duration , more simple administration , and better medication compliance .", "label": "", "metadata": {}, "score": "59.822704"}
{"text": "Drugs Affected by Organic Anion Transport Polypeptides .Potential pharmacokinetic interaction with drugs that are substrates for OATP1B1 .Specific Drugs .Alfuzosin .Possible increased alfuzosin concentrations ; may result in hypotension 1 .", "label": "", "metadata": {}, "score": "59.892612"}
{"text": "Assess plasma HCV RNA levels at baseline and at total treatment duration of 4 , 8 , 12 , and 24 weeks . 1 Also assess at completion of therapy , during follow - up , and when clinically indicated . 1 ( See Laboratory Monitoring under Cautions . )", "label": "", "metadata": {}, "score": "59.89897"}
{"text": "\" We are very encouraged by the strong SVR12 rates from this simplified 2-DAA , once - daily regimen that includes our lead HCV protease inhibitor , ABT-450 , \" commented Jay R. Luly , Ph.D. , President and Chief Executive Officer .", "label": "", "metadata": {}, "score": "59.90433"}
{"text": "Both of the patients in group A who were in- fected with HCV genotype 1b had sustained viro- logic response at weeks 12 and 24 after treatment .", "label": "", "metadata": {}, "score": "59.947914"}
{"text": "The study showed that rs12979860 and rs8099917 were associated with SVR , and the univariate and multivariate analyses confirmed that rs8099917 can be used as an independent predictor of the SVR [ 69 ] .", "label": "", "metadata": {}, "score": "59.982628"}
{"text": "Sovaldi ( sofosbuvir ) was authorised in the EU in January 2014 , Daklinza ( dataclasvir ) in August 2014 and Harvoni ( sofosbuvir / ledipasvir ) in November 2014 .", "label": "", "metadata": {}, "score": "60.07189"}
{"text": "The randomized phase 3 PEARL trials evaluated the safety and efficacy of the 3D regimen of ABT-450/ritonavir / ombitasvir and dasabuvir with or without ribavirin ( RBV ) in HCV genotype 1-infected patients .", "label": "", "metadata": {}, "score": "60.11692"}
{"text": "Information for healthcare professionals .Severe bradycardia and heart block have been reported in patients taking amiodarone and Harvoni , or amiodarone and a combination of Sovaldi and Daklinza .", "label": "", "metadata": {}, "score": "60.22757"}
{"text": "In this range , the impact of the changes in the HCV RNA concentration on the SVR was not linear ; when the HCV RNA was lower than 400000 IU / mL , an increase in the amount of virus decreases the SVR rate .", "label": "", "metadata": {}, "score": "60.29213"}
{"text": "Regardless of the danoprevir / r dose , or treatment duration , 97 % achieved SVR-24 ( one person was lost to follow up ) .", "label": "", "metadata": {}, "score": "60.30012"}
{"text": "The unprecedented program will make the Caucasian country a testbed for uprooting the liver - destroying disease , using Gilead 's highly effective but costly pill Sovaldi , plus its newer product Harvoni once approved .", "label": "", "metadata": {}, "score": "60.383842"}
{"text": "The long - term use of this drug can also lead to resistance mutations , including V36A / M , T54A / S , V55A , R155K / T and A156/S / T / V. .", "label": "", "metadata": {}, "score": "60.47432"}
{"text": "NIs can simulate natural polymerase nucleotide substrates and act as a terminator that can be incorporated into RNA .The highly conserved HCV RdRp activation center showed that NIs have a similar efficacy on different HCV genotypes , as well as a high barrier to and low incidence of resistance genes .", "label": "", "metadata": {}, "score": "60.49054"}
{"text": "The most common adverse event was diarrhea , which was mild or moderate in all cases .Grade 3 or 4 neutropenia occurred in six patients , all of whom were receiving peginterferon and ribavi- rin in addition to the two direct - acting antiviral agents .", "label": "", "metadata": {}, "score": "60.626137"}
{"text": "All rights reserved .Page 7 .The new england journal of medicine n engl j med 366;3 nejm.org january 19 , 2012 222 of daclatasvir and asunaprevir alone in group A initially led to a rapid reduction in HCV RNA , with all 11 patients achieving greater than a 4-log10 decline .", "label": "", "metadata": {}, "score": "60.67633"}
{"text": "Potential pharmacokinetic interaction with drugs that are substrates of CYP3A4/5 with possible increased exposure to concomitant drug and subsequent increased or prolonged adverse or therapeutic effects .", "label": "", "metadata": {}, "score": "60.683"}
{"text": "Hepatology .2012 ; 56 : 308a .[PubMed ] [ DOI ] .Hopkins S , Gallay P. Cyclophilin inhibitors : an emerging class of therapeutics for the treatment of chronic hepatitis C infection .", "label": "", "metadata": {}, "score": "60.708122"}
{"text": "In one patient , HCV RNA levels were less than the LLOQ at week 48 after treatment ( asterisk ) and were undetectable on retesting 13 days later .", "label": "", "metadata": {}, "score": "60.73064"}
{"text": "[PubMed ] [ DOI ] .Liver Int .[PubMed ] [ DOI ] .Rumi MG , Aghemo A , Prati GM , D'Ambrosio R , Donato MF , Soffredini R , Del Ninno E , Russo A , Colombo M. Randomized study of peginterferon - alpha2a plus ribavirin vs peginterferon - alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology .", "label": "", "metadata": {}, "score": "60.73269"}
{"text": "Resistance - associated variants most frequently observed in patients not achieving SVR in clinical trials were V36 M , T54S , and R155 K in HCV genotype 1a , and T54A , T54S , V55A , A156S , and V170A in HCV genotype 1b .", "label": "", "metadata": {}, "score": "60.741"}
{"text": "Supplementation therapy : In vitro , vitamin B 12 acts as a natural inhibitor of HCV replication .A study assessed the effect of vitamin B 12 on the virological response in antiviral therapy - naive patients with chronic HCV infection .", "label": "", "metadata": {}, "score": "60.801064"}
{"text": "In contrast to group A , no viral breakthrough occurred in patients in group B , who were re- ceiving quadruple therapy .All 10 patients in group B achieved a sustained virologic response at week 12 after treatment and all but 1 had a sustained virologic response at week 24 after treat- ment .", "label": "", "metadata": {}, "score": "60.85076"}
{"text": "Chu X , Cai X , Cui D et al .In vitro assessment of drug - drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters .", "label": "", "metadata": {}, "score": "60.86934"}
{"text": "In the treatment - na\u00efve group without RBV , on - treatment virologic breakthrough was reported in one patient ( 2 percent ) and two patients ( 5 percent ) experienced post - treatment relapse .", "label": "", "metadata": {}, "score": "60.91397"}
{"text": "1C ) .At week 2 , the median decrease from baseline in HCV RNA was 5.3 Table 1 .Baseline Demographic Characteristics of the Patients and Characteristics of the Disease .", "label": "", "metadata": {}, "score": "60.98491"}
{"text": "All G1a patients added peginterferon due to high rates of virologic breakthrough and are not included .Feld et al .13 Baseline viral load higher in partial vs. null responder .", "label": "", "metadata": {}, "score": "60.989708"}
{"text": "All rights reserved .Page 6 .Direct - Acting Antiviral Agents for Hepatitis C n engl j med 366;3 nejm.org january 19 , 2012 221 R155 K and D168A / E / T / V / Y. The patient with viral relapse had a preexisting NS3 protease resistance variant , R155 K , at baseline and at the time of vi- ral relapse , whereas the NS5A resistance variant Q30E was detected only at relapse .", "label": "", "metadata": {}, "score": "61.001373"}
{"text": "Hepatology 2003;38 : 481 - 92 .Ge D , Fellay J , Thompson AJ , et al .Ge- netic variation in IL28B predicts hepatitis C treatment - induced viral clearance .", "label": "", "metadata": {}, "score": "61.15734"}
{"text": "Recurrence was also seen on rechallenge with the antivirals 8 days after stopping amiodarone , but not 8 weeks after stopping .Amiodarone should only be initiated in patients treated with Harvoni , or Sovaldi plus Daklinza , if other antiarrhythmics are contra - indicated or not tolerated .", "label": "", "metadata": {}, "score": "61.16735"}
{"text": "Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia .Risk of Reduced Therapeutic Effect of Harvoni Due to P - gp Inducers : Rifampin and St. John 's wort are not recommended for use with Harvoni as they may significantly decrease ledipasvir and sofosbuvir plasma concentrations .", "label": "", "metadata": {}, "score": "61.19641"}
{"text": "One patient in Arm 2 discontinued due to noncompliance in week 1 .All remaining patients in Arms 1 and 2 completed treatment and achieved SVR12 .", "label": "", "metadata": {}, "score": "61.236206"}
{"text": "Adults .Treatment of Chronic HCV Infection .Oral .800 mg 3 times daily ( every 7 - 9 hours ) in conjunction with peginterferon alfa and ribavirin for a total treatment duration that depends on response ( response - guided therapy ) . 1 ( See Table 1 . )", "label": "", "metadata": {}, "score": "61.28963"}
{"text": "In this review , we summarize the development of anti - HCV agents and assess the main factors affecting the efficacy of antiviral treatments .Core tip : Understanding the effectiveness and affecting factors of antiviral regimens are critical for making informed treatment decisions for hepatitis C virus ( HCV ) infection .", "label": "", "metadata": {}, "score": "61.404613"}
{"text": "Adverse Reactions .Drug Interactions .In addition to rifampin and St. John 's wort , coadministration of Harvoni is also not recommended with carbamazepine , oxcarbazepine , phenobarbital , phenytoin , rifabutin , rifapentine , and tipranavir / ritonavir .", "label": "", "metadata": {}, "score": "61.459217"}
{"text": "The adverse reactions of danoprevir mainly include anemia , neutropenia , and rash .The resistance mutations R155 K and D168T / E have been observed .", "label": "", "metadata": {}, "score": "61.463364"}
{"text": "In addition , IFN and RBV have several severe side effects .Therefore , strategies to improve sustained virological response ( SVR ) rates have been an important focus for clinical physicians .", "label": "", "metadata": {}, "score": "61.481873"}
{"text": "\" These trials will begin to report results by the end of 2013 , and it is likely that AbbVie will submit a licensing application in early 2014 for this three - drug , interferon - free combination in order to achieve marketing approval in the second half of 2014 ..... HCV Drug Combo Cures Most in Select Group WASHINGTON -- An investigational two - drug combination treatment for hepatitis C ( HCV ) -- using none of the standard medications -- led to cures in 90 % or more of a selected group of patients , a researcher said here .", "label": "", "metadata": {}, "score": "61.5814"}
{"text": "Zeuzem S. Heterogeneous virologic response rates to interferon - based therapy in patients with chronic hepatitis C : who responds less well ?Ann Intern Med .", "label": "", "metadata": {}, "score": "61.598877"}
{"text": "Pregnancy and concomitant use with ribavirin When VIEKIRAX + EXVIERA are used in combination with ribavirin , women of childbearing potential or their male partners must use an effective form of contraception during the treatment and 6 months after the treatment .", "label": "", "metadata": {}, "score": "61.651558"}
{"text": "PubMed ] [ DOI ] .Gastroenterology .e18 .[PubMed ] [ DOI ] .Halfon P , Bourliere M , Ouzan D , Maor Y , Renou C , Wartelle C , P\u00e9naranda G , Tran A , Botta D , Oules V. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus .", "label": "", "metadata": {}, "score": "61.679665"}
{"text": "There were seven adverse events leading to dose reductions of peginterferon or ribavirin in four patients in group B , including neutropenia ( three events ) , anemia ( two ) , leukopenia ( one ) , and depression ( one ) .", "label": "", "metadata": {}, "score": "61.703037"}
{"text": "Additionally , this treatment regimen has several side effects , including granulocytopenia , anemia , and depression , and it is associated with a long treatment duration and increased cost .", "label": "", "metadata": {}, "score": "61.718304"}
{"text": "Sovaldi + peginterferon alfa + ribavirin combination therapy were fatigue , headache , nausea , insomnia , and anemia .Sovaldi + ribavirin combination therapy were fatigue , and headache .", "label": "", "metadata": {}, "score": "62.085224"}
{"text": "Bristol - Myers Squibb 's research efforts are focused on advancing late - stage compounds to deliver the most value to patients with hepatitis C. At the core of our pipeline is daclatasvir , a NS5A complex inhibitor which continues to be investigated in multiple treatment regimens and in patients with co - morbidities .", "label": "", "metadata": {}, "score": "62.168934"}
{"text": "Although the effects of partial drugs on non - type 1 infection have been evaluated , there have been no sufficient data to clarify the relationship between the genotype and the effect of DAAs .", "label": "", "metadata": {}, "score": "62.186844"}
{"text": "Results of C - SALVAGE Study Showed High Sustained Virologic Response Rates in Patients Who Failed Prior Combination Therapy with Certain Direct Acting Antiviral ( DAA )", "label": "", "metadata": {}, "score": "62.198345"}
{"text": "A Japanese study showed that rs8099917 was correlated with the HCV treatment response and was one of the most important predictors of non - response after the logistic regression analysis [ 65 ] .", "label": "", "metadata": {}, "score": "62.21897"}
{"text": "Biochemical markers of liver fibro- sis in patients infected by hepatitis C vi- rus : longitudinal validation in a random- ized trial .J Viral Hepat 2002;9:128 - 33 .", "label": "", "metadata": {}, "score": "62.307045"}
{"text": "The main factors influencing the efficacy of HCV antiviral treatments are divided into two categories : viral and host - related .The viral category includes the HCV genotype , baseline viral load , and virological response during treatment , and the host category includes age , gender , race , drinking habits , obesity , degree of liver fibrosis , and IL28B gene polymorphisms .", "label": "", "metadata": {}, "score": "62.466236"}
{"text": "NS5B polymerase inhibitors : NS5B is an RNA - dependent RNA polymerase ( RdRp ) in the HCV replication complex that catalyzes the synthesis of positive- and negative - stranded viral RNAs .", "label": "", "metadata": {}, "score": "62.501427"}
{"text": "One patient discontinued therapy after 31 days due to headache , but still achieved SVR12 .Nine patients in the cirrhosis cohort relapsed post - treatment , and one had detectable HCV RNA at the end of treatment ; there were no on - treatment virologic breakthroughs .", "label": "", "metadata": {}, "score": "62.569515"}
{"text": "Budesonide or fluticasone ( nasal spray / oral inhalation ) : Possible increased corticosteroid concentrations ; possible reduced serum cortisol concentrations 1 .Dexamethasone : Possible decreased boceprevir concentrations ; possible loss of virologic efficacy 1 .", "label": "", "metadata": {}, "score": "62.634438"}
{"text": "Metabolized primarily by aldo - keto reductase ( AKR ) ; clinically important drug interactions not reported to date with AKR inhibitors .Partially metabolized by 1 and is a potent inhibitor of CYP3A4/5 . 1 6 25 Does not or only minimally inhibits CYP1A2 , 2A6 , 2B6 , 2C8 , 2C9 , 2C19 , 2D6 , or 2E1 in vitro ; 1 does not induce CYP1A2 , 2B6 , 2C8 , 2C9 , 2C19 , or 3A4/5 in vitro .", "label": "", "metadata": {}, "score": "62.94274"}
{"text": "VIEKIRAX \u00ae + EXVIERA \u00ae EU Indication VIEKIRAX is indicated in combination with other medicinal products for the treatment of chronic hepatitis C ( CHC ) in adults .", "label": "", "metadata": {}, "score": "63.079857"}
{"text": "Both patients with HCV genotype 1b infection who were treated with the combination of direct - acting antiviral agents alone had a sustained virologic response .", "label": "", "metadata": {}, "score": "63.091934"}
{"text": "[PubMed ] [ DOI ] .Ghany MG , Nelson DR , Strader DB , Thomas DL , Seeff LB .An update on treatment of genotype 1 chronic hepatitis C virus infection : 2011 practice guideline by the American Association for the Study of Liver Diseases .", "label": "", "metadata": {}, "score": "63.21234"}
{"text": "In addition to rifampin and St. John 's wort , coadministration of Sovaldi is not recommended with carbamazepine , oxcarbazepine , phenobarbital , phenytoin , rifabutin , rifapentine , and tipranavir / ritonavir .", "label": "", "metadata": {}, "score": "63.386444"}
{"text": "A few cases of severe slow heart rate or interference with electrical signals in the heart have been reported in patients taking the medicines Harvoni or Sovaldi plus Daklinza ( used to treat hepatitis C , a liver infection ) at the same time as the heart medicine amiodarone .", "label": "", "metadata": {}, "score": "63.503517"}
{"text": "Enrollment was open to GT1-infected patients regardless of IL28B host genotype and ribavirin dosing was weight - based .93 percent ( 13 of 14 ) of treatment- naive patients infected with HCV GT1", "label": "", "metadata": {}, "score": "63.54439"}
{"text": "[PubMed ] [ DOI ] .Kumada H , Toyota J , Okanoue T , Chayama K , Tsubouchi H , Hayashi N. Telaprevir with peginterferon and ribavirin for treatment - naive patients chronically infected with HCV of genotype 1 in Japan .", "label": "", "metadata": {}, "score": "63.61423"}
{"text": "Due to the side effect profile of pegylated interferons , interferon - sparing regimens have become the main target in chronic hepatitis C treatment research .", "label": "", "metadata": {}, "score": "63.785446"}
{"text": "One patient recovered spontaneously and three after additional treatment with oral GC , given to re - establish immune suppression in the suspect of an autoimmune hepatitis .", "label": "", "metadata": {}, "score": "63.93264"}
{"text": "Ge D , Fellay J , Thompson AJ , Simon JS , Shianna KV , Urban TJ , Heinzen EL , Qiu P , Bertelsen AH , Muir AJ , Sulkowski M , McHutchison JG , Goldstein DB : Genetic variation in IL28B predicts hepatitis C treatment - induced viral clearance .", "label": "", "metadata": {}, "score": "63.937397"}
{"text": "Ritonavir is used to increase the plasma concentration of ABT-450 , prolong its half - life , and reduce the risk of drug resistance , enabling an ABT-450 dose regimen of once daily [ 40 , 41 ] .", "label": "", "metadata": {}, "score": "63.977158"}
{"text": "Virologic Response during and after Treatment .The analyses were performed in the modified intention - to - treat popu- lation ( all patients who received at least one dose of study medication ) .", "label": "", "metadata": {}, "score": "64.07586"}
{"text": "Total - anti - HBc qualifies as a useful marker of HBV - induced - liver - disease that might help to discriminate major phases of chronic HBV infection and to predict sustained response to antivirals .", "label": "", "metadata": {}, "score": "64.0943"}
{"text": "Patients with GT1b HCV infection were also studied but not included in the efficacy analysis for the NDA submission ; the results in patients with GT4 HCV were reported in The Lancet .", "label": "", "metadata": {}, "score": "64.21547"}
{"text": "Use with concomitant medicinal products Use caution when administering VIEKIRAX with fluticasone or other glucocorticoids that are metabolized by CYP3A4 .A reduction in colchicine dosage or interruption in colchicine is recommended in patients with normal renal or hepatic function .", "label": "", "metadata": {}, "score": "64.30927"}
{"text": "DAAs have shown a trend toward a gradual replacement of the SOC scheme .Although the efficacy of DAAs is significantly improved , the incidence of treatment - related side effects appears to be high , and because of the direct - acting antiviral effect , resistance mutations appear to be more likely to appear .", "label": "", "metadata": {}, "score": "64.31244"}
{"text": "In genotypes 2 and 3 , a retreatment regimen -- especially for people with HCV genotype 3 who do not have any options -- should be prioritised by pharmaceutical companies .", "label": "", "metadata": {}, "score": "64.33157"}
{"text": "J Hepatol .2012 ; 56 : S476-S477 .[PubMed ] [ DOI ] .Chu TW , Kulkarni R , Gane EJ , Roberts SK , Stedman C , Angus PW , Ritchie B , Lu XY , Ipe D , Lopatin U. Effect of IL28B genotype on early viral kinetics during interferon - free treatment of patients with chronic hepatitis C. Gastroenterology .", "label": "", "metadata": {}, "score": "64.4715"}
{"text": "In the 2011 European guidelines [ 61 ] for the prevention and treatment of hepatitis C , the following adjustments are made .For the genotype 1/4 patients , if the baseline viral load was low before treatment and RVR was acquired after treatment , the duration could be reduced to 24 wk .", "label": "", "metadata": {}, "score": "64.533035"}
{"text": "Conclusion : 12 weeks of treatment with Lambda + DCV + RBV achieved a high SVR4 rate in treatment - na\u00efve , non - cirrhotic HCV genotype 1b - infected patients .", "label": "", "metadata": {}, "score": "64.63678"}
{"text": "2012 ; 107:669 - 89 ; quiz 690 .[ PubMed 22525303 ] .Food and Drug Administration .FDA drug safety communication : Interactions between certain HIV or hepatitis C drugs and cholesterol - lowering statin drugs can increase the risk of muscle injury .", "label": "", "metadata": {}, "score": "64.70369"}
{"text": "Of those who were either ineligible for or intolerant of treatment with interferon , the cure rate was 87.4 percent , while 80.5 percent of past nonresponders to the older drugs were deemed cured .", "label": "", "metadata": {}, "score": "64.81535"}
{"text": "Effect of HCV treatment on transmission of HCV unknown ; patients should take appropriate precautions to prevent transmission .Importance of informing clinicians of existing or contemplated concomitant therapy , including prescription and OTC drugs and dietary or herbal supplements , as well as any concomitant illnesses .", "label": "", "metadata": {}, "score": "64.82263"}
{"text": "ELECTRON Phase 2 Gilead Sciences Drugs : GS-5885 ( NS5a inhibitor ) with sofosbuvir ( nucleotide polymerase inhibitor ) with ribavirin Duration : 12 weeks .", "label": "", "metadata": {}, "score": "64.86473"}
{"text": "[PubMed ] [ DOI ] .Gal - Tanamy M , Bachmetov L , Ravid A , Koren R , Erman A , Tur - Kaspa R , Zemel R. Vitamin D : an innate antiviral agent suppressing hepatitis C virus in human hepatocytes .", "label": "", "metadata": {}, "score": "64.86946"}
{"text": "Infected Subjects and 47 % of Previous Non - Responders .The objectives of this phase 2 study were to assess safety and tolerability 12-week interferon - free regimens in HCV GT1 patients who were either treatment naive or previous non - responders .", "label": "", "metadata": {}, "score": "64.88907"}
{"text": "J Hepatol .[PubMed ] [ DOI ] .Gembitski\u012d EV , Glazunov AV , Zhiliaev EV , Proskurina TV .Extrahepatic syndromes ( vascular manifestations ) in patients HCV infection .", "label": "", "metadata": {}, "score": "64.97186"}
{"text": "In the null responder arm , one patient experienced breakthrough and three patients relapsed .PEARL - I is a phase-2b , interferon - free , 320 patient study being conducted by AbbVie to evaluate the once - daily , two - DAA regimen consisting of ABT-450/r ( protease inhibitor plus ritonavir ) + ABT-267 ( AbbVie 's NS5A inhibitor ) in HCV treatment - na\u00efve patients and treatment - experience patients .", "label": "", "metadata": {}, "score": "65.10188"}
{"text": "Duration : 12 or 24 weeks .SVR-1293 % ( 42/45 ) for 4-drug regimen.89 % ( 40/45 ) for ABT 450/r , ABT-267 and ribavirin(12-week treatment group only ; follow up of 24-week treatment group is ongoing ) .", "label": "", "metadata": {}, "score": "65.16475"}
{"text": "21Although overall efficacy was comparable , lambda was significantly less likely to cause flulike symptoms and laboratory abnormalities such as anemia and neutropenia than peginterferon alfa-2a .", "label": "", "metadata": {}, "score": "65.2121"}
{"text": "At present , it is also believed that vitamin D has an anti - HCV activity in vitro that is mediated through its active metabolite , calcitriol [ 53 ] .", "label": "", "metadata": {}, "score": "65.22255"}
{"text": "Treatment - experienced genotype 3 patients with cirrhosis receiving Sovaldi plus PEG / RBV demonstrated SVR12 rates of 86 percent ( 30/35 ) .Genotype 2 patients also demonstrated high SVR12 rates across all treatment arms .", "label": "", "metadata": {}, "score": "65.24611"}
{"text": "Nature .[PubMed ] [ DOI ] .Thomas DL , Thio CL , Martin MP , Qi Y , Ge D , O'Huigin C , Kidd J , Kidd K , Khakoo SI , Alexander G. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus .", "label": "", "metadata": {}, "score": "65.27554"}
{"text": "In a separate study , known as \" Pilot \" , 91 percent of genotype 1 infected , treatment - naive patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks , achieved sustained viral response at 24 weeks ( SVR24 ) .", "label": "", "metadata": {}, "score": "65.32067"}
{"text": "In the HCV cohort there were 2,213 cancer diagnoses ( 1524/100000 ) during the 5 year period and 1,654 cancer diagnoses when liver cancer was excluded ( 1139/100000 ) .", "label": "", "metadata": {}, "score": "65.43483"}
{"text": "Bio - mathematical modelling of viral dynamics during dual therapy has potentially higher accuracy than rapid virologic in the identification of patients who will eventually achieve sustained response .", "label": "", "metadata": {}, "score": "65.4467"}
{"text": "Ghany MG , Strader DB , Thomas DL , Seeff LB , American Association for the Study of Liver Diseases .Diagnosis , man- agement , and treatment of hepatitis C : an update .", "label": "", "metadata": {}, "score": "65.52553"}
{"text": "PEGIFN - \u03b1 combined with RBV is currently the most classic and widely used standard treatment ; however , its limited efficacy and significant side effects , as well as the absence of an HCV vaccine , promoted the development of new drugs .", "label": "", "metadata": {}, "score": "65.538925"}
{"text": "Transient elevations of alanine aminotransferase levels were observed in six patients ; these eleva- tions were not associated with clinically signifi- ca nt increases in bilirubin level .", "label": "", "metadata": {}, "score": "65.585335"}
{"text": "[PubMed ] [ DOI ] .Tanaka Y , Nishida N , Sugiyama M , Kurosaki M , Matsuura K , Sakamoto N , Nakagawa M , Korenaga M , Hino K , Hige S. Genome - wide association of IL28B with response to pegylated interferon - alpha and ribavirin therapy for chronic hepatitis C. Nat Genet .", "label": "", "metadata": {}, "score": "65.62119"}
{"text": "New oral - only drug therapy is quite safe and the eradication rate is so high .\" Dr. Chayama continues , \" These results , which were quite amazing , were expected after conducting the phase II trial , and we are very happy to confirm them in the phase III trial .", "label": "", "metadata": {}, "score": "65.66612"}
{"text": "When all cancers are considered the rate is 2.5 times higher in the HCV cohort ; when liver cancers are excluded , the rate is still almost 2 times higher .", "label": "", "metadata": {}, "score": "65.72829"}
{"text": "[PubMed ] [ DOI ] .Nimer A , Mouch A. Vitamin D improves viral response in hepatitis C genotype 2 - 3 na\u00efve patients .", "label": "", "metadata": {}, "score": "65.832504"}
{"text": "Differing provisions from the publisher 's actual policy or licence agreement may be applicable .\" In vitro , the resistance profile of DCV has been established in authentic and hybrid HCV replicons representing GT1 through GT6 [ 10 ] while in proof - of - concept clinical studies , efforts have mostly focused on HCV GT1", "label": "", "metadata": {}, "score": "66.006775"}
{"text": "Table 1 .Standard of care treatment and sustained virological response rates for chronic hepatitis C patients .New standard of care ( NSOC ) treatment for HCV infection .", "label": "", "metadata": {}, "score": "66.024475"}
{"text": "Two of the patients needed treatment with a pacemaker and one patient died .Patients who need these hepatitis C combinations should not also be given amiodarone unless there is no other suitable alternative .", "label": "", "metadata": {}, "score": "66.03008"}
{"text": "This triple combination regimen was evaluated for 12 weeks of treatment in a cohort of patients with genotype 1b infection ( Study AI452 - 008c ) .", "label": "", "metadata": {}, "score": "66.06152"}
{"text": "The results showed that the regimen was highly effective in clearing the virus and well tolerated in a group of patients who historically have had unfavorable prognoses ... .", "label": "", "metadata": {}, "score": "66.08776"}
{"text": "A total of 353 patients were given i.v .GC and 23 were excluded for various conditions .ALD was detected in 4/376 patients candidate to i.v .", "label": "", "metadata": {}, "score": "66.20251"}
{"text": "The product information for Harvoni , Sovaldi and Daklinza will be updated appropriately .A letter will also be sent to healthcare professionals involved in hepatitis C treatment explaining these risks and the measures to manage them .", "label": "", "metadata": {}, "score": "66.31137"}
{"text": "[PubMed ] [ DOI ] .Abu - Mouch S , Fireman Z , Jarchovsky J , Zeina AR , Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C ( genotype 1)-na\u00efve patients .", "label": "", "metadata": {}, "score": "66.31688"}
{"text": "EASL guidelines showed that IL28B polymorphisms can be used to predict treatment response but have a low predictive value [ 61 ] .In contrast , AASLD argues that for determining the treatment regimen ( SOC regimen combined with or without DAA ) , the IL28B polymorphism is a very strong predictor [ 68 ] .", "label": "", "metadata": {}, "score": "66.450356"}
{"text": "In fact , there have been two late relapses , between 24 and 48 weeks after treatment with an interferon - free regimen : one in Abbott 's PILOT trial 1 and one in Boehringer Ingelheim 's SOUND - C2 trial .", "label": "", "metadata": {}, "score": "66.49411"}
{"text": "About VIEKIRAX \u00ae + EXVIERA \u00ae VIEKIRAX + EXVIERA is approved in the European Union for the treatment of genotype 1 ( GT1 ) chronic hepatitis C virus ( HCV ) infection , including patients with compensated cirrhosis .", "label": "", "metadata": {}, "score": "66.52907"}
{"text": "A fixed - dose combination of two investigational hepatitis C ( HCV ) drugs needs a boost in patients with advanced fibrosis or cirrhosis , a researcher said here .", "label": "", "metadata": {}, "score": "66.550026"}
{"text": "Table 2 .Update : Interferon - Free Regimens in HCV Genotype 1 , Treatment - Naive .Study , Sponsor & Regimen .AVIATOR Phase 2b .", "label": "", "metadata": {}, "score": "66.5849"}
{"text": "However , given the very small number of available studies , additional studies are needed to assess potential differences in the associations between vitamin B 12 /vitamin D and SVR for HCV .", "label": "", "metadata": {}, "score": "66.58743"}
{"text": "Paritaprevir was discovered during the ongoing collaboration between AbbVie and Enanta Pharmaceuticals ( NASDAQ : ENTA ) for HCV protease inhibitors and regimens that include protease inhibitors .", "label": "", "metadata": {}, "score": "66.598465"}
{"text": "Viral relapse was defined as confirmed detectable HCV RNA levels during the post - treatment follow - up period in patients who had had undetectable HCV RNA levels at the end of treatment .", "label": "", "metadata": {}, "score": "66.604034"}
{"text": "Table 1 .Recommended Response - guided Therapy Regimen and Total Treatment Duration.1 .Patient Type and Initial Response ( HCV RNA Levels at Week 8/Week 24 ) .", "label": "", "metadata": {}, "score": "66.61333"}
{"text": "\" We are pleased that the FDA has granted priority review for our all - oral , interferon - free treatment for patients with chronic GT4 HCV infection , \" said Michael Severino , M.D. , executive vice president , research and development and chief scientific officer , AbbVie . \"", "label": "", "metadata": {}, "score": "66.704834"}
{"text": "Six randomized clinical trials assessed the efficacy of the triple therapy compared with the SOC in naive HCV genotype 1 patients [ 22 - 27 ] .", "label": "", "metadata": {}, "score": "66.89345"}
{"text": "These inhibitors include members of the direct acting antiviral ( DAA ) inhibitor classes- protease ( partnered with Abbott ) , NS5A ( partnered with Novartis ) , nucleotide polymerase , and a host targeted antiviral ( HTA ) inhibitor class targeted against cyclophilin .", "label": "", "metadata": {}, "score": "67.01428"}
{"text": "No preview \u00b7 Article \u00b7 Jun 2015 \u00b7 Thyroid : official journal of the American Thyroid Association .[ Show abstract ] [ Hide abstract ] ABSTRACT : Adoptive transfer of lymphocytes expressing engineered T cell receptors ( TCR ) is a promising option for cancer treatment and could include hepatocellularcarcinoma ( HCC ) , where therapeutic options are limited .", "label": "", "metadata": {}, "score": "67.02832"}
{"text": "J Hepatol .[PubMed ] [ DOI ] .Westin J , Lagging M , Dhillon AP , Norkrans G , Romero AI , Pawlotsky JM , Zeuzem S , Schalm SW , Verheij - Hart E , Negro F. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection .", "label": "", "metadata": {}, "score": "67.12939"}
{"text": "2012 ; 56 : S555-S556 .[PubMed ] [ DOI ] .Poordad F , Lawitz E , Kowdley KV , Cohen DE , Podsadecki T , Siggelkow S , Heckaman M , Larsen L , Menon R , Koev G. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med .", "label": "", "metadata": {}, "score": "67.304565"}
{"text": "Food increases boceprevir exposure by up to 65 % relative to fasting state . 1 Effects are similar regardless of meal type ( low - fat or high - fat ) or whether the drug is taken 5 minutes prior to , during , or following meal .", "label": "", "metadata": {}, "score": "67.68065"}
{"text": "[ PubMed 21898493 ] .Yee HS , Chang MF , Pocha C et al .Update on the management and treatment of hepatitis C virus infection : recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office .", "label": "", "metadata": {}, "score": "67.70784"}
{"text": "Thirteen patients recovered and one died , resulting in a mortality of 0.09 % .First , the total MPA cumulative dose should not exceed 8.5 g ( the average dose in patients without ALD ) .", "label": "", "metadata": {}, "score": "67.75459"}
{"text": "[PubMed ] [ DOI ] .Tarantino G , Conca P , Sorrentino P , Ariello M. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus - related chronic hepatitis .", "label": "", "metadata": {}, "score": "67.808846"}
{"text": "HCV Combo Promising in Difficult Patients WASHINGTON --The combination of two novel hepatitis C ( HCV ) drugs that are close to market yielded good efficacy in hard - to - treat patients , a researcher said .", "label": "", "metadata": {}, "score": "67.824005"}
{"text": "1B ) .Peak HCV RNA levels at the ini- tiation of rescue therapy ranged from 6.5\u00d7102 to 3.2\u00d7106 IU per milliliter .The remaining two patients never achieved undetectable HCV RNA , and treatment was discontinued .", "label": "", "metadata": {}, "score": "67.83649"}
{"text": "No patients discontinued due to treatment - related adverse events .Two serious adverse events - pyelonephritis and B - cell lymphoma - were reported but were not considered to be related to study medicine .", "label": "", "metadata": {}, "score": "67.95747"}
{"text": "One serious adverse event of hospitalization for alcohol abuse was re- ported 1 month after the completion of rescue therapy .There were no instances of grade 3 or 4 anemia or thrombocytopenia .", "label": "", "metadata": {}, "score": "68.07724"}
{"text": "Copyright \u00a9 2012 Massachusetts Medical Society .Abstract Background Patients with chronic hepatitis C virus ( HCV ) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addition of mul- tiple direct - acting antiviral agents to their treatment regimen .", "label": "", "metadata": {}, "score": "68.101425"}
{"text": "Patients who achieve SVR12 are considered cured of HCV infection .These data will be presented this week during the 64th Annual Meeting of the American Association for the Study of Liver Diseases ( The Liver Meeting 2013 ) in Washington , D.C. .", "label": "", "metadata": {}, "score": "68.14436"}
{"text": "Both patients who did not achieve SVR4 experienced relapse posttreatment .No patients discontinued treatment due to AEs or treatment futility ; there were no deaths and no serious AEs .", "label": "", "metadata": {}, "score": "68.21849"}
{"text": "The phase IIb ASPIRE study demonstrated that simeprevir is a highly potent , efficacious , and well - tolerated once - daily PI for the majority of prior null or partial responders and relapsers compared to IFN - based therapy .", "label": "", "metadata": {}, "score": "68.44721"}
{"text": "Sustained virologic response results at 4- and 12-weeks post - treatment are expected to be available in the fourth quarter of 2013 .Both companies continue to retain all rights to their respective compounds during this collaboration ....", "label": "", "metadata": {}, "score": "68.54443"}
{"text": "For the genotype 2/3 patients , if the baseline viral load was low and RVR was acquired , the duration could be shortened to 12 - 16 wk .", "label": "", "metadata": {}, "score": "68.55292"}
{"text": "In HCV genotype 1 patients , RVR and SVR rates were 100 % and 100 % , while in HCV genotype 2 and genotype 3 patients they were 100 % and 91 % , respectively [ 43 ] .", "label": "", "metadata": {}, "score": "68.59985"}
{"text": "In the HCV cohort there were 2,213 cancer diagnoses ( 1,524/100,000 ) during the 5-year period and 1,654 cancer diagnoses when liver cancer was excluded ( 1,139/100,000 ) .", "label": "", "metadata": {}, "score": "68.60025"}
{"text": "McPhee F. Identification and preclini- cal profile of the novel HCV NS3 protease inhibitor BMS-650032 .J Hepatol 2010;52 : Suppl 1:S296 . abstract .", "label": "", "metadata": {}, "score": "68.6044"}
{"text": "\u00a7 One patient in group A who had virologic response at weeks 4 , 12 , and 24 af- ter treatment had detectable but not quantifiable HCV RNA levels at 48 weeks after treatment and undetectable HCV RNA levels on retesting 43 days later .", "label": "", "metadata": {}, "score": "68.60443"}
{"text": "Colchicine for treatment of gout flares : In those receiving boceprevir , use initial colchicine dose of 0.6 mg followed by 0.3 mg 1 hour later and repeat dose no earlier than 3 days later 1 .", "label": "", "metadata": {}, "score": "68.627716"}
{"text": "HCV RNA levels are shown from the initiation of rescue therapy ( day 0 ) until the time the database was locked .Patients received rescue therapy for up to 48 weeks , after which all treatment was discontinued .", "label": "", "metadata": {}, "score": "68.72983"}
{"text": "Estrogens used for hormone replacement therapy : Monitor patient for clinical signs of estrogen deficiency 1 .Etravirine .Decreased etravirine concentrations and AUC ; 1 20 slightly increased boceprevir concentrations and AUC 1 20 200 .", "label": "", "metadata": {}, "score": "68.81814"}
{"text": "Randomization was stratified according to HCV subtype ( 1a or 1b ) , with no more than two patients with genotype 1b enrolled in each treatment group .", "label": "", "metadata": {}, "score": "69.08354"}
{"text": "Important Safety Information About Harvoni .Warnings and Precautions .Risk of Serious Symptomatic Bradycardia When Coadministered with Amiodarone : Amiodarone is not recommended for use with Harvoni due to the risk of symptomatic bradycardia , particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease .", "label": "", "metadata": {}, "score": "69.41494"}
{"text": "Viral relapse occurred in one patient ( with HCV genotype 1a ) at week 4 after treatment .This pa- tient had had undetectable HCV RNA at week 4 during the treatment period , and the levels had remained undetectable through week 24 ( end of treatment ) .", "label": "", "metadata": {}, "score": "69.57486"}
{"text": "Patients receiving a variety of immunosuppressive agents were permitted .In the cirrhosis cohort , patients transplanted during treatment could receive 12 weeks of extended treatment immediately post - transplant , regardless of treatment duration before transplant .", "label": "", "metadata": {}, "score": "69.61851"}
{"text": "With approved DAAs on the market , more clinical treatment choices have been provided .The efficient and reliable prediction of the efficacy is essential to create individual antivirus solutions , improve the efficacy , reduce the side effects , and lower the treatment cost .", "label": "", "metadata": {}, "score": "69.63311"}
{"text": "Additionally , RUBY - I data showed no virologic failures to date . 1 To date , eight of 13 genotype 1a ( GT1a ) patients had a RBV dose interruption . \" RUBY - I is part of AbbVie 's broader Phase 3b program and demonstrates our continued focus on people living with hepatitis C that have specific needs , \" said Scott Brun , M.D. , vice president , pharmaceutical development , AbbVie . \" Studies in our Phase 3b program will help to further expand our knowledge of the utility of VIEKIRAX + EXVIERA in special populations encountered in clinical practice . \"", "label": "", "metadata": {}, "score": "69.85367"}
{"text": "Given the recent advances in therapy , one can be assured that no true progress has been achieved while those infected by viral hepatitis still have to face stigma and discrimination .", "label": "", "metadata": {}, "score": "69.90198"}
{"text": "Results of C - SWIFT Study Provide Proof - of - Concept for Shorter Than Twelve Weeks Duration of Treatment with Triple - DAA Regimen in Patients with Chronic Hepatitis C Virus ( HCV ) Genotypes 1 and 3 Infection .", "label": "", "metadata": {}, "score": "69.9425"}
{"text": "Interim findings were previously presented at the 65 th American Association for the Study of Liver Diseases in November 2014 .SVR12 results by treatment arm in the modified intent to treat population are shown above ( table 1 ) .", "label": "", "metadata": {}, "score": "69.9651"}
{"text": "J Hepatol .2012 ; 56 Suppl 1 : S56-S65 .[PubMed ] [ DOI ] .Peveling - Oberhag J , Arcaini L , Hansmann ML , Zeuzem S. Hepatitis C - associated B - cell non - Hodgkin lymphomas .", "label": "", "metadata": {}, "score": "70.08527"}
{"text": "HCV drugs in the future .New drugs for the treatment of hepatitis C are now being investigated in phase II and phase III clinical trials ( Tables 5 and 6 ) .", "label": "", "metadata": {}, "score": "70.08952"}
{"text": "The IL28B genotype was assayed with the use of a TaqMan genotyping assay ( Applied Biosys- tems ) for the rs12979860 single - nucleotide poly- morphism ( SNP ) .", "label": "", "metadata": {}, "score": "70.18427"}
{"text": "Update : Interferon - free regimens in HCV genotype 1 , treatment - naive ) .When Is a Cure Really a Cure ?The term sustained virologic response ( SVR ) is used when the hepatitis C viral load ( also called HCV RNA ) remains undetectable after completing HCV treatment ; it indicates that hepatitis C has been cured .", "label": "", "metadata": {}, "score": "70.18839"}
{"text": "Absorption .Bioavailability .Administered as a 1:1 mixture of 2 diastereomers that rapidly interconvert in plasma to a ratio of 2:1 favoring the active diastereomer ( SCH534128 ) over the inactive diastereomer ( SCH534129 ) .", "label": "", "metadata": {}, "score": "70.20693"}
{"text": "Most participants were G1a : 85 % ( 17/20 ) in the twice - daily asunaprevir QUAD arm and 91 % ( 19/21)in the once - daily asunaprevir QUAD arm .", "label": "", "metadata": {}, "score": "70.224"}
{"text": "Moderate inhibitor of organic anion transport polypeptide ( OATP ) 1B1 ; 25 also may inhibit OATP1B3 .25 Not a substrate for OATP1B1 , 1B3 , or 2B1 .", "label": "", "metadata": {}, "score": "70.25851"}
{"text": "Important EU Safety Information Contraindications : VIEKIRAX + EXVIERA are contraindicated in patients with severe hepatic impairment ( Child - Pugh C ) .Patients taking ethinyl estradiol - containing medicinal products must discontinue them and switch to an alternative method of contraception prior to initiating VIEKIRAX + EXVIERA .", "label": "", "metadata": {}, "score": "70.305695"}
{"text": "PubMed ] [ DOI ] .Mauss S , Hueppe D , John C , Goelz J , Heyne R , Moeller B , Link R , Teuber G , Herrmann A , Spelter M. Estimating the likelihood of sustained virological response in chronic hepatitis C therapy .", "label": "", "metadata": {}, "score": "70.46058"}
{"text": "pdf ) .Perz JF , Armstrong GL , Farrington LA , Hutin YJ , Bell BP .The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide .", "label": "", "metadata": {}, "score": "70.56939"}
{"text": "J Viral Hepat .2013 ; 20 : e115-e123 .[PubMed ] [ DOI ] .Muir AJ , Shiffman ML , Zaman A , Yoffe B , de la Torre A , Flamm S , Gordon SC , Marotta P , Vierling JM , Lopez - Talavera JC .", "label": "", "metadata": {}, "score": "70.660706"}
{"text": "However there is not yet a clear direction for IFN - free therapies in treatment na\u00efve patients or more complex non responders .HCV genotype 1 is the most prevalent and hard - to - cure genotype .", "label": "", "metadata": {}, "score": "70.67258"}
{"text": "Cirrhosis ( any / not detected ) .Weeks 1 - 4 : Peginterferon alfa and ribavirin ; Weeks 5 - 48 : Boceprevir , peginterferon alfa , and ribavirin .", "label": "", "metadata": {}, "score": "70.723045"}
{"text": "Data Sets Include Treatment - Na\u00efve , Treatment - Experienced and HIV Co - Infected Patients with Chronic Hepatitis C Virus Genotypes 1 , 4 or 6 Infection .", "label": "", "metadata": {}, "score": "70.74658"}
{"text": "He reported that 41 of the 42 treatment - naive patients had no detectable virus at the end of treatment and 40 reached the SVR12 ; the two who did not were lost to follow - up rather than suffering virologic failure .", "label": "", "metadata": {}, "score": "70.77375"}
{"text": "Dateline : .The data was presented as a late - breaker at The International Liver Congress \u2122 2015 , the 50 th annual meeting of the European Association for the Study of the Liver ( EASL ) in Vienna , Austria from April 22 - 26 . \" Transplant patients take a variety of immunosuppressive medications to prevent organ rejection ; that complicates the treatment of hepatitis C. In ALLY-1 , we saw no drug - drug interactions between transplant and hepatitis C therapies and no need to make dose adjustments to patients ' transplant - related drugs while they received the daclatasvir - based regimen that resulted in high SVR12 rates . \"", "label": "", "metadata": {}, "score": "70.8055"}
{"text": "The information on this site does not constitute medical or health related advice .Victrelis .Introduction .Uses for Victrelis .Chronic Hepatitis C Virus ( HCV ) Infection .", "label": "", "metadata": {}, "score": "71.00963"}
{"text": "Gilead 's agent is the \" holy grail of HCV treatment , \" analyst Julie Hoggatt tells MM&M. May 30 Janssen / Idenix Collaborate : Simeprevir and Samatasvir ( IDX719 )", "label": "", "metadata": {}, "score": "71.04351"}
{"text": "Sovaldi plus PEG / RBV and Sovaldi plus RBV were well tolerated .The most common adverse events in the study were fatigue , headache , insomnia and nausea .", "label": "", "metadata": {}, "score": "71.08116"}
{"text": "Gastroenterology .[PubMed ] [ DOI ] .Gastroenterology .[PubMed ] [ DOI ] .Foster GR , Zeuzem S , Pianko S , Sarin SK , Piratvisuth T , Shah S , Andreone P , Sood A , Chuang WL , Lee CM .", "label": "", "metadata": {}, "score": "71.143265"}
{"text": "The difference was especially obvious in the patients with a genotype 1 infection .Some studies investigated the antiviral therapy administered to patients with a genotype 2/3 infection .", "label": "", "metadata": {}, "score": "71.19397"}
{"text": "Ten of 18 with G1a had viral breakthrough ; 8/18 added peginterferon and are being followed ( one achieved SVR-4 ; 100 % ( 4/4 ) G1b achieved SVR-4 ) .", "label": "", "metadata": {}, "score": "71.40847"}
{"text": "It will be conducted at two clinical sites in France and will include HCV - infected patients of any genotype who have previously failed or relapsed following treatment with the standard - of - care ....", "label": "", "metadata": {}, "score": "71.50261"}
{"text": "If successful during the abbreviated approval process , Gilead expects the drug to be approved by December 8 of this year , making it the first , in a new generation of drugs that target the virus itself , to hit the market .", "label": "", "metadata": {}, "score": "71.5341"}
{"text": "All patients who did not have viral breakthrough have completed 48 weeks of post- treatment follow - up .Safety Assessments Adverse events and results of clinical laboratory tests were recorded throughout the treatment and follow - up periods .", "label": "", "metadata": {}, "score": "71.53653"}
{"text": "OBV / PTV / r must not be used in patients with severe hepatic impairment or with certain medications , which may result in serious and/or life - threatening events or loss of therapeutic effect .", "label": "", "metadata": {}, "score": "71.59311"}
{"text": "\" The poor response with genotype 1a is problematic , but again this might be overcome with PPI-668 in their new study .\"The study was supported by Boehringer Ingelheim .", "label": "", "metadata": {}, "score": "71.626045"}
{"text": "NS5B enzyme activity can be inhibited by two different types of compounds : nucleoside / nucleotide derivative inhibitors ( NIs ) and NNIs .NIs can competitively bind to RdRp active sites , whereas NNIs target allosteric enzyme binding sites .", "label": "", "metadata": {}, "score": "71.73542"}
{"text": "Lawitz presented results for 82 patients with genotype 1b infection ( with or without cirrhosis ) treated for 12 weeks .Data for other patient groups is to be presented later , he said .", "label": "", "metadata": {}, "score": "72.03229"}
{"text": "Pt1 relapsed ; Pt2 experienced breakthrough at Wk4 ; Pts3 and 4 achieved a sustained virologic response .No substitutions associated with DCV - resistance were detected at baseline .", "label": "", "metadata": {}, "score": "72.04216"}
{"text": "Possible increased concentrations of ergot alkaloids and potential for serious and/or life - threatening effects such as ergot toxicity ( peripheral vasospasm , ischemia of the extremities and other tissues ) 1 .", "label": "", "metadata": {}, "score": "72.05835"}
{"text": "From a global health perspective , the urgency for establishing initiatives such as the patent pool for hepatitis C drugs and political pressure for much earlier access should make such a deferred timeline unacceptable .", "label": "", "metadata": {}, "score": "72.12837"}
{"text": "Liver disease associated with HCV infection is growing rapidly , and there is an acute need for new therapies that are safer and more effective .", "label": "", "metadata": {}, "score": "72.30084"}
{"text": "The peak alanine aminotransferase level was 370 U per liter , and the maximum direct bili- rubin level was 0.6 mg per deciliter .There was no evidence of an association between elevations of alanine aminotransferase levels and response to therapy or viral breakthrough .", "label": "", "metadata": {}, "score": "72.30588"}
{"text": "The Metavir score is used to quantify the degree of inflammation and fibrosis of the liver .Liver fibrosis is scored on a four - point scale .", "label": "", "metadata": {}, "score": "72.521355"}
{"text": "Data sources include Micromedex \u00ae ( updated Jan 25th , 2016 ) , Cerner Multum \u2122 ( updated Feb 1st , 2016 ) , Wolters Kluwer \u2122 ( updated Feb 1st , 2016 ) and others .", "label": "", "metadata": {}, "score": "72.53346"}
{"text": "N Engl J Med 2009;361:580 - 93 .[ Erratum , N Engl J Med 2009;361:1027 . ]Schiff E , Poordad F , Jacobson I , et al .", "label": "", "metadata": {}, "score": "72.65285"}
{"text": "Infected Subjects .The objectives of the 12-week , phase 2 study were to assess the safety , tolerability , pharmacokinetics , and antiviral activity of ABT-450/r 150/100 mg QD and ABT-072 400 mg QD + ribavirin administered for 12 weeks .", "label": "", "metadata": {}, "score": "72.71004"}
{"text": "VIEKIRAX + EXVIERA is taken for 12 weeks with or without RBV , except in GT1a and GT4 patients with compensated cirrhosis , who should take it for 24 weeks with RBV .", "label": "", "metadata": {}, "score": "73.00251"}
{"text": "Hepatology .2006 ; 44 : 267a-268a .[PubMed ] [ DOI ] .EASL Clinical Practice Guidelines : management of hepatitis C virus infection .", "label": "", "metadata": {}, "score": "73.010216"}
{"text": "Statistical Analysis For binary end points related to antiviral activity , including the primary efficacy end point , the analyses included all patients who received at least one dose of study medication ( modified intention- to - treat population ) .", "label": "", "metadata": {}, "score": "73.1821"}
{"text": "HCV RNA assays were per- formed at baseline and on days 1 through 7 , 9 , 11 , and 14 ; at week 3 ; and every 2 weeks from week 4 through week 12 .", "label": "", "metadata": {}, "score": "73.18659"}
{"text": "Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics .Medivir is a collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C. We are passionate and uncompromising in our mission to develop and commercialize innovative pharmaceuticals that improve people 's lives . 0 comments : .", "label": "", "metadata": {}, "score": "73.211655"}
{"text": "Citation : Zhu Y , Chen S. Antiviral treatment of hepatitis C virus infection and factors affecting efficacy .World J Gastroenterol 2013 ; 19(47 ) : 8963 - 8973 .", "label": "", "metadata": {}, "score": "73.26724"}
{"text": "The AE profile of the regimen was similar with and without RBV regardless of age , gender , race , ethnicity , or history of diabetes .", "label": "", "metadata": {}, "score": "73.31072"}
{"text": "Similar results were obtained for the treatment - experienced patients .The adverse responses of faldaprevir include jaundice , skin changes ( e.g . , rash ) , photosensitivity , pruritus , nausea , vomiting , diarrhea , and drying .", "label": "", "metadata": {}, "score": "73.5382"}
{"text": "About Medivir AB .Medivir is an emerging research - based pharmaceutical company focused on infectious diseases .Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio .", "label": "", "metadata": {}, "score": "73.66141"}
{"text": "Clin Gastroenterol Hepatol .[PubMed ] [ DOI ] .Restivo L , Zampino R , Guerrera B , Ruggiero L , Adinolfi LE .", "label": "", "metadata": {}, "score": "73.83169"}
{"text": "Of the patients with chronic HCV infection , 40%-75 % still exhibit extrahepatic manifestations including metabolic , hematological , vascular and rheumatological diseases [ 2 - 5 ] .", "label": "", "metadata": {}, "score": "73.9447"}
{"text": "PubMed ] [ DOI ] .Hill A , van der Lugt J , Sawyer W , Boffito M. How much ritonavir is needed to boost protease inhibitors ?", "label": "", "metadata": {}, "score": "73.95192"}
{"text": "The rate ratios between the HCV and non HCV cohorts for the total number of cancer cases including and excluding liver cancer are shown in Table 1 .", "label": "", "metadata": {}, "score": "74.066315"}
{"text": "STOCKHOLM , Mar 04 , 2013 ( BUSINESS WIRE ) -- Regulatory News : .Simeprevir is jointly developed by Medivir AB and Janssen R&D Ireland , an affiliate of the Janssen Pharmaceutical Companies .", "label": "", "metadata": {}, "score": "74.08853"}
{"text": "More effective in G1b ; of the 8 treatment failures reported,75 % ( 6 of 8) had G1a .All participants were IL28b CC .Thompson et al .", "label": "", "metadata": {}, "score": "74.089"}
{"text": "A total of 4 patients in group A ( 36 % ; 2 of 9 with HCV genotype 1a and 2 of 2 with genotype 1b ) had a sustained virologic response at 12 weeks after treatment and also at 24 weeks after treatment .", "label": "", "metadata": {}, "score": "74.11851"}
{"text": "This may include monitoring in hospital for 48 hours after starting treatment .Because amiodarone remains in the body for a long time , monitoring is also needed when the hepatitis C treatment is given to patients who stopped amiodarone treatment within the last few months .", "label": "", "metadata": {}, "score": "74.39615"}
{"text": "INCREASED CANCER RATES IN PATIENTS WITH CHRONIC HEPATITIS C : AN ANALYSIS OF THE CANCER REGISTRY IN A LARGE U.S. HEALTH MAINTENANCE ORGANIZATION .Background and Aims : Hepatitis C virus ( HCV ) is an oncogenic virus , and an increased risk of malignancy in HCV has previously been reported .", "label": "", "metadata": {}, "score": "74.44913"}
{"text": "Colchicine for treatment of familial Mediterranean fever ( FMF ) : In those receiving boceprevir , use maximum colchicine dosage of 0.6 mg daily ( may be given as 0.3 mg twice daily ) 1 .", "label": "", "metadata": {}, "score": "74.55809"}
{"text": "PubMed ] [ DOI ] .Penney MS , De Souza C , Seepersaud S , Alves K , Koziel MJ , Kauffman RS , Di Bisceglie AM , Botfield MC , Grp ZS .", "label": "", "metadata": {}, "score": "74.57574"}
{"text": "L - Carnitine is a necessary nutrient factor in energy production and has been proposed as a potential adjuvant treatment to improve anemia , thrombocytopenia , and leukopenia .", "label": "", "metadata": {}, "score": "74.71097"}
{"text": "No other uses without permission .Copyright \u00a9 2012 Massachusetts Medical Society .All rights reserved .Page 3 .Daclatasvir was ad- ministered orally at a dose of 60 mg once daily , and asunaprevir was administered orally at a dose of 600 mg twice daily .", "label": "", "metadata": {}, "score": "74.71292"}
{"text": "VIENNA , April 25 , 2015 /PRNewswire/ -- AbbVie ( NYSE : ABBV ) today announced new , preliminary safety and efficacy data from the first cohort of its ongoing , Phase 3b RUBY - I study .", "label": "", "metadata": {}, "score": "74.97261"}
{"text": "In PEARL - I , SVR12 rates of 95 % ( 40/42 ) in hepatitis C ( HCV ) GT-1b treatment - na\u00efve patients and 90 % ( 36/40 ) among prior null responders will be presented in this intent - to - treat analysis .", "label": "", "metadata": {}, "score": "75.16623"}
{"text": "These findings certainly point to the suggestion that hepatitis C may be associated with an increased risk of cancer .However , the findings must be interpreted with caution , as the study also showed that confounding factors such as alcohol abuse , tobacco , obesity , and diabetes modified the results . \"", "label": "", "metadata": {}, "score": "75.19067"}
{"text": "The most common adverse events were gastrointestinal and dermatologic : nausea , vomiting , diarrhea , rash , and photosensitivity .\" First , this is a phase 2b trial , and their phase 3 study is still ongoing , \" said Dr. Davis , who was not involved in the trial . \"", "label": "", "metadata": {}, "score": "75.22963"}
{"text": "Importance of informing patients of other important precautionary information . 1 ( See Cautions . )Preparations .Excipients in commercially available drug preparations may have clinically important effects in some individuals ; consult specific product labeling for details .", "label": "", "metadata": {}, "score": "75.309326"}
{"text": "For nearly 30 years , Merck has been at the forefront of the response to the HCV epidemic .Merck employees are dedicated to applying their scientific expertise , resources and global reach to deliver innovative health care solutions that support people living with HCV worldwide .", "label": "", "metadata": {}, "score": "75.40352"}
{"text": "Those who had no detectable levels of the virus in their blood 24 weeks after completing the therapy were deemed to be cured , a measure known as SVR24 , for sustained virologic response .", "label": "", "metadata": {}, "score": "75.40976"}
{"text": "From FDA website .Accessed 2012 Apr 23 .Panel on Antiretroviral Guidelines for Adults and Adolescents , US Department of Health and Human Services ( HHS ) .", "label": "", "metadata": {}, "score": "75.54393"}
{"text": "Female patients should not take ethinyl estradiol - containing medications during treatment with OBV / PTV / r , as they are at greater risk for liver enzyme elevations when taking these medications .", "label": "", "metadata": {}, "score": "75.62404"}
{"text": "Viral breakthrough occurred in six patients ( 55 % ) , all with HCV geno- type 1a , as early as week 3 and as late as week 12 .", "label": "", "metadata": {}, "score": "75.72768"}
{"text": "Wai CT , Greenson JK , Fontana RJ , et al .A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepa- tology 2003;38:518 - 26 .", "label": "", "metadata": {}, "score": "75.84505"}
{"text": "Interferon - free therapy is evolving rapidly , and I hope that it will be in primary care physicians ' backyards in the near future .", "label": "", "metadata": {}, "score": "76.16185"}
{"text": "In 12-week , 3-drug arms : 86 % to 100 % in IL-28B CC vs. 85 % to 88 % in non - CC .", "label": "", "metadata": {}, "score": "76.19332"}
{"text": "SVR-1256 % ( 27/48 ) for partial responders triple therapy vs. 86 % ( 43/50 ) for QUAD.84 % ( 62/74 ) in null responders , 24 weeks of quad therapy ; 48-week treatment group ongoing .", "label": "", "metadata": {}, "score": "76.24196"}
{"text": "Five serious adverse events were reported , none of which were considered related to study drug .One patient discontinued treatment due to an adverse event that was not considered to be drug - related .", "label": "", "metadata": {}, "score": "76.26892"}
{"text": "\" The safety and efficacy of these investigational uses of Harvoni and Sovaldi have not been established .Important Safety Information About Sovaldi .Contraindications .", "label": "", "metadata": {}, "score": "76.43258"}
{"text": "Among all ALLY-1 patients , 94 % of those with post - transplant HCV recurrence and 83 % of all participants with advanced cirrhosis achieved cure ( sustained virologic response 12 weeks after treatment ; SVR12 ) .", "label": "", "metadata": {}, "score": "76.44356"}
{"text": "3 In HCV genotype 2 , SVR-12 was close to 100 % , but in HCV genotype 3 , SVR-12 was only 61 % ( see Table 1 .", "label": "", "metadata": {}, "score": "76.52718"}
{"text": "Total per - patient lifetime costs were \u20ac 25,200-\u20ac26,000 with model - guided strategy and \u20ac 28,800-\u20ac29,900 with guideline - guided strategy .When comparing model - guided with guideline - guided strategy the former resulted more effective and less costly .", "label": "", "metadata": {}, "score": "76.66638"}
{"text": "Merck 's Commitment to HCV .For nearly 30 years , Merck has been at the forefront of the response to the HCV epidemic .Merck employees are dedicated to applying their scientific expertise , resources and global reach to deliver innovative health care solutions that support people living with HCV worldwide .", "label": "", "metadata": {}, "score": "76.788956"}
{"text": "1 Obtain a report of a negative pregnancy test for female patients of childbearing potential immediately prior to initiating ribavirin and perform pregnancy tests monthly during and for 6 months after ribavirin treatment is completed .", "label": "", "metadata": {}, "score": "76.81518"}
{"text": "One patient had a grade 3 liver function test elevation ( aspartate aminotransferase [ AST ] greater than five times the upper limit of normal ) , which was asymptomatic and resolved during continued dosing .", "label": "", "metadata": {}, "score": "76.93891"}
{"text": "Shepard CW , Finelli L , Alter MJ .Global epidemiology of hepatitis C virus infection .Lancet Infect Dis .[PubMed ] [ DOI ] .", "label": "", "metadata": {}, "score": "77.21214"}
{"text": "91 percent of patients achieved SVR24 , .In the trial , the most common adverse events reported were headache , fatigue , nausea and dry skin .", "label": "", "metadata": {}, "score": "77.30547"}
{"text": "Host factors .Polymorphisms of the IL28B gene : In 2009 , three genome - wide association studies ( GWAS ) found that single nucleotide polymorphisms ( SNPs ) in the IL-28B gene , located on chromosome 19 , are associated with hepatitis C treatment efficacy [ 62 - 64 ] .", "label": "", "metadata": {}, "score": "77.482315"}
{"text": "Possible increased vardenafil concentrations and increased risk of tadalafil - associated adverse effects ( hypotension , syncope , visual changes , priapism ) 1 .Use with caution and with reduced vardenafil dosage ( do not exceed 2.5 mg every 24 hours ) ; 1 increase monitoring for adverse effects 1 .", "label": "", "metadata": {}, "score": "77.57692"}
{"text": "The regimen was generally well tolerated , he said -- the most common adverse event was headache -- there were no serious adverse events related to the study drugs , and no patients stopped treatment because of adverse events or abnormal laboratory findings ...... .", "label": "", "metadata": {}, "score": "77.619095"}
{"text": "WATERTOWN Mass.April .4 2012 /- Phase 2 Data Highlights ...In the study known as Co - Pilot different doses of ABT-450/r plus A ..", "label": "", "metadata": {}, "score": "77.93236"}
{"text": "PegIFN- \u03bb -1a : IFN - \u03bb is a class III interferon and has completely different receptors from those of IFN - alpha in vivo .", "label": "", "metadata": {}, "score": "78.17255"}
{"text": "Hepatology .[PubMed ] [ DOI ] .Antivir Ther .2013;Epub ahead of print .[PubMed ] [ DOI ] .J Hepatol .", "label": "", "metadata": {}, "score": "78.32718"}
{"text": "All 10 patients in group B had a sus- tained virologic response at 12 weeks after treatment , and 9 had a sustained viro- logic response at 24 weeks after treatment .", "label": "", "metadata": {}, "score": "78.3414"}
{"text": "The ALLY-1 trial included 16 patients with decompensated cirrhosis Child - Pugh class C ; nine ( 56 % ) achieved SVR12 .Over the course of the study , four advanced cirrhotic patients received a liver transplant during treatment ; 3 of 4 extended treatment post - transplant ( see study design below ) , and all 4 achieved SVR12 .", "label": "", "metadata": {}, "score": "78.58899"}
{"text": "Relapse occurred in 19 % of those in the TID16W group , 2 % of those in the TID28W group , 2 % of those in the TID40W group , 0 % of those in the BID28W group , and 10 % of those in the TIDW - NR group .", "label": "", "metadata": {}, "score": "78.91013"}
{"text": "Gilead filed the NDA for sofosbuvir on April 8 , 2013 , and FDA has set a target review date under the Prescription Drug User Fee Act ( PDUFA ) of December 8 , 2013 .", "label": "", "metadata": {}, "score": "79.067474"}
{"text": "Ninety - three percent of patients with genotype 4 ( 41/44 ) and 95 percent of patients with genotype 5 ( 39/41 ) achieved SVR12 .", "label": "", "metadata": {}, "score": "79.09993"}
{"text": "Currently , resistance mutants have not been found .The design of NNIs involves targeting one of at least five non - contiguous sites of RdRp allosteric enzymes , resulting in conformational changes that inhibit the enzyme activity , which have limitations on the genotype compared with NIs .", "label": "", "metadata": {}, "score": "79.15529"}
{"text": "In patients without alternative , viable treatment options , cardiac monitoring is recommended .Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia .", "label": "", "metadata": {}, "score": "79.19235"}
{"text": "Actual costs to patients will vary depending on the use of specific retail or mail - order locations and health insurance copays .Victrelis 200MG Capsules ( SCHERING ) : 12/$183.99 or 36/$521.98 .", "label": "", "metadata": {}, "score": "79.26065"}
{"text": "A complete list can be found on the journal 's Web site .Dr. Davis is on the Data Safety and Monitoring Boards for Gilead and BMS .", "label": "", "metadata": {}, "score": "79.30203"}
{"text": "Drug Interactions .Concomitant use with certain drugs is contraindicated or requires particular caution . 1 ( See Specific Drugs under Interactions . )Laboratory Monitoring .", "label": "", "metadata": {}, "score": "79.484726"}
{"text": "Updates may be available at HHS AIDS Information ( AIDSinfo ) website .About .Terms & Privacy .Connect .Subscribe to receive email notifications whenever new articles are published .", "label": "", "metadata": {}, "score": "79.60098"}
{"text": "The most common adverse events ( affecting more than 10 percent of patients ) were asthenia , headache and fatigue .Most adverse events were mild or moderate in severity and none resulted in treatment discontinuation .", "label": "", "metadata": {}, "score": "79.61654"}
{"text": "Female patients of childbearing potential and their male partners must use two forms of non - hormonal contraception during treatment and for at least 6 months after treatment has concluded .", "label": "", "metadata": {}, "score": "79.62606"}
{"text": "Do not give VIEKIRAX and EXVIERA with strong or moderate enzyme inducers .Do not give EXVIERA with certain drugs that are strong inhibitors of CYP2C8 .", "label": "", "metadata": {}, "score": "79.63169"}
{"text": "\" Gilead can not cure hepatitis C globally on our backs alone .There have to be other players that come in and make that investment , \" he said .", "label": "", "metadata": {}, "score": "79.93593"}
{"text": "Grupo Otimismo , a support group for people with hepatitis and a nongovernmental organization in Brazil , used an online tool to survey 1,217 people infected with hepatitis B or C , Naveira explained .", "label": "", "metadata": {}, "score": "79.97597"}
{"text": "The prevalence of hepatitis C virus infec- tion in the United States , 1999 through 2002 .Ann Intern Med 2006;144:705 - 14 . html ) .", "label": "", "metadata": {}, "score": "80.14687"}
{"text": "AbbVie cautions that these forward - looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward - looking statements .", "label": "", "metadata": {}, "score": "80.15326"}
{"text": "Virologic failure was reported for three patients in the trial .All three patients had resistance associated variants at baseline and relapsed after completion of study treatment .", "label": "", "metadata": {}, "score": "80.25149"}
{"text": "Serious adverse events occurred in 6 % of patients ; 5 % discontinued treatment due to an adverse event .Grade 3/4 laboratory abnormalities included neutropenia ( 22 % ) , lymphopenia ( 16 % ) , anemia ( 6 % ) , thrombocytopenia ( 4 % ) , and ALT / AST elevations ( 3 % each ) .", "label": "", "metadata": {}, "score": "80.49644"}
{"text": "[PubMed ] [ DOI ] .Shirakawa H , Matsumoto A , Joshita S , Komatsu M , Tanaka N , Umemura T , Ichijo T , Yoshizawa K , Kiyosawa K , Tanaka E ; Nagano Interferon Treatment Research Group .", "label": "", "metadata": {}, "score": "80.51407"}
{"text": "It is not a substitute for professional care .If you have or suspect you may have a health problem , consult your health care provider .", "label": "", "metadata": {}, "score": "80.54725"}
{"text": "\" We remain on track to submit a New Drug Application with the U.S. Food and Drug Administration in the first half of 2015 . \" C - EDGE TN Overview and Additional Findings .", "label": "", "metadata": {}, "score": "80.56458"}
{"text": "We found that genotype 1a patients are indeed difficult to treat , achieving lower cure rates .That would have been attractive maybe three , four years ago , but not nowadays .", "label": "", "metadata": {}, "score": "80.68396"}
{"text": "[PubMed ] [ DOI ] .Zeuzem S , Fried MW , Reddy KR , Marcellin P , Diago M , Craxi A , Pockros P , Rizzetto M , Berstein D , Shiffman ML .", "label": "", "metadata": {}, "score": "80.83385"}
{"text": "Alton admits the scheme may prompt other governments to ask for free drugs as well , but he said it was unrealistic to simply give away product globally .", "label": "", "metadata": {}, "score": "80.83549"}
{"text": "For personal use only .No other uses without permission .Copyright \u00a9 2012 Massachusetts Medical Society .All rights reserved .Page 4 .Direct - Acting Antiviral Agents for Hepatitis C n engl j med 366;3 nejm.org january 19 , 2012 219 had peginterferon and ribavirin added to their regimens as rescue therapy classified as having had treatment failure .", "label": "", "metadata": {}, "score": "80.915634"}
{"text": "All 10 patients in group B had a sustained virologic response at 12 weeks after treatment , and 9 had a sustained virologic response at 24 weeks after treatment .", "label": "", "metadata": {}, "score": "80.92447"}
{"text": "Genetic markers need further verification , which can be performed in the preclinical testing stage .At the same time , accurately predicting the success of treatment and the progression of the disease will enhance the treatment compliance of patients , which will aid in maximizing the treatment effect .", "label": "", "metadata": {}, "score": "81.014435"}
{"text": "The primary end point was SVR at 24 weeks after treatment ( SVR24 ) .Results : Baseline characteristics were similar among patients within each HCV genotype group .", "label": "", "metadata": {}, "score": "81.32301"}
{"text": "P- Reviewers : Narciso - Schiavon JL , Lonardo A , Malaguarnera MA S- Editor : Cui XM L- Editor : Wang TQ E- Editor : Wang CH .", "label": "", "metadata": {}, "score": "81.41928"}
{"text": "( % ) 1a9 ( 82 ) 9 ( 90 ) 1b 2 ( 18 ) 1 ( 10 ) IL28B rs12979860 genotype - no .", "label": "", "metadata": {}, "score": "81.61754"}
{"text": "In this study , virologic failure occurred in 13 patients ( 4 % ) in the immediate treatment group , including one virologic breakthrough and 12 virologic relapses .", "label": "", "metadata": {}, "score": "81.626076"}
{"text": "[PubMed ] [ DOI ] .Gane EJ , Stedman CA , Hyland RH , Ding X , Svarovskaia E , Symonds WT , Hindes RG , Berrey MM .", "label": "", "metadata": {}, "score": "81.657364"}
{"text": "[PubMed ] [ DOI ] .[PubMed ] [ DOI ] .Nelson DR , Benhamou Y , Chuang WL , Lawitz EJ , Rodriguez - Torres M , Flisiak R , Rasenack JW , Kryczka W , Lee CM , Bain VG .", "label": "", "metadata": {}, "score": "81.66612"}
{"text": "Results : From 2008 to 2012 , 145,210 patient years were included in the HCV cohort , and 13,948,826 patient years were included in the non HCV cohort .", "label": "", "metadata": {}, "score": "81.66742"}
{"text": "If concomitant use with amiodarone can not be avoided , patients should be closely monitored .Because amiodarone persists for a long time in the body , monitoring is also needed if patients start such hepatitis C treatments within a few months of stopping amiodarone .", "label": "", "metadata": {}, "score": "81.68538"}
{"text": "Duration : 8 , 12 or 24 weeks .Update : Interferon - Free Regimens in HCV Genotype 1 , Treatment Experienced ) .8-week , 4-drug arm:86 % in G1a versus 96 % in G1b.12-week , 4-drug arm : 98 % in G1a vs. 100 % for G1b .", "label": "", "metadata": {}, "score": "81.76426"}
{"text": "The KPSC cancer registry is an accredited program maintaining a complete profile of all cancer diagnoses for all KP members .In this study , we recorded all cancer diagnoses in patients ?", "label": "", "metadata": {}, "score": "81.82938"}
{"text": "2011 ; 18 : e81-e90 .[PubMed ] [ DOI ] .Conjeevaram HS , Kleiner DE , Everhart JE , Hoofnagle JH , Zacks S , Afdhal NH , Wahed AS ; Virahep - C Study Group .", "label": "", "metadata": {}, "score": "81.88878"}
{"text": "ab-stract .Copyright \u00a9 2012 Massachusetts Medical Society . an nejm app for iphone The NEJM Image Challenge app brings a popular online feature to the smartphone .", "label": "", "metadata": {}, "score": "81.956566"}
{"text": "PubMed ] [ DOI ] .Jacobson IM , Sulkowski MS , Gane EJ , Koziel MJ , De Souza C , Kieffer TL , Penney MS , Zhang EZ , George S , Kauffman RS .", "label": "", "metadata": {}, "score": "81.96242"}
{"text": "It was considered that there was a likely relationship of these events to the medicines .The possible mechanism behind these effects is unknown and further investigation of other cases with Sovaldi and other hepatitis C medicines is ongoing .", "label": "", "metadata": {}, "score": "82.02931"}
{"text": "The Image Challenge app randomly selects from 300 challenging clinical photos published in NEJM , with a new image added each week .View an image , choose your answer , get immediate feedback , and see how others answered .", "label": "", "metadata": {}, "score": "82.17786"}
{"text": "Study Design This was an open - label , proof - of - concept , phase 2a study .Eligible patients were randomly assigned , The New England Journal of Medicine Downloaded from nejm.org on January 13 , 2016 .", "label": "", "metadata": {}, "score": "82.39085"}
{"text": "FAIR USE NOTICE : .This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner .It is being made available in an effort to advance the understanding of Hepatitis C , New hepatitis c drugs , Related clinical trials and ongoing research , HIV / HCV coinfection , HIV / AIDS , Other factors of liver disease , and so on .", "label": "", "metadata": {}, "score": "82.95748"}
{"text": "Dosage Forms .Strengths .Brand Names .Manufacturer .Oral .Capsules .200 mg .Victrelis .Merck .Comparative Pricing .This pricing information is subject to change at the sole discretion of DS Pharmacy .", "label": "", "metadata": {}, "score": "83.04768"}
{"text": "Twenty - eight patients dropped out of the study - a 12.6 percent discontinuation rate - and about 6 percent , or 13 patients , reported serious side effects , primarily elevated liver enzymes , an indication of inflammation .", "label": "", "metadata": {}, "score": "83.19534"}
{"text": "It is supplied as 200 mg capsules in 56- , 70- , and 84-count bottles .The Rebetol discontinuation is effective February 1 , 2016 .", "label": "", "metadata": {}, "score": "83.2957"}
{"text": "It is supplied as 50mcg/0.5mL , 80mcg/0.5mL , 120mcg/0.5mL , and 150mcg/0.5mL single - use vials and single - use pre - filled pens .No effective date is available for the PegIntron discontinuation .", "label": "", "metadata": {}, "score": "83.306335"}
{"text": "In chronic hepatitis C , the progression of liver fibrosis is slow , but steady .It has been reported that the progression rate of liver fibrosis is 0.10 - 0.13 U / year in untreated patients [ 8 ] .", "label": "", "metadata": {}, "score": "83.34555"}
{"text": "Study Oversight The study was approved by the institutional review board at each participating site and was conducted in compliance with the Declaration of Helsinki , Good Clinical Practice guidelines , and local reg- ulatory requirements .", "label": "", "metadata": {}, "score": "83.494804"}
{"text": "Patients were enrolled at seven cen- ters in the United States during the period from December 2009 through February 2010 . .19- 21 Patients were required to have had no response to previ- ous HCV therapy , as defined previously .", "label": "", "metadata": {}, "score": "83.74644"}
{"text": "2011 ; 54 : S6 .[PubMed ] [ DOI ] .Bronowicki JP , Hezode C , Bengtsson L , Pol S , Bourliere M , Serfaty L , de Ledinghen V , Tran A , Benhamou Y , Grange JD .", "label": "", "metadata": {}, "score": "83.93765"}
{"text": "PubMed ] [ DOI ] .McHutchison JG , Lawitz EJ , Shiffman ML , Muir AJ , Galler GW , McCone J , Nyberg LM , Lee WM , Ghalib RH , Schiff ER .", "label": "", "metadata": {}, "score": "83.95119"}
{"text": "Results A total of 4 patients in group A ( 36 % ; 2 of 9 with HCV genotype 1a and 2 of 2 with genotype 1b ) had a sustained virologic response at 12 weeks after treatment and also at 24 weeks after treatment .", "label": "", "metadata": {}, "score": "84.24472"}
{"text": "The scheme , which has the backing of the U.S. Centers for Disease Control and Prevention , will cover an initial 5,000 patients in 2015 , with a second phase treating up to 20,000 a year .", "label": "", "metadata": {}, "score": "84.36128"}
{"text": "Keywords : .Review .Introduction .Hepatitis C virus ( HCV ) chronically infects an estimated 170 million people worldwide [ 1 ] .HCV infection is one of the major causes of end - stage liver disease and hepatocellular carcinoma ( HCC ) worldwide [ 2 - 4 ] .", "label": "", "metadata": {}, "score": "84.41002"}
{"text": "Special Populations .Hepatic Impairment .Dosage adjustments not required in patients with mild , moderate , or severe hepatic impairment ; 1 safety and efficacy not studied in patients with decompensated cirrhosis .", "label": "", "metadata": {}, "score": "84.60326"}
{"text": "About Gilead .Gilead Sciences is a biopharmaceutical company that discovers , develops and commercializes innovative therapeutics in areas of unmet medical need .The company 's mission is to advance the care of patients suffering from life - threatening diseases .", "label": "", "metadata": {}, "score": "84.68466"}
{"text": "We also demonstrate our commitment to increasing access to health care through far - reaching policies , programs and partnerships .Forward - Looking Statement .", "label": "", "metadata": {}, "score": "84.81956"}
{"text": "We also demonstrate our commitment to increasing access to health care through far - reaching policies , programs and partnerships .Forward - Looking Statement .", "label": "", "metadata": {}, "score": "84.81956"}
{"text": "The percentage of patients experiencing any treatment - emergent adverse event ( AE ) , severe AE , serious AE , and AE leading to treatment discontinuation was determined according to sex , age , race , ethnicity , and history of diabetes .", "label": "", "metadata": {}, "score": "84.90147"}
{"text": "HCV genotype 4 and 5 are less prevalent than other genotypes and therefore , have traditionally not been closely studied , \" said Armand Abergel , MD , PhD , Department of Hepatology and Gastroenterology , Centre Hospitalier Universitaire - Estaing , Universit\u00e9 d'Auvergne , Clermont - Ferrand , France .", "label": "", "metadata": {}, "score": "84.92464"}
{"text": "2 While genotype 1 ( GT1 ) is the most prevalent form of HCV in the U.S. , accounting for approximately 73 percent of all cases , GT4 infection accounts for up to 6 percent of HCV infections .", "label": "", "metadata": {}, "score": "85.02568"}
{"text": "A retrospective study at Kaiser Permanente , Southern California , USA , was conducted .The study authors recorded all cancer diagnoses in patients over 18 years of age with or without HCV during 2008 - 2012 .", "label": "", "metadata": {}, "score": "85.05966"}
{"text": "[PubMed ] [ DOI ] .McHutchison JG , Everson GT , Gordon SC , Jacobson IM , Sulkowski M , Kauffman R , McNair L , Alam J , Muir AJ .", "label": "", "metadata": {}, "score": "85.13935"}
{"text": "The combination was well tolerated and no additional safety and tolerability concerns were observed compared with peginterferon / ribavirin regimens .Copyright \u00a9 2015 .Published by Elsevier B.V. .", "label": "", "metadata": {}, "score": "85.16138"}
{"text": "About the PEARL - I Study .Treatment - na\u00efve GT4 patients were randomized in a 1:1 ratio to receive OBV / PTV / r with or without RBV .", "label": "", "metadata": {}, "score": "85.23543"}
{"text": "Pediatric Use .Geriatric Use .Hepatic Impairment .Safety and efficacy not studied in patients with decompensated cirrhosis .Renal Impairment .Common Adverse Effects .", "label": "", "metadata": {}, "score": "85.302605"}
{"text": "Feld et al . 13 Jacobson et al .18 Regimen more effective in genotype 1b versus 1a .Although numbers were small , efficacy of triple and QUAD did not differ between people with mild to moderate liver fibrosis .", "label": "", "metadata": {}, "score": "85.40379"}
{"text": "Consequently , a large retrospective cohort study was performed .The relationship between ALD and several potential risk factors was assessed in 1076 consecutive patients with GO given ivGC .", "label": "", "metadata": {}, "score": "85.498856"}
{"text": "Benzodiazepines ( alprazolam , midazolam , triazolam ) .Midazolam : Increased midazolam concentrations and AUC ; potential for serious and/or life - threatening effects ( e.g. , prolonged or increased sedation or respiratory depression ) 1 .", "label": "", "metadata": {}, "score": "85.52504"}
{"text": "Data from both studies will be presented in oral sessions at the 50th Annual Meeting of the European Association for the Study of the Liver ( The International Liver Congress \u2122 2015 ) in Vienna , Austria .", "label": "", "metadata": {}, "score": "85.7298"}
{"text": "All 10 patients had a sustained virologic response at week 12 after treatment and all but 1 had a sustained virologic response at week 24 after treatment ( Table 2 , and Fig . 1 in the Supplementary Appendix ) .", "label": "", "metadata": {}, "score": "85.75287"}
{"text": "SVR-12Overall 72%33/46 .12-week group : 82 % ( 9/11 ) .36-week group : 89 % ( 24/27 ) .100 % ( 5/5 for 12 weeks of triple in G1b vs. 67 % ( 4/6 ) in G1a.85 % ( 11/13 ) in 36-week group in G1b vs. 93 % ( 13/14 ) in G1a .", "label": "", "metadata": {}, "score": "85.7942"}
{"text": "GC is a relatively rare adverse event .Provided an accurate selection of patients and a series of preventive measures are applied , i.v .GC is a safe treatment for the liver .", "label": "", "metadata": {}, "score": "85.90113"}
{"text": "No adjustments have been made for multiple testing .Results Patients A total of 21 patients were enrolled ( 11 in group A and 10 in group B ) ( Fig . 1 in the Supplementary Appendix ) .", "label": "", "metadata": {}, "score": "86.07849"}
{"text": "Budesonide or fluticasone ( nasal spray / oral inhalation ) : If possible , avoid concomitant use ( particularly for extended duration ) 1 .Dexamethasone : Avoid concomitant use when possible ; use with caution if concomitant use necessary 1 .", "label": "", "metadata": {}, "score": "86.08429"}
{"text": "[PubMed ] [ DOI ] .Hopkins S , Bobardt M , Chatterji U , Garcia - Rivera JA , Lim P , Gallay PA .", "label": "", "metadata": {}, "score": "86.15006"}
{"text": "Adverse events that occurred in those pa- tients are included here .The New England Journal of Medicine Downloaded from nejm.org on January 13 , 2016 .", "label": "", "metadata": {}, "score": "86.41437"}
{"text": "[PubMed ] [ DOI ] .Buskila D. Hepatitis C - associated rheumatic disorders .Rheum Dis Clin North Am .[PubMed ] [ DOI ] .", "label": "", "metadata": {}, "score": "86.71974"}
{"text": "Obtain CBC ( with WBC differential ) at baseline , at total treatment duration of 2 , 4 , 8 , and 12 weeks , and as clinically indicated . 1 ( See Hematologic Effects under Warnings / Precautions . )", "label": "", "metadata": {}, "score": "87.12219"}
{"text": "Cirrhosis rates become significant after 20 years of HCV infection .About 20 - 30 % of patients could develop a progressive liver disease leading to cirrhosis and HCC [ 5 , 7 ] .", "label": "", "metadata": {}, "score": "87.14405"}
{"text": "The material in this site is provided for educational and informational purposes only , and is not intended to be a substitute for a health care provider 's consultation .", "label": "", "metadata": {}, "score": "87.4705"}
{"text": "Viral hepatitis is not only a silent disease , but also a silencing event , \" Marcelo Naveira , MD , of Brazil 's Ministry of Health , said during a press conference at the congress .", "label": "", "metadata": {}, "score": "87.55614"}
{"text": "1 The review was in the context of a \" safety signal \" .A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation .", "label": "", "metadata": {}, "score": "87.558365"}
{"text": "5 It is transmitted when an infected person 's blood enters the bloodstream of another person .6 There are six major HCV genotypes ( GT1 - 6 ) .", "label": "", "metadata": {}, "score": "87.63684"}
{"text": "[PubMed ] [ DOI ] .Shah SR , Patel K , Marcellin P , Foster GR , Manns M , Kottilil S , Healey L , Pulkstenis E , Subramanian GM , McHutchison JG .", "label": "", "metadata": {}, "score": "87.74509"}
{"text": "\u00a9 2015 , Antonio Bertoletti , Maurizia Brunetto , Mala K Maini , Ferruccio Bonino , Waseem Qasim , and Hans Stauss .The aim of this study was to evaluate the frequency of ALD after the introduction of a series of exclusion criteria and preventive measures .", "label": "", "metadata": {}, "score": "87.89444"}
{"text": "Competing interests .Dr. Tatsuo Kanda reports receiving lecture fees from Chugai Pharmaceutical , MSD , Ajinomoto , GlaxoSmithKlein and Mitsubishi Tanabe Pharma , and Prof. Osamu Yokosuka received grant support from Chugai Pharmaceutical , Bayer , MSD , Daiichi - Sankyo , and Mitsubishi Tanabe Pharma .", "label": "", "metadata": {}, "score": "87.91992"}
{"text": "These and other risks are described in detail in Gilead 's Annual Report on Form 10-K for the year ended December 31 , 2014 , as filed with the U.S. Securities and Exchange Commission .", "label": "", "metadata": {}, "score": "87.986305"}
{"text": "Sovaldi and Harvoni are registered trademarks of Gilead Sciences , Inc. , or its related companies .Source : Gilead Sciences , Inc. .Gilead Sciences , Inc.", "label": "", "metadata": {}, "score": "88.17035"}
{"text": "Proof - of - concept has been established : hepatitis C , a disease that claims more than 350,000 lives annually , can be cured with three months of oral antiviral drugs .", "label": "", "metadata": {}, "score": "88.35571"}
{"text": "PubMed ] [ DOI ] .Patton HM , Patel K , Behling C , Bylund D , Blatt LM , Vall\u00e9e M , Heaton S , Conrad A , Pockros PJ , McHutchison JG .", "label": "", "metadata": {}, "score": "88.37419"}
{"text": "This press release contains \" forward - looking statements \" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research , development and commercialization of pharmaceutical products .", "label": "", "metadata": {}, "score": "88.51654"}
{"text": "About Enanta Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the infectious disease field .", "label": "", "metadata": {}, "score": "88.5532"}
{"text": "Researchers suggest an extrahepatic manifestation of hepatitis C may be an increased risk of cancer .European Association for the Study of the Liver .April 24 , 2015 , Vienna , Austria : Results announced today at The International Liver CongressTM 2015 show that cancer rates in patients with the hepatitis C virus ( HCV ) were significantly increased compared to the non - HCV cohort .", "label": "", "metadata": {}, "score": "88.63861"}
{"text": "[PubMed ] [ DOI ] .Sulkowski M , Gardiner D , Lawitz E , Hinestrosa F , Nelson D , Thuluvath P , Rodriguez - Torres M , Lok A , Schwartz H , Reddy KR .", "label": "", "metadata": {}, "score": "88.71416"}
{"text": "These tests are done to determine whether or not hepatitis C infection has occurred as a result of the exposure .It is believed that this use constitutes a ' fair use ' of any such copyrighted material as provided for in section 107 of the US Copyright Law .", "label": "", "metadata": {}, "score": "88.73035"}
{"text": "No other potential conflict of interest relevant to this article was reported .Disclosure forms provided by the authors are available with the full text of this article at NEJM.org .", "label": "", "metadata": {}, "score": "88.77369"}
{"text": "The sponsor collected the data , monitored the study conduct , and performed the statistical analy- ses .The first draft of the manuscript was pre- pared by the principal academic and sponsor au- thors , with assistance from a medical writer paid by Bristol - Myers Squibb and with input from all the other authors .", "label": "", "metadata": {}, "score": "88.89708"}
{"text": "1 Mean peak plasma concentrations were 28 and 62 % higher , respectively .1 Exposure was similar between adults with mild ( Child - Pugh score 5 - 6 ) hepatic impairment and those with normal hepatic function .", "label": "", "metadata": {}, "score": "88.91883"}
{"text": "Hepatology .[PubMed ] [ DOI ] .Hanouneh IA , Feldstein AE , Lopez R , Yerian L , Pillai A , Zein CO , Zein NN .", "label": "", "metadata": {}, "score": "88.92288"}
{"text": "There is now a lot of focus on cardiac and hepatotoxicity due to Bristol - Myers Squibb 's ( NYSE : BMY ) failed purine nuc , he said .", "label": "", "metadata": {}, "score": "88.9716"}
{"text": "Forward - Looking Statement .These risks , uncertainties and other factors could cause actual results to differ materially from those referred to in the forward - looking statements .", "label": "", "metadata": {}, "score": "89.02577"}
{"text": "( Funded by Bristol - Myers Squibb ; ClinicalTrials.gov number , NCT01012895 . )Full - text .Address reprint requests to Dr. Lok at the Department of Internal Medi- cine , Division of Gastroenterology , 3912 Taubman Center , SPC 5362 , University of Michigan Medical Center , Ann Arbor , MI 48109 , or at aslok@med.umich.edu .", "label": "", "metadata": {}, "score": "89.08937"}
{"text": "PubMed ] [ DOI ] .Sood A , Midha V , Hissar S , Kumar M , Suneetha PV , Bansal M , Sood N , Sakhuja P , Sarin SK .", "label": "", "metadata": {}, "score": "89.97749"}
{"text": "[PubMed ] [ DOI ] .Pockros PJ , Jensen D , Tsai N , Taylor R , Ramji A , Cooper C , Dickson R , Tice A , Kulkarni R , Vierling JM .", "label": "", "metadata": {}, "score": "90.13289"}
{"text": "[PubMed ] [ DOI ] .Ge D , Fellay J , Thompson AJ , Simon JS , Shianna KV , Urban TJ , Heinzen EL , Qiu P , Bertelsen AH , Muir AJ .", "label": "", "metadata": {}, "score": "90.41582"}
{"text": "Overall , 16 percent of patients had liver cirrhosis .In this study , virologic failure occurred in seven patients ( 3 % ) , including six virologic relapses and one reinfection .", "label": "", "metadata": {}, "score": "90.47609"}
{"text": "Copyright \u00a9 2014 Editrice Gastroenterologica Italiana S.r.l .Published by Elsevier Ltd.All rights reserved .We performed a randomized , double - blind , phase 2b study to assess whether adding daclatasvir , a nonstructural protein 5A ( NS5A ) inhibitor that is active against these genotypes , improves efficacy and shortens therapy .", "label": "", "metadata": {}, "score": "90.8909"}
{"text": "Today 's Merck is a global health care leader working to help the world be well .Merck is known as MSD outside the United States and Canada .", "label": "", "metadata": {}, "score": "90.99828"}
{"text": "Today 's Merck is a global health care leader working to help the world be well .Merck is known as MSD outside the United States and Canada .", "label": "", "metadata": {}, "score": "90.99828"}
{"text": "SVR4 results are reported here with SVR12 available at presentation .Results : Baseline characteristics were male 46 % , Caucasian 96 % , and IL28B non - CC genotype 67 % .", "label": "", "metadata": {}, "score": "91.01929"}
{"text": "Four patients ( 36 % ) had a sustained virologic response at 12 weeks after the end of the treatment period , and all four also had a sustained virologic response at week 24 after treatment ( Table 2 ) .", "label": "", "metadata": {}, "score": "91.33081"}
{"text": "Population pharmacokinetic analysis indicates age ( range 19 - 65 years ) , gender , and race do not effect exposure .Actions and Spectrum .", "label": "", "metadata": {}, "score": "91.35892"}
{"text": "Merck undertakes no obligation to publicly update any forward - looking statement , whether as a result of new information , future events or otherwise except as required by applicable law .", "label": "", "metadata": {}, "score": "91.37683"}
{"text": "Abstract 80 .Links to other websites are current at date of posting but not maintained .This article was provided by HIV i - Base .", "label": "", "metadata": {}, "score": "91.406685"}
{"text": "This year , the congress is expected to attract approximately 10,000 delegates from all corners of the globe .2015 is a very special year for EASL and the hepatology community as they will celebrate the 50th annual meeting .", "label": "", "metadata": {}, "score": "91.48831"}
{"text": "About Hepatitis C .Hepatitis C , a blood - borne infectious disease of the liver and a leading cause of chronic liver disease and liver transplants , is a rapidly evolving treatment area with a clear need for innovative treatments .", "label": "", "metadata": {}, "score": "92.55598"}
{"text": "No other uses without permission .Copyright \u00a9 2012 Massachusetts Medical Society .All rights reserved .Page 2 .We report preliminary data from the exploratory cohort , including the per- centages of patients with sustained virologic re- sponse at 12 , 24 , and 48 weeks after the end of the treatment period .", "label": "", "metadata": {}, "score": "92.56042"}
{"text": "All the authors reviewed major changes to the drafts and approved the final man- uscript .All the authors had access to the data and assume responsibility for the veracity and com- pleteness of the reported data and for the fidelity of the study to the protocol .", "label": "", "metadata": {}, "score": "93.37523"}
{"text": "( Date:2/5/2016 ) ... ... , ...After years as an active staff surgeon and having served as ... Wayne Carman transitioned to chief of the Division of Plastic Surgery at what is ... chief and began a second three - year term in January of 2016 . , The original ... .", "label": "", "metadata": {}, "score": "93.425156"}
{"text": "After diagnosis , 55.8 % of patients reported an effect on self - esteem and 41.4 % reported feeling shame .More than 40 % of respondents reported their diagnoses affected their jobs , friends and sexual relationships ; approximately 10 % of respondents were dismissed from their jobs due to their hepatitis .", "label": "", "metadata": {}, "score": "93.621796"}
{"text": "Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page .Forward - Looking Statements Some statements in this news release may be forward - looking statements for purposes of the Private Securities Litigation Reform Act of 1995 .", "label": "", "metadata": {}, "score": "93.771194"}
{"text": "Following oral administration , peak plasma concentrations attained approximately 2 hours after a dose .Based on studies using 800-mg and 1200-mg doses , peak plasma concentrations and AUC increase in a less - than - dose - proportional manner ; diminished absorption may occur at higher doses .", "label": "", "metadata": {}, "score": "93.81539"}
{"text": "Globally , prescribing information varies ; refer to the individual country product label for complete information .About AbbVie AbbVie is a global , research - based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories .", "label": "", "metadata": {}, "score": "93.86426"}
{"text": "GC over a period of 5 years .The study includes 376 GO patients candidate to i.v .GC .Several liver tests were performed before , during , and after i.v .", "label": "", "metadata": {}, "score": "93.98564"}
{"text": "J Hepatol .2012 ; 56 : S560-S560 .[PubMed ] [ DOI ] .Lancet Infect Dis .[PubMed ] [ DOI ] .", "label": "", "metadata": {}, "score": "93.9998"}
{"text": "The FDA grants priority review designation to investigational therapies that treat a serious condition and , if approved , would provide a significant improvement in safety or effectiveness .", "label": "", "metadata": {}, "score": "94.168274"}
{"text": "Desipramine .Possible increased desipramine concentrations may result in dizziness , hypotension , and syncope 1 .Concomitant use not recommended pending further accumulation of data 200 .", "label": "", "metadata": {}, "score": "94.53157"}
{"text": "Onset of bradycardia was within 24 hours of initiating hepatitis C treatment in 6 cases and within 2 to 12 days in the other 2 cases .", "label": "", "metadata": {}, "score": "95.35594"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Due to shared routes of transmission , acute and chronic infection with hepatitis C virus is common among persons living with HIV infection in many regions of the world .", "label": "", "metadata": {}, "score": "95.364105"}
{"text": "While Gilead has slashed the price for several low - income countries to $ 300 per bottle of 28 pills , it also wants to involve international donors in a broad eradication drive .", "label": "", "metadata": {}, "score": "95.40428"}
{"text": "Among GT3 patients , virologic relapse occurred in one non - cirrhotic patient receiving eight weeks of treatment , and in one cirrhotic patient receiving 12 weeks of treatment .", "label": "", "metadata": {}, "score": "95.65378"}
{"text": "\" - by Katrina Altersitz .For More Information : .Varaldo CN .Abstract P1275 .Presented at : International Liver Congress ; April 22 - 26 , 2015 ; Vienna .", "label": "", "metadata": {}, "score": "96.51878"}
{"text": "It also has a wide range of viral variations and different types of patients .What is more , the country is a manageable size , with a population of around 5 million , and has viral screening systems , making it ideal for scientific study , according to Gregg Alton , the U.S. drugmaker 's head of corporate and medical affairs .", "label": "", "metadata": {}, "score": "96.6569"}
{"text": "While 70 % of health professionals were reported to treat patients properly , 24.6 % reported the practitioners kept a certain distance and 6.9 % of respondents were denied care .", "label": "", "metadata": {}, "score": "96.86951"}
{"text": "Hepatology .[PubMed ] [ DOI ] .J Hepatol .2012 ; 56 : S5-S6 .[PubMed ] [ DOI ] .", "label": "", "metadata": {}, "score": "97.00198"}
{"text": "According to the World Health Organization , up to 20 percent of people with chronic hepatitis C will develop cirrhosis ; of those , up to 20 percent may progress to liver cancer .", "label": "", "metadata": {}, "score": "97.061325"}
{"text": "In the trial the most common adverse events were fatigue ( 42 percent ) , nausea ( 22 percent ) and headache ( 20 percent ) .", "label": "", "metadata": {}, "score": "97.22839"}
{"text": "Oral Administration .Administer orally 3 times daily ( every 7 - 9 hours ) with food ( meal or light snack ) .Dosage .", "label": "", "metadata": {}, "score": "97.267914"}
{"text": "1 RUBY - I was presented as a late - breaker today at The International Liver Congress \u2122 ( ILC ) 2015 , the 50 th annual meeting of the European Association for the Study of the Liver ( EASL ) in Vienna , Austria . \"", "label": "", "metadata": {}, "score": "97.51882"}
{"text": "These statements are based upon the current beliefs and expectations of Merck 's management and are subject to significant risks and uncertainties .There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful .", "label": "", "metadata": {}, "score": "97.73379"}
{"text": "These statements are based upon the current beliefs and expectations of Merck 's management and are subject to significant risks and uncertainties .There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful .", "label": "", "metadata": {}, "score": "97.73379"}
{"text": "Most patients experienced at least 1 AE , but the majority of events were mild .There were no statistically significant differences in event rates according to the categories analyzed ( Table ) .", "label": "", "metadata": {}, "score": "98.07898"}
{"text": "Such risks and uncertainties include , but are not limited to , challenges to intellectual property , competition from other products , difficulties inherent in the research and development process , adverse litigation or government action , and changes to laws and regulations applicable to our industry .", "label": "", "metadata": {}, "score": "98.35297"}
{"text": "J Hepatol .2012 ; 56 : S430-S431 .[PubMed ] [ DOI ] .J Hepatol .2011 ; 54 : S27 .", "label": "", "metadata": {}, "score": "98.371506"}
{"text": "Friday , April 24 , 2015 1:00 am EDT .These data were presented at The International Liver Congress TM 2015 - the 50 th annual congress of the European Association for the Study of the Liver ( Abstract # G07 , E -", "label": "", "metadata": {}, "score": "98.46243"}
{"text": "( Date:2/5/2016 ) ...( PRWEB ) , ... February 05 , 2016 , ... -This week , ... the benefits of having a tankless water heater .", "label": "", "metadata": {}, "score": "98.50661"}
{"text": "AbbVie undertakes no obligation to release publicly any revisions to forward - looking statements as a result of subsequent events or developments , except as required by law .", "label": "", "metadata": {}, "score": "98.638306"}
{"text": "\" Protection against the damage inflicted by viral hepatitis is a matter of public health and basic human rights , \" Naveira said .\" It troubles us in Brazil - it worries us a lot - that even in a society so open to change , people still have to deal with consequences of disease like viral hepatitis .", "label": "", "metadata": {}, "score": "99.84714"}
{"text": "AbbVie employs more than 26,000 people worldwide and markets medicines in more than 170 countries .Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page .", "label": "", "metadata": {}, "score": "99.91478"}
{"text": "Please note you have not been blocked Or Removed From Our Member List : As of January 11 , 2016 - Google removed all followers that did not use a \" Google Account \" when initially joining our site .", "label": "", "metadata": {}, "score": "99.92108"}
{"text": "About Hepatitis C .Hepatitis C is a virus that infects the liver and is transmitted through direct contact with infected blood and blood products .", "label": "", "metadata": {}, "score": "100.31038"}
{"text": "No other uses without permission .Copyright \u00a9 2012 Massachusetts Medical Society .All rights reserved .Page 8 .All 3 patients had undetectable HCV RNA on retesting .", "label": "", "metadata": {}, "score": "100.39896"}
{"text": "The most common adverse events were diarrhea , fatigue , headache , and nausea ( Table 3 ) .Most adverse events were mild to moderate .", "label": "", "metadata": {}, "score": "100.71437"}
{"text": "The most common ( greater than 5 % incidence ) adverse events reported were fatigue ( 13 % ) , headache ( 12 % ) and nausea ( 9 % ) .", "label": "", "metadata": {}, "score": "101.14925"}
{"text": "This annual congress is the biggest event in the EASL calendar , attracting scientific and medical experts from around the world to learn about the latest in liver research .", "label": "", "metadata": {}, "score": "101.457146"}
{"text": "All rights reserved .Page 5 .The new england journal of medicine n engl j med 366;3 nejm.org january 19 , 2012 220 log10 IU per milliliter , and 6 patients ( 60 % ) had a rapid virologic response .", "label": "", "metadata": {}, "score": "101.66261"}
{"text": "About AbbVie AbbVie is a global , research - based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories .The company 's mission is to use its expertise , dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world 's most complex and serious diseases .", "label": "", "metadata": {}, "score": "102.73419"}
{"text": "\" Oral Presentations .Oral Presentation , Eric Lawitz et al .; Thursday , April 19 , 16:00 - 18:00 CET / 10:00 am - 12:00 pm EDT .", "label": "", "metadata": {}, "score": "103.62226"}
{"text": "Hepatitis C virus ( HCV ) infection is the leading cause of chronic liver - related diseases , including cirrhosis , liver failure , and hepatocellular carcinoma .", "label": "", "metadata": {}, "score": "104.63568"}
{"text": "The purpose of this No Cost Dental Day is to provide dental care ... .( Date:2/5/2016 ) ... ... 05 , 2016 , ... Health and wellness is a topic that should concern ... they are experiencing an illness .", "label": "", "metadata": {}, "score": "104.85301"}
{"text": "About the Hepatitis C Virus Hepatitis C is a liver disease affecting over 170 million people worldwide .The virus is spread through direct contact with the blood of an infected person .", "label": "", "metadata": {}, "score": "105.255104"}
{"text": "Beyond Europe , it is approved in Japan , as well as multiple countries in Latin and South America , the Middle East and Asia Pacific .", "label": "", "metadata": {}, "score": "107.26063"}
{"text": "1 Importance of promptly seeking medical attention if symptoms of allergic reaction occur ( e.g. , itching ; hives ; trouble breathing or swallowing ; swelling of face , eyes , lips , tongue , or throat ) .", "label": "", "metadata": {}, "score": "107.30498"}
{"text": "For the 37.5 million American adults who report ... present to make hearing health a 2016 healthy aging ... .It is expected to expand ...", "label": "", "metadata": {}, "score": "107.76219"}
{"text": "( Date:2/5/2016 ) ... , Feb. 5 , 2016 As people age , it ... multitude of recommended screenings and tests that are linked ... priority .", "label": "", "metadata": {}, "score": "108.54619"}
{"text": "Editorial assistance was provided by Jennifer Tobin at Articulate Science and was funded by Bristol- Myers Squibb .The New England Journal of Medicine Downloaded from nejm.org on January 13 , 2016 .", "label": "", "metadata": {}, "score": "108.92181"}
{"text": "For Enanta Investor Relations , please contact : Paul Mellett 617 - 607 - 0761 .SOURCE Enanta Pharmaceuticals , Inc.Copyright \u00a9 2010 PR Newswire .", "label": "", "metadata": {}, "score": "108.93098"}
{"text": "The words \" believe , \" \" expect , \" \" anticipate , \" \" project \" and similar expressions , among others , generally identify forward - looking statements .", "label": "", "metadata": {}, "score": "109.56616"}
{"text": "The most frequently observed NS5A substitutions emerge at positions 28 , 30 , 31 , and 93 , although substitutions at 32 , 58 , 62 and 92 have been reported [ 11 ] [ 12 ] [ 13 ] [ 14 ] [ 15].", "label": "", "metadata": {}, "score": "110.54047"}
{"text": "The New England Journal of Medicine Downloaded from nejm.org on January 13 , 2016 .For personal use only .No other uses without permission .", "label": "", "metadata": {}, "score": "111.25508"}
{"text": "The New England Journal of Medicine Downloaded from nejm.org on January 13 , 2016 .For personal use only .No other uses without permission .", "label": "", "metadata": {}, "score": "111.25508"}
{"text": "The New England Journal of Medicine Downloaded from nejm.org on January 13 , 2016 .For personal use only .No other uses without permission .", "label": "", "metadata": {}, "score": "111.25508"}
{"text": "The New England Journal of Medicine Downloaded from nejm.org on January 13 , 2016 .For personal use only .No other uses without permission .", "label": "", "metadata": {}, "score": "111.25508"}
{"text": "In accordance with Title 17 U.S.C. Section 107 , the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes .", "label": "", "metadata": {}, "score": "111.50151"}
{"text": "Boston , Massachusetts : Program and abstracts of 63rd Annual Meeting of the American Association for the Study of Liver Diseases ; 2012 .Boston , Massachusetts : Program and abstracts of 63rd Annual Meeting of the American Association for the Study of Liver Diseases ; 2012 .", "label": "", "metadata": {}, "score": "111.96636"}
{"text": "No other uses without permission .Copyright \u00a9 2012 Massachusetts Medical Society .All rights reserved .Page 9 .n engl j med 366;3 nejm.org january 19 , 2012 224 Direct - Acting Antiviral Agents for Hepatitis C References 1 .", "label": "", "metadata": {}, "score": "112.62244"}
{"text": "York , New York ( PRWEB ) , ... February 05 , 2016 , ... ... gym use and find themselves having to wait longer to access the treadmills .", "label": "", "metadata": {}, "score": "114.58101"}
{"text": "( Funded by Bristol - Myers Squibb ; ClinicalTrials.gov number , NCT01012895 . )The New England Journal of Medicine Downloaded from nejm.org on January 13 , 2016 .", "label": "", "metadata": {}, "score": "114.949875"}
{"text": "About Bristol - Myers Squibb .Bristol - Myers Squibb is a global biopharmaceutical company whose mission is to discover , develop and deliver innovative medicines that help patients prevail over serious diseases .", "label": "", "metadata": {}, "score": "115.87927"}
{"text": "Late - Breaking Oral Presentation , Fred Poordad , et al . ; Saturday , April 21 , 15:30 - 17:30 CET / 9:30 - 11:30 am EDT .", "label": "", "metadata": {}, "score": "116.08709"}
{"text": "Please consult your own appropriate health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions .", "label": "", "metadata": {}, "score": "116.57065"}
{"text": "Since EASL 's foundation in 1966 , this not - for - profit organisation has grown to over 4,000 members from more than 100 countries around the world .", "label": "", "metadata": {}, "score": "117.28467"}
{"text": "When asked who they informed , 94.1 % of respondents told family , 73.7 % told friends , 57.4 % told a partner and 46.1 % told coworkers , but only 31.4 % told support groups , 9.1 % told a social network and 2.1 % told no one .", "label": "", "metadata": {}, "score": "117.34932"}
{"text": "While each has their pros and cons , the type chosen ...", "label": "", "metadata": {}, "score": "117.47464"}
{"text": "Merck Media : Doris Li , 908 - 246 - 5701 or Sarra Herzog , 201 - 669 - 6570 or Investors : Joe Romanelli , 908 - 740 - 1986 or Justin Holko , 908 - 740 - 1879 .", "label": "", "metadata": {}, "score": "117.89468"}
{"text": "( Date:2/5/2016 ) ...Atlanta , Georgia ( PRWEB ) , ... February 05 , 2016 , ... ... pleased to announce their 2nd Annual No Cost Dental Day to individuals in need . ...", "label": "", "metadata": {}, "score": "119.30032"}
{"text": "All rights reserved .Data provided are for informational purposes only .Although carefully collected , accuracy can not be guaranteed .The impact factor represents a rough estimation of the journal 's impact factor and does not reflect the actual current impact factor .", "label": "", "metadata": {}, "score": "120.81029"}
{"text": "\u00a9 Copyright , 2004 - 2016 , Selected Revisions September 4 , 2013 .American Society of Health - System Pharmacists , Inc. , 7272 Wisconsin Avenue , Bethesda , Maryland 20814 .", "label": "", "metadata": {}, "score": "120.96762"}
{"text": "Steady state is achieved after 1 day of 3-times daily dosing ; accumulation is minimal ( 0.8- to 1.5-fold ) .Special Populations .", "label": "", "metadata": {}, "score": "122.09757"}
